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SUMMARY
This study investigated the effect of several hormones on the rat corticosteroid binding
globulin proximal promotor and for the first time showed that modulation occurs at the
promotor level and can be correlated with changes in corticosteroid binding globulin
mRNA and protein levels. The effect of various physical and psychological stressors on
rat liver corticosteroid binding globulin mRNA levels was also tested and it was shown
that voluntary running had no effect on rat corticosteroid binding globulin levels but
that involuntary swimming and immobilization decreased rat corticosteroid binding
globulin mRNA levels. Glucocorticoid responsiveness of the corticosteroid binding
globulin promoter was investigated further by using truncated contructs of the
corticosteroid binding globulin proximal promoter. Glucocorticoid responsiveness was
delineated to between -296 and -145bp from the transcription start site an area that
contains putative binding sites for D-site binding protein, hepatic nuclear factor-3 and
CAAT/enhancer binding protein suggesting that these transcription factors may be
involved in glucocorticoid responsiveness of the corticosteroid binding globulin
proximal promoter.
The dissociative glucocorticoid activity of medroxyprogesterone acetate and Compound
A, both putative dissociated glucocorticoids, was compared to standard glucocorticoids
by examining transactivation of glucocorticoid response element-containing reporter
constructs and transrepression of corticosteroid binding globulin gene expression in
hepatic cell lines. Results showed that medroxyprogesterone acetate, but not Compound
A, trans activates only in the presence, but not in the absence, of co-transfected
glucocorticoid receptor. Medroxyprogesterone acetate down modulated dexamethasone
transactivation while the modulatory effect of Compound A depends on the order of
III
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addition of Compound A. If added together Compound A has no effect on
dexamethasone transactivation, however, if Compound A was added before
dexamethasone, Compound A significantly decreased dexamethasone transactivation.
Both medroxyprogesterone acetate and Compound A, like glucocorticoids,
transrepressed the rat corticosteroid binding globulin proximal promoter. The potency
of repression was similar but Compound A repressed with a higher efficacy than
medroxyprogesterone acetate. We conclude that Compound A is a completely
dissociated glucocorticoid in contrast to medroxyprogesterone acetate that displays only
partial dissociation, which is dependent on glucocorticoid receptor levels.
IV
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OPSOMMING
Tydens hierdie ondersoek is die effek van verskeie hormone op die rot kortikosteroied
bindings globulien proksimale promoter ondersoek en vir die eerste keer is getoon dat
modulering plaasvind op promoter-vlak en dat repressie korrileer met die verandering in
kortikosteroied bindings globulien mRNA-en proteinvlakke. Die effek van verskeie
fisiese en fisiologiese stressors op rotlewer kortikosteroied bindings globulien-mRNA-
vlakke is ook getoets en daar is getoon dat willikeurige hardloop geen effek op rot
kortikosteroied bindings globulien-mRNA-vlakke het nie maar dat gedwonge swem en
immobilisering rot kortikosteroied bindings globulien-mRNA-vlakke verlaag.
Glukokortikoied responsiewiteit van die kortikosteroied bindings globulien proksimale
promoter is verder ondersoek deur verkorte konstrukte van die kortikosteroied bindings
globulien te toets. Glukokotikoied responsiewiteit is afgebaken tot tussen -296 en -
145bp vanaf die transkripsie beginplek 'n area wat beweerde bindings setels vir D-setel
bindings protein, hepatosiet faktoor-3 en CCAAT-bindings protein-2 bevat en dus
suggereer dat hierdie transkripsie faktore betrokke mag wees met glukokortikoied
effekte op die kortikosteroied bindings globulien-proksimale promoter.
Die dissosiatiewe glukokortikoied aktiwiteit van medroksiprogesteroon asetaat en
Verbinding A, beide beweerde dissosiatiewe glukokortikoiede, relatief tot standaard
glukokortikoiede is vergelyk deur transaktivering van glukokortikoied reseptor
e1elment-bevattende konstrukte en onderdrukking van kortikosteroied bindings
globulien geen ekspressie in lewersellyne te bestudeer. Medroksiprogesteroon asetaat,
maar nie Verbinding A nie, transaktiveer slegs in die teenwoordigheid, maar nie in die
afwesigheid, van ko-getransfekteerde glukokortikoied reseptore. Medroksiprogesteroon
asetaat moduleer deksametasoon transaktivering afwaarts terwyl die modulerende effek
v
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van Verbinding A afhanklik van die orde van Verbinding A byvoeging is. Indien saam
bygevoeg het Verbinding A geen effek op deksametasoon transaktivering nie, maar
indien Verbinding A voor deksametasoon bygevoeg word verlaag Verbinding A
deksametasoon transaktivering. Beide medroksiprogesteroon asetaat and Verbinding A,
soos glukokortikoiede, onderdruk die rot kortikosteroied bindings globulien-proksimale
promoter. Die sterkte van onderdrukking is dieselfde maar Verbinding A onderdruk met
'n hoër effektiwiteit as medroksiprogesteroon asetaat. Ons toon dat Verbinding A 'n
totale dissosiatiewe glukokortikoied is in teenstelling met medroksiprogesteroon asetaat,
wat slegs gedeeltelik dissosiatief is afhangende van glukokortikoied reseptor-vlakke.
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CHAPTERl
Aim and strategy of study
1
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Glucocorticoids (GCs) have a wide variety of functions in the body. Chapter 2 provides
an extensive background on GCs and glucocorticoid receptor (GR)-mediated gene
regulation. GCs are also used pharmacologically for the suppression of inflammation in
chronic inflammatory diseases. Unfortunately this use is often accompanied by side-
effects. This chapter also reviews the literature on the synthetic dissociative GCs tested
up to now in the search for a drug with less side-effects. GCs are transported by
corticosteroid binding globulin (CBG) and the second part of this literature review
summarizes the function and gene organization of CBG and focuses on the regulation of
CBG. This broad and extensive background is necessary to explain the results obtained
in this study, to compare the results with what is known in the literature, and to place
the results within the context of exciting paradigms.
CBG protein and mRNA levels are regulated by numerous hormones, conditions and
factors, however whether this regulation is at the transcriptional level is unknown. To
address this question we therefore investigated as described in chapter 3, the regulation
of the CBG proximal promotor by several hormones reported to influence CBG
production and attempted to correlate this regulation with CBG mRNA and protein
levels. Experimentally this was carried out in human and mouse hepatoma cell-lines as
CBG is produced primarily by the liver. In addition, some work with rats was also
carried out. Northern blotting was used to determine CBG mRNA levels and CBG
protein levels were determined by radio-immuno assay (RIA) while promoter regulation
was studied by using transiently and stably transfected promoter-reporter constructs of
the rat CBG proximal promoter. Further work focused on GC regulation of CBG levels
and transfection experiments with truncated proximal promoter reporter constructs were
performed to delineate the GC responsiveness on the rat CBG promoter. We also
2
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investigated whether GC responsiveness of the CBG promoter was dependent on the
levels of GR by transiently co-transfecting a GR expression vector and by evaluating
the effect of the GR antagonist, RU486 on GC repression. The results with the truncated
CBG promoter constructs implicated three transcription factors in GC responsiveness of
the CBG promoter. To test for mutual transrepression the effect of these putative
transcription factors on transactivation of a glucocorticoid response element (GRE)-
containing promoter by liganded GR was then investigated.
GCs, both endogenous and exogenous, have been shown to decrease CBG expression
resulting in an increase in free GCs thus amplifying the effect of endogenous levels of
GCs or pharmacological analogues. Therefore we used transrepression of a rat CBG
proximal promoter reporter construct and transactivation of GRE-containing reporters,
as the two parameters to evaluate dissociated GC activity. As described in chapter 4 we
investigated and compared the dissociative GC activity of the steroidal compound,
medroxyprogesterone acetate (MPA) and the non-steroidal compound, (2-(4-
acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride) (Compound A) relative to
conventional GCs. To test whether the transrepressive or transactivation potential was
influenced by the GR expression levels, GR expression vectors were co-transfected and
to strengthen the case that the observed repression of the CBG promoter reporter
construct by CpdA was mediated by the GR the effect of the glucocorticoid antagonist,
RU486, on transrepression was also investigated. In addition, the effect of the test
compounds on CBG mRNA levels in the absence and presence of co-transfected GR
and co-transfected dimerization deficient GR, was investigated to establish if these
effects correlated with the CBG promoter reporter results. Dimerization deficient GR
was used to check for a dimerization requirement in transrepression of CBG mRNA as
3
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transrepression may be mediated through direct binding of the GR to nGREs that
requires dimerization or via a tethering mechanism that does not require DNA binding
or dimerization by the GR.
The results of this study are summarized in chapter 5 where conclusions and possible
explanations for the results obtained are presented as well as a discussion of future
experiments. In chapter 6 the methods of all experiments performed in this study are
described in detail. Data from this study has been presented inpart at several national
and international conferences and at the end of the thesis a list of conference abstracts
may be found.
4
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CHAPTER2
Literature review
5
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2.1 Glucocorticoid receptor mediated gene regulation
2.1.1 Mechanism of action
Endogenous GCs are important in maintaining basal and stress-related homeostasis and
preventing excessive immune responses to antigenic challenges [Chrousos and Gold
1992]. Pharmacologically, GCs are also the most effective therapy in the long-term
treatment of inflammation and autoimmune diseases [Cato and Wade 1996].
GCs exert their effects by binding to the GR and the mineralocorticoid receptor (MR)
[Beato et al 1995 & Beato and Sachez-Pacheco 1996b]. While the GR is widely
expressed in most cells of the organism, the MR is restricted to certain organs such as
the brain, the kidney (epithelial cells), the colon and exocrine glands [Kellendonk et al
2002]. In addition, although the MR binds GCs with higher affinity than the GR, the
presence of l l-beta-hydroxy-steroid dehydrogenase (11betaHSD2), which inactivates
GCs, provides functional distinction in most tissues, with the exception of the heart and
brain [De Kloet et al 1998]. Most biological effects of endogenous GCs are thus
mediated by the GR, as are the effects of modem synthetic GCs, which are for the most
part GR selective [Newton 2000].
The inactive cytoplasmic GR is bound to a protein complex, that includes two subunits
of the heat shock protein hsp90 plus a number of other proteins such as p23, preventing
the nuclear localization of unoccupied GR [Bresnick et al 1989; DeRijk et al 2002].
Upon hormone binding the GR, a ligand-dependent transcription factor, dissociates
from these cytoplasmic chaperone molecules and translocates to the nucleus, where the
activated receptor can transactivate or transrepress specific genes [Beato et al 2000].
The different models of GR transcriptional modulation are illustrated in Fig. 2.1 and the
genes regulated by these models are summarized in Table 2.1.
6
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Transactivation is mediated by binding of a GR dimer to GREs in the promoter region
of GC responsive genes, followed by recruitment of coactivators, chromatin
remodelling, and increased gene transcription (Fig. 2.1A) [Adcock 2000]. Examples of
genes upregulated by GCs via simple GREs include lipocortin I (now known as annexin
I), and pll/calpactin binding protein, which are involved in suppressing the release of
arachidonic acid during inflammation [Flower and Rothwell 1994; Pitzalis et al 2002;
Yao et al 1999]. Other examples of genes that are upregulated by GCs via GREs
include, the P2-adrenergic receptors [Collins 1988 et al; Mak et al 1995; Cornett et al
1998], secretory leucocyte protease inhibitor (SLPI) [Abbinante-Nissen et aI1995], the
decoy interleukin-I (IL-I) type II receptor [Colotta et a11993; Muller et al 2002], the
tyrosine aminotransferase (TAT) gene [Sassi et al 1998] and the mouse mammary
tumour virus (MMTV) gene [Lee et aI1998].
The GR can act in synergy with other transcription factors to transactivate or repress
from composite elements (also called glucocorticoid response units - GRUs) with DNA
binding of both the GR and the other transcription factors (Fig. 2.1B & G) [Diamond et
al 1990; Pearce and Yamamoto 1993; Pearce et al 1998]. The term "composite" GRE
thus describes a non-consensus sequence that binds GR with low affinity and
transactivates (Fig 2.1B) or transrepresses (Fig 2.1G) [Diamond et al 1990]. This
"composite" DNA binding element may have binding sites for GR and other
transcription factors and GCs may activate or repress transcription from these binding
sites, depending on cell type. The phospoenolpyruvate carboxykinase (PEPCK) gene is
an example of a gene containing a composite GRE, through which it is upregulated, in
liver and kidney, or downregulated, in adipose tissue, by GCs [Scott et a11998; Wang et
a11999; Stafford et a12001a; Stafford et a12001b; Hanson and Reshef 1997]. Induction
7
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GR transactivation GR transrepression
A
Simple
GRE
nGRE
B
Composite
GRE
Competitive
nGRE
C F
Tethering
nGRE
Tethering
GRE
G
Composite
nGRE
Figure 2.1. Models of GR transcriptional modulation. (A) Homodimers of GR bind
cooperatively to classical GRE sites to activate transcription. (B) Interaction of GR with
another transcription factor can activate transcription from composite binding sites with
DNA binding of both factors. (C) Interaction of GR with a second transcription factor
may result in activation of transcription without DNA binding of GR. (D) Homodimers
of GR repress transcription from a nGRE. (E) At a competitive nGRE, binding of GR to
the GRE site prevents binding of factors that are necessary for transcriptional regulation
and thus cause repression. (F) Interaction of GR with a second transcription factor may
result in repression of transcription without needing DNA binding of GR. (G)
Interaction of GR with a second transcription factor can repress transcription from
composite binding sites in a manner that involves DNA binding of both factors [taken
from Newton 2000].
of the PEPCK gene in liver by GCs is achieved through a complex GRU consisting of
two low affinity GR-binding sites, GR1 and GR2, and binding sites for transcription
factors that act as accessory factors for the glucocorticoid response. Three accessory
factor-binding sites (AFs), AF1, AF2 and AF3, have been identified in this GRU. The
proteins that mediate accessory activities through AF1 have been identified as hepatic
nuclear factor-4 (HNF-4) and chicken ovalbumin upstream transcription factor (COUP-
TF) [Hall et al 1995]. Members of the hepatic nuclear factor-3 (HNF-3) family bind to
AF2 and COUP-TF acts as the accessory factor through AF3 [Wang et a11996; Scott et
al 1996]. All three AF elements as well as a downstream element, the cAMP response
8
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element (CRE), are needed for a complete GC transactivation response. The GR can
also interact with other transcription factors, resulting in repression of transcription from
composite binding sites that involve DNA binding of both factors (Fig. 2.1G). For
example, as discussed above, transcription of the cytosolic form of PEPCK (PEPCK-C)
gene is repressed in white adipose tissue via two nonconsensus sequence GREs that
bind GR with a low affinity [Olswang et al 2003]. The GR, in the presence of ligand,
inhibits activation of the PEPCK-C gene promoter by CAAT/enhancer binding protein
(C/EBP)a or CIEBPP in adipose tissue, most probably through binding to the AF2
element. There is evidence that this may not be a true composite negative GRE
(nGRE), as DNA-binding of the GR may not be required for transrepression [Olswang
et a12003].
The third mechanism of GR transactivation involves the interaction of the GR with
another transcription factor without GR binding to DNA. This is illustrated by the
synergistic induction of the rat serine protease inhibitor-3 (SPI-3) gene by interleukin-6
(IL-6) and dexamethasone that involve the interaction of GR with signal transducers and
activators of transcription 3 (STAT3) and C/EBP, without GR binding to DNA (Fig.
2.1C) [Kordula and Travis 1996]. This synergy between the transcription factor STAT5
and the GR appears to involve direct interaction between STAT5 and GR without
requiring GR DNA binding, as shown for the p-casein gene in mammary cells [Stëcklin
et a11996; Cella et aI1998].
Transrepression may also be mediated via direct binding of the GR to DNA via nGREs
(Fig. 2.1D & E). nGREs are present in various genes and include the corticotropin
releasing hormone (CRR) gene promoter [Malkoski and Dorin 1999; King et aI2002],
<
é
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the pro-opiomelanocortin (POMC) gene [Tumey and Kovacs 2001], the prolactin gene
[Subramaniam et al 1998], the IL-I gene [Zhang et al 1997] and the osteocalcin gene
[Aslam et al 1995]. The POMC gene is an example of a promoter repressed by GCs
where multimers of GR were shown to bind a nGRE causing repression of transcription
[Charron and Drouin 1986; Drouin et al 1993, Tumey and Kovacs 2001]. Specific/ally,
this involves binding of a GR homodimer followed by binding of a GR monomer. The
mechanism of action involves protein-protein interactions with other factors (for
example NUR77) on the promoter or direct inhibition due to steric hindrance, which
may be due to the close proximity to the TATA box and the transcription start site. The
binding of GR to the nGRE may block binding of positive factors and thus cause
transcriptional repression (Fig. 2.1E) [Murphy and Conneely 1997]. Another example of
a gene repressed by GCs is the glycoprotein hormone a subunit gene [Akkerblom et al
1988; Stauber et al 1992]. This promoter contains overlapping binding sites for a CRE-
binding protein (CREB) as well as GR and is positively regulated by CREB. DNA
binding by GR is thought to inhibit transcriptional activation by preventing binding of
CREB (Fig. 2.1E). The osteocalcin promoter is a further example of repression through
a competitive nGRE that overlaps the TATA box [Stromstedt et al 1991; Meyer et al
1997]. Binding of the GR may prevent binding of the basal transcription factor, TATA
binding protein (TBP), which will result in repression of transcription. Furthermore, in
the bovine prolactin gene GR-dependent repression may be via competition between
factors that bind or via the inhibition of positive activation by binding of GR to the
nGRE [Sakai et a11988; Subramaniam et aI1998]. The GR was also shown to suppress
keratin gene expression through interaction of nGREs with four GR monomers [Radoja
et al 2000]. In all of these examples, DNA binding by the GR is necessary for
repression.
10
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Table 2.1 Specific examples of genes to illustrate models of GR transcriptional
modulation.
MECHANISM
GENES
(numbering of models as REFERENCE
REGULATED
in Fig.2.1)
Simple GRE (2.lA) lipocortin I Flower and Rothwell 1994; Pitzalis
et a12002;
pIl /calpactin binding Yao et al1999
protein
~2-adrenergic receptors Collins 1988 et al; Mak et al 1995;
Cornett et al 1998
SLPI Abbinante-Nissen et al1995
decoy IL-I type II Colotta et a11993;
receptor Muller et al 2002
TAT gene Sassi et al1998
MMTV gene Lee et al 1998
Composite GRE (2.lB) PEPCKgene Scott et al 1998; Wang et al 1999;
Stafford et al 2001a; Stafford et al
2001b; Hanson and Reshef 1997
Tethering GRE (2.lC) rat SPI-3 gene Kordula and Travis 1996
~-casein gene Stëcklin et a11996; Cella et al1998
nGRE(2.lD) CRH gene promoter Malkoski and Dorin 1999; King et al
2002
POMC gene Tumey and Kovacs 2001
prolactin gene Subramaniam et al 1998
IL-1 gene Zhang et al 1997
osteocalcin gene Aslam et al1995
keratin gene Radoja et al2000
Competitive nGRE (2.lE) glycoprotein hormone Akkerblom et al 1988; Stauber et al
a subunit gene 1992
osteocalcin gene Stromstedt et al 1991; Meyer et al
1997
bovine prolactin gene Sakai et al 1988; Subramaniam et al
1998
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Tethering nGRE (2.1F) IL-8 gene Nissen et al2000
ICAMI gene Nissen et al2000
collagenase-3 gene Rogatsky et al 2001
Composite nGRE (2.1G) PEPCK-C Olswang et al 2003
Alternatively, transrepression may proceed without direct DNA-binding by the GR, but
via protein-protein interactions. This may only require direct or indirect binding of the
GR monomer to other transcription factors such as nuclear factor-KB (NF-KB),
activating protein-I (AP-I), STAT proteins and CIEBP (Fig. 2.IF) [McEwan et a1I997;
Webster and Cidlowski 1999]. As this effect does not require direct binding of GR to
DNA, the term "tethering GRE" is used to describe these elements. Most of the anti-
inflammatory effects of GCs are mediated through repression of inflammatory and
immune genes that do not contain GREs in their promoters [Cato and Wade 1996].
These inhibitory effects of GCs are mostly due to protein-protein interactions between
activated GR and transcription factors such as AP-I, NF-KB and C/EBPP, which
mediate expression of inflammatory genes [Barnes 1998]. GCs have been shown to
repress NF-KB-mediated activation of proinflammatory genes like interleukin-8 (IL-8)
and intercellular adhesion molecule (ICAMI ) via protein-protein interactions between
NF-KB and the GR [Nissen et al 2000]. In addition, the collagenase-3 gene repression
by GCs is mediated by the GR forming protein-protein interactions with AP-I
[Rogatsky et a1200I].
2.1.2 The GR
The GR is a ligand-activated transcription factor and a member of the nuclear hormone
receptor superfamily, which includes the MR, the progesterone receptor (PR), the
estrogen receptor (ER), the androgen receptor (AR), the thyroid hormone receptor (TR),
12
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the retinoic acid receptor, and the vitamin D receptor (VDR) [Beato et al 1991;
Mangelsdorf et a11995; Aranda and Pascual2001]. The GR, AR, PR and ER share over
50% identity in their amino acid sequences, have a similar three-dimensional structure
and are classified as steroid receptors or Class IIInuclear receptors [Tsai and O'Malley
1994; Bledsoe et al 2002; Aranda and Pascual 2001]. Phylogenetic analysis and
sequence alignments show that the GR, MR, PR and AR form a subfamily of oxosteroid
receptors that are separate from the ER subfamily.
2.1.2.1 Structure of the GR
2.1.2.1.1 Human GRgene
GRs are expressed in most cell types and their density vanes from 2000-30000
molecules per cell [Adcock et al 1996]. Cloning of the GR from different species
revealed that it consists of about 800 amino acid residues. The human GR (hGR) has
777 amino acids [Hollenberg et al 1985] and the gene is located on chromosome 5
(locus q11-q13) and consists of 9 exons [Encio and Detera-Wadleigh 1991; Yudt and
Cidlowski 2002]. Exon 1 and the first part of exon 2 contain the 5'UTR, exon 2-9 the
coding sequences and exon 9 the 3'UTR. It has also been shown that two more exons
exist, called exon lA and 1B, located upstream from the original exon 1 (now exon IC)
[Breslin et aI2001]. The activity of the mouse and human GR-gene is regulated by three
promoters of which the first two promoters are located in the 3 kb region upstream of
exon 1C (promoter 1B and 1C). Both promoters contain a few GC boxes, which are
binding sites for the transcription factor SP-I. Promoter 1B also contains YY1 sites and
promoter IC contains a putative AP-2 site but no TATA or CAAT elements are present
in these promoters [Encio and Detera- Wadleigh 1991]. Promoter 1A is located further
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upstream and contains a putative interferon regulatory factor-binding element, as well as
a sequence that resembles a GRE [Breslin et al 2001]. The structure of the hGR is
shown in Fig. 2.2.
2.1.2.1.2 GR isoforms and subtypes
An additional level of complexity of steroid hormone receptors is the presence of
multiple receptor subtypes and isoforms. For the human GR, two classes of cDNAs
have been described which are the result of alternative splicing of a single gene
transcript and that encode the hGRa and hGRp isoforms of the receptor [Hollenberg et
al 1985; Bamberger et al 1995]. Both mRNA transcripts contain exons 1-8 and differ
only in that the hGRa mRNA (5.5kb) contains exon 9a while hGRp (4.3kb) contains
exon 9p [DeRijk et al 2002]. In addition, a third mRNA transcript (7.0kb) has been
identified that is thought to also code for the hGRa [Oakley et a11996].
Both GR protein isoforms are identical up to 727 amino acids, with hGRa (777 amino
acids) larger than hGRp (742 amino acids). GRp cannot bind GCs and has a dominant
negative effect on the transcriptional effects of GRa. The P-isoform was first thought to
be a cloning artefact but was later shown to be expressed at varying levels in different
tissues.
In the blood of patients with GC-resistant asthma, higher numbers of hGRp positive
cells were found, further suggesting a dominant negative function of the human GRp
[Leung et al 1997]. Evidence for a physiological role for the GRp isoform in
neutrophils was recently found. The GC sensitivity of human neutrophils was compared
14
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to that of peripheral blood cells and the presence of GRa/GRp heterodimers was only
observed in neutrophils [Strickland et a/2001]. Also, transfection ofneutrophils from
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Figure 2.2. Structure of the hGR. (A) Schematic representation of the hGR gene, the
mRNAs encoding hGRa and hGRp as well as the A and B-isoforms. (B) Structure of
the hGRa protein. The different domains of the receptor and several functions mapped
to regions of the protein are indicated [taken from DeRijk et a/2002].
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nuce with a functional hGR~ led to an inhibition of GC induced apoptosis. The
GRa/GR~ heterodimers may thus be functionally inactive, but their expression might
limit the GC responsiveness mediated via the GRa homodimer.
In addition, two forms of hGRa are produced by alternative translation of the same
mRNA and are called GR-A and GR-B [Yudt and Cidlowski 2001]. The longer GR,
GR-A (aa 1-777; 94kDa) is generated from the initial ATG start codon (methionine 1)
and the shorter GR, GR-B (aa 27-777; 91kDa) is translated from the internal ATG
corresponding to methionine 27. Both receptors display similar subcellular localization
and nuclear translocation after ligand activation and are present in several human cell
lines and rodent tissues. Functional assays of these splice variants with GC responsive
promoters showed that the shorter hGR-B is nearly twice as effective as the longer
hGR-A in transactivation, but not in transrepression [Yudt and Cidlowski 2001]. A
similar mechanism of alternative translation initiation has been proposed, but not yet
proven, for the hGR~ [Yudt and Cidlowski 2001].
2.1.2.1.3 Functional domains of the GR
The GR, like other steroid receptors, has several functional domains, namely a ligand-
binding domain (LBD), a N-terminal domain and a DNA-binding domain (DBD) (Fig.
2.2B, pIS) [Giguere 1986]. The N-terminal domain in the hGRa consists of amino acids
1-427 and the amino acids 428-488 form the DBD. The C-terminal LBD, separated
from the DBD by a hinge region, consists of amino acids 527-777, of which 50 amino
acids at the end are encoded by exon 9a. The LBD of the hGR~ is the same as that of
hGRa up to amino acids 727. After that the structures of hGRa and hGR~ diverge. In
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hGRp the last 15 amino acids are encoded by exon 9p and form the C-terminal part of
the LBD ofhGRp, which does not in fact bind ligand [DeRijk et aI2002].
The N-terminal domain (r l or AF-I) is involved in transactivation after DNA binding
has taken place and may also be involved in binding to other transcription factors. The
human GR also contains a second transactivation domain ('t2 or AF-2), which is
adjacent to the GC binding domain. This region is also important for nuclear
translocation of the receptor.
The three-dimensional structure of the DBD of the GR by 2D-NMR showed that the
two zinc fingers form a single structural domain consisting of two a-helices, one
adjacent to each zinc finger. The GR is folded in a manner so that two zinc fingers
protrude out from the surface, which enables it to interact with DNA. All receptors with
a conserved DBD have these two zinc fingers, which are expressed by separate exons
(Fig. 2.3) [Evans 1988].
The one ZInC finger is responsible for receptor-DNA contact by binding a specific
hormone response element (RRE) and the other one is involved in receptor
dimerization. The important amino acid residues responsible for the DNA-receptor
interaction in the wild type GR are situated in the P-box of the first zinc finger as well
as in the interfinger region. A change in the secondary structure from a p-strand to an
a-helix, near the P-box, is observed and was called a DNA-recognition helix [Luisi et
al 1991]. The D-box of the second zinc finger up to the amino acid D485 builds an
extended coil, which is followed by a second helix. The tetrameric co-ordinative
binding of four cysteins with a central Zn2+ion determines the molecular shape of the
17
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Figure 2.3. Organization and structure of the DNA binding domain of the MR, GR
and AR. White boxes, untranslated exons; grey boxes, translated exons. Amino acid
sequence in one letter code: grey letters, DNA identification sequence. Amino acids
marked with a plus sign form a helices. ZF, zinc finger [Wickert and Selbig 2002].
two zmc fingers [Luisi et al 1991]. The conserved ammo acid sequence and the
resulting 3D structure provides for the optimal, specific DNA binding and is a
requirement for regulating target gene expression by steroid hormone receptors.
Alternative splicing of exon 3 and 4 of the GR as well as the MR leads to mRNAs with
an additional inframe insertion in the interfinger region between the two zinc fingers of
the DBD as shown in Fig. 2.3. GR receptors from different species with an insertion of
one (GR+ 1 in primates) or nine (GR+9 in fish) additional amino acid residues have
been described [Brandon et a11991; Ducouret et aI1995]. The interfinger region of the
GR DBD seems to be flexible and can cope with insertions of up to 27 amino acid
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residues [Zandi et al 1993]. Structure predictions by Wickert et al indicated that the
hinge region of the zinc finger coding exons of the GR could be flexible due to the
insertion of several amino acids [Wickert and Selbig 2002].
2.1.2.2 Function of the GR
The GR is predominantly localised in the cytoplasm of target cells and upon binding of
GCs to the GR it translocates to the nucleus where it dimerizes and modulates
transcription of GC-responsive genes [Oakley et a11999; Beato et a11996b].
2.1.2.2.1 Ligand binding
The LBD is located at the carboxyl terminus of the molecule and is separated from the
DBD by a hinge region. The LBD contains 12 a-helices, which are folded to form a
hydrophobic pocket for the ligand [Baumann et al 1993]. Ligand binding results in a
conformational change, in which the helix 12 folds back and "closes" the pocket. The
LBD also contains a ligand-dependent activation function (AF-2), which is regulated by
hormone binding. In the absence of hormone, the GR is retained in the cytoplasm by
association with chaperone proteins like hsp90, which binds to the LBD. After hormone
binding the chaperone proteins are released from the GR and this allows for
dimerization and translocation into the nucleus. Receptor dimerization is partly
mediated through the LBD. In the nucleus the GR can bind to DNA elements and can
either activate or repress transcription, both requiring the intact function of the LBD.
Mutations of the receptor at Tyrosine735, have identified this amino acid as being
important for ligand binding and ligand-dependent transactivation [Ray et al 1999].
Tyr735 interacts with the D ring of the synthetic glucocorticoid agonist, dexamethasone,
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and contributes to the conformational change of helix 12, which is predicted to be
necessary for efficient recruitment of transcriptional coactivator molecules.
Previously, the crystal structures of nuclear receptor LBDs in the apo-state or bound to
agonist or antagonist revealed that the LBDs fold into a canonical three-layer helical
sandwich that embeds a hydrophobic pocket for ligand binding. It also emphasizes the
importance of the C-terminal (AF-2) helix in ligand-dependent regulation [Bourquet et
al 1995; Brzozowski et a11997; Wagner et a11995]. In the apo-or antagonistic bound
receptor, the AF-2 helix is destabilized from its active conformation, which allows the
LBD to interact with corepressors, such as nuclear corepressor (N-CoR) [Chen et al
1995; Horlein et a11995]. Agonist binding on the other hand, induces a conformational
change of the AF-2 helix which stabilises the receptor in an active conformation to
facilitate its association with coactivator proteins like steroid receptor coactivator-I
(SRC-1) and transcriptional intermediary factor 2 (TIF2) [Onate et a11995; Voegel et al
1996]. Crystal structures of receptor/coactivator complexes revealed that the coactivator
LXXLL motifs adopt a two-turn a-helix and both helical ends are stabilised by a charge
clamp formed partly by a conserved acidic residue from the AF-2 helix [Darimont et al
1998; Nolte et al 1998; Shiau et a11998].
Recently, the crystal structure of the LBD bound to dexamethasone revealed that the
LBD adopts a dimer configuration, which involves the formation of an intermolecular
beta sheet that could be important for GR-mediated activation [Bledsoe et al 2002].
Bledsoe et al also found that the GR uses two charge clamps to define its sequence-
specific binding to the TIF third motif [Bledsoe et al 2002]. The first charge clamp
consists of the E755 from the AF-2 helix and K579 from helix 3, which cap the
20
Stellenbosch University http://scholar.sun.ac.za
backbone amides and carbonyls of the coactivator helix. Both of these residues are
highly conserved in the nuclear hormone receptor superfamily and also share a common
binding mode for all LXXLL motifs. The second charge clamp consists of R585 and
D590 that form hydrogen bonds with the side chains of residues R+2 and D+6, which
are present in the TIF2 third motif but not in the first or second motif. The interactions
with the second charge clamp are partly responsible for the binding specificity of the
GR for the TIF2 third motif. The residues from the second charge clamp are conserved
in the GR, AR, PR and MR but are not found in the ER and thus may be responsible for
the differential binding of coactivator motifs by nuclear receptors. Structures of the
endogenous steroid hormones are shown in Fig. 2.4. Comparing the structures of the
GR, AR, PR and ER provides information into how functional specificity is achieved by
steroid receptors. There is 50% homology in amino acid sequences between these
steroid receptors and they also share a similar three-dimensional structure. In these
structures, the core steroid template (A, B, C and D rings) assumes a general orientation
with the A ring orientated towards the conserved arginine from helix 5 and the Dring
toward the AF-2 helix. Small differences in the secondary structure and the ligand
binding pockets exist in steroid receptors. In the GR, helices 6 and 7 differ from the ER,
PR and AR and produce a unique side pocket in the GR. This unique side pocket may
explain the GR selectivity for GCs, which like mineralocorticoids that bind MR, have
larger substituents at the C17a position in comparison with estrogen, progesterone and
testosterone. The polar substituents in steroid hormones are mostly situated at positions
C3 or C17. In the GR structure, but also conserved in the AR and PR, the C3 ketone
accepts hydrogen bonds from Q570 and R611. In the ER, the glutamine is replaced by a
glutamate, which prefers to accept a hydrogen bond from the ligand. This accounts for
the ERs selectivity for a hydroxyl group at the C3 position. The differences in hydrogen
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bond formation may explain why the GR, AR, PR and MR prefer steroid hormones with
a ketone at position C3, whereas the ER favours a hydroxyl group (Fig. 2.4) Although
the GR and MR have a similar side pocket, the MR selectivity for
mineralocorticosteroids may be due to differences in hydrogen bonding patterns
between the receptors and the ligands. The MR selective steroids all lack the 17a-
hydroxyl group, which forms a specific hydrogen bond with Q642 in the GR structure.
H AR PR ERpH H~~
Cortisol Corticosterone Testosterone prógestrone 17~-Estr8dlol
Fig. 2.4. Structures of the endogenous steroid hormones [taken from Bledsoe et al
2002].
Several diseases like Cushing's syndrome, autoimmune diseases and numerous cancers
have been associated with missense mutations in the GR LBD, which may be explained
by the structure of the GR LBD [Bledsoe et al 2002]. These mutations can be classified
into two groups, based on their location in the GR structure. The first group includes the
G507C, M601L, M604P, M646T, Y735S, C736S and L753F mutations. In the GR
structure, these residues make direct contacts with dexamethasone and this results in a
GR defective in ligand binding. The second group includes P541A, I559D, C638Y,
vn9I, Y764N and F774A mutations. These residues are involved in hydrophobic
interactions within the GR protein structure and their mutations may destabilize the
protein. With the availability of the GR LBD structure [Bledsoe et aI2002], correlations
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between the location of mutations and various diseases associated with these mutations
may now be understood.
2.1.2.2.2 Dissociation from heat shock proteins
Inactive GR is bound to a protein complex (300 kDa), which includes two subunits of
heat shock protein hsp90. They act as molecular chaperones preventing nuclear
localization of unoccupied GR [Bresnick et aI1989]. Hsp90 associates with the LBD of
the GR (Fig. 2.2, p15), and this association keeps the receptor in a conformation that
can bind steroid [Picard et al 1990]. Other factors, present in the protein complex and
required for formation of a stable GR-hsp90 complex are p23, p60, hsp40, hsp70 as well
as several immunophilins, for example hsp56. The immunophilins appear not to be
needed for complex formation [reviewed by Pratt and Toft 1997]. Hsp90 complexation
with GRs also opens up the LBD to permit the attachment of thiol residues by a thiol-
derivatizing agent as well as the proteolytic cleavage at basic amino acids by trypsin
[Stancato et al 1996; Modarress et al 1997]. These results support the idea that the
hsp90-based chaperone machinery directs the partial unfolding of the LBD and thus the
opening of the hydrophobic steroid-binding cavity for access by the steroid [Pratt 1993].
A seven amino acid sequence (547-553) of the rat GR is essential for hsp90 binding as
well as steroid binding [Giannoukos et aI1999]. Steroid binding activity depends on a
LXXLL motif at amino acids 550-554 and the LXXLL motifs have been previously
described to mediate protein-protein interactions of transcriptional co-factors with
steroid receptors [Heery et al 1997; Ding et al 1998]. Recently, Kaul et al, using GR
LBD fusion proteins, demonstrated that the presence, but not the sequence of the seven-
amino acid segment (position 547-553) within helix 1 of the rat GR LBD, is necessary
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for LBD-hsp90 heterocomplex assembly as well as steroid binding activity [Kaul et al
2002]. Additional support for this came from the findings that when a GR fragment
ending in this segment (547-553) is fused to the complementary retinoic acid receptor
LBD fragment, the chimera IS complexed with hsp90 and undergoes
cytoplasmic/nuclear translocation in response to retinoic acid [Mackern et al 2001].
Thus, the GR LBD confers hsp90 binding to the retinoic acid receptor, which normally
does not bind hsp90. After GC binding to GR, hsp90 dissociates which allows nuclear
localization of the activated GR-GC complex [Truss and Beato 1993].
2.1.2.2.3 Phosphorylation
The GR-mediated transcription IS regulated positively and negatively by
phosphorylation. Although ligand binding is important for activation of the GR, the
receptor is also subject to post-translational modification through phosphorylation
[Bodwell et al 1998]. In the absence of hormone, the GR is phosphorylated and
becomes hyperphosphorylated in the presence of agonist [Orti et al 1993]. Hormone-
dependent phosphorylation of GR may determine target promoter specificity, cofactor
interaction, receptor signalling and receptor stability.
Eight phosphorylation sites have been identified in the mouse GR (mGR), of which five
are conserved in the hGR [Almlof et a11995]. All five phosphorylation sites are located
in the r l region in the N-terminal domain of the receptor (Fig. 2.2B, pIS). The GR has
been shown to be poly-phosphorylated on serine and threonine residues [Yudt and
Cidlowski 2002]. The rat GR (rGR) is phosphorylated at Thr171, Ser224, Ser232 and
Ser246 [Krstic et al 1997]. Mitogen activated protein kinase (MAPK) phosphorylates
the rat GR at Thr171 and Ser246 while cyclin-dependent kinase (Cdk) phosphorylates it
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at Ser224 and Ser232. Cdk positively regulates GR-mediated transcription whereas
MAPK negatively regulates GR-mediated transcription [Krstic et al 1997]. In the rGR
Ser224 and Ser232 correspond to Ser203 and Ser211 in the hGR. In the absence of
hormone, the level of GR phosphorylation at Ser211 is low compared to
phosphorylation at Ser203 but phosphorylation of both sites increase with addition of
the agonist, dexamethasone [Wang et al 2002]. Biochemical fractionation studies and
immunofluorescence showed that the Ser203-phosphorylated form of the receptor is
predominantly located in the cytoplasm, whereas Ser211-phosphorylated GR is present
in the nucleus. These results suggest that differently phosphorylated receptors are
located in separate subcellular compartments and may modulate distinct receptor
functions [Wang et a12002].
It has been reported that phosphorylation of Thr171 by glycogen synthase kinase-3 and
Ser246 by c-Jun NH2-terminal kinase (INK) inhibits rat GR-mediated activation of
transcription [Rogatsky et al 1998a; Rogatsky et al 1998b]. The molecular mechanism
by which INK negatively regulates GR-mediated signals remains unclear, but INK
phosphorylation of GR might modulate ligand-dependent nuclear-cytoplasmic shuttling
of GR. Recently, Itoh et al showed that INK-mediated phosphorylation of the hGR at
Ser226 (corresponds to Ser246 in rGR) enhances GR nuclear export and may contribute
to the inhibition of GR-mediated transcription [Itoh et a12002]. However, the biological
effect of GR phosphorylation remains unknown.
2.1.2.2.4 Nuclear translocation
Ligand-bound GRu is transported into the nucleus with the help of two nuclear
localization (NL) signals, NLI and NL2 [Savory et aI1999]. NL1 is located in the C-
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terminal part of the DBD, extending into the hinge between DBD and LBD and is
located between amino acid 478 and 500 [Brink et al 1992]. NL1 catalyzes rapid
transport of the GR through the nuclear pore via the classic importin pathway. This
region is conserved (100%) between the rGR and hGR [Baumann et al 1993]. NL2 is
located in the LBD of GRa and contributes to a slower traffic via an unknown
mechanism [Picard and Yamamoto 1987].
Several N-terminal GR fusion chimeras to green fluorescent protein (GFP) were
constructed to investigate the importance of the LBD for intracellular GR trafficking
[Kino et aI2001]. GFP-hGRa was transported within 12 min from the cytoplasm to the
nucleus after addition of dexamethasone. GFP-hGR514, which does not contain a LBD
and does not bind hsp, as well as GFP-hGR~, which has a unique LBD and low affinity
for hsp, entered the nucleus immediately. hGR514 contains only NL1 and this signal
may thus be responsible for fast translocation. Therefore, it can be concluded that
hGRa, hGR514 and hGR~, through their Nl region, interact with importin a and can
enter the nucleus through the nucleur pores via the classical importin pathway. The
GFP-hGRaI559N mutant receptor, in which Ile was replaced by Asn at position 559,
which is located close to NL1, was situated mostly in the cytoplasm. Only high dose or
prolonged exposure of dexamethasone led to transport of this mutant into the nucleus in
about 180 min. This mutation appears to impair the NL1 function of the receptor and
change the nucleocytoplasmic shuttling activity of the mutant receptor [Kino et al
2001]. Another group also using a chimera of GFP (GFP-GR), showed dynamic
cytoplasmic to nucleus translocation of GR upon ligand binding [Htun et al 1996].
Subcellular localization of the GR was also compared to the MR in living cells and
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whereas unliganded GR was predominantly in the cytoplasm, the GFP-MR was
distributed both in the cytoplasm and nucleus [Nishi et al 2001].
Although little is known about what regulates steroid receptor movement through the
cytoplasm and into the nucleus, several studies suggested that movement is influenced
by reversible phosphorylation. Treatment with okadaic acid, a potent Ser/Thr protein
phosphatase inhibitor, results in inefficient nuclear retention of agonist-bound GR as
well as the cytoplasmic "trapping" of GR which is then unable to recycle [DeFranco et
al 1991]. More studies also indicated that phosphatase type 5 (PP5) associates with the
GR-hsp90 complex, which suggests that PP5 might influence GR actions [Silverstein et
al 1997]. In the absence of ligand, GR-GFP is localised in the cytoplasm, but treatment
with dexamethasone resulted in translocation of GR-GFPs into the nucleus. In contrast,
nuclear accumulation of GR-GFP was observed in the absence of GCs, when the
expression of PP5 was suppressed by treatment with ISIS 15534 [Dean et al 2001]. The
results suggest that PP5 participates in the regulation of GR shuttling between the
cytoplasm and nucleus and that the GR-induced transcriptional activity observed during
suppression of PP5 expression results from nuclear accumulation of GR. This form of
GR is capable of binding DNA but still needs agonist for maximal transcriptional
activation [Dean et al 2001]. Previous studies demonstrated that antidepressants could
enhance GR translocation and function, possibly through activation of cAMP and
downstream cAMP-dependent protein kinases. Therefore, GR function was investigated
in cells treated with rolipram, a phosphodiesterase (PDE) type 4 inhibitor, which
antagonises cAMP breakdown [Miller et al 2002]. Rolipram alone, or in combination
with dexamethasone, enhanced GR function in reporter genes driven by a GRE. This
enhancement of GR function by rolipram was reversed by RU486 and was associated
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with reduced cytosolic GR binding, which indicated rolipram enhanced GR nuclear
translocation.
Nucleocytoplasmic shuttling is predicted to be a general property of nuclear receptors
and this would integrate cytoplasmic signalling events with the regulation of
transcription [Doucas et al 2000]. Nuclear import involves recognition of a nuclear
localization signal (NLS) by importins, which mediated translocation into the nucleus.
The well-characterised nuclear export pathway uses Crm as a receptor for proteins that
contain a leucine-rich nuclear export signal (NES) [Black et a12001]. Nuclear receptors
like GR, AR, TR and PR lack a leucine-rich NES and export is insensitive to
leptomycin B, which indicates that nuclear export is not mediated by Crm 1. Results
showed that all 60 amino acids of the GR DBD are important and necessary for export
[Black et aI2001]. Further analysis revealed that a 15 amino acid sequence between the
two zinc-binding loops in the GR-DBD confers nuclear export to a GFP reporter
protein. NLS-mediated import and DBD-mediated export was proposed to form a
shuttling cycle, which integrates the compartmentalization and activity of nuclear
receptors.
2.1.2.2.5 Dimerization and DNA binding
Nuclear receptors regulate transcription by binding to specific DNA sequences in target
genes known as hormone response elements (HREs). After the GR is activated, it forms
a dimer, which binds to DNA at consensus sites called GREs in the promoter region of
target genes [Adcock 2000]. This interaction leads to activation or repression of these
genes.
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The rGR was shown to interact in solution as a dimer and this interaction is delimited to
a novel interface within the hinge region (488-527) of GR, which may be essential and
sufficient for direct protein-protein contacts between receptor monomers [Savory et al
200l]. Using GR homodimers isolated from rat liver cytosol it was shown that
dimerization of the GR involves both coiled-coil dimerization interfaces and the
conserved heptad repeats of leucine [Jaya et al 200l]. These leucine-rich regions of
proteins, called leucine zippers, are heptad repeats which contain leucine at every
seventh amino acid residue and were proposed as possible sites of protein dimerization
[Landshulz et aI1988]. Receptor dimerization is mediated partly through the LBD.
The functional significance of the GR dimer interface was confirmed by mutagenesis
studies [Bledsoe et al 2002]. Mutations in the dimer interface, mutant I628A and
P625A, decrease the transactivation potential of the GR LBD but have different effects
on transrepression. The P625A GR is inactive in repression and defective in nuclear
translocation upon ligand binding, whereas the I628A mutant has normal effects on
transrepression as well as nuclear localization. The I628A mutation decreases the LBD-
LBD dimerization affinity. The effects seen with the I628A mutant correspond to those
observed with the mouse GRdim mutant, which showed that a defect in DBD
dimerization results in GR activation function loss but has no affect on transrepression
activity [Reichardt et al 1998]. Therefore, a mutation in the dimer interface can
selectively decrease the potency for transactivation by the GR LBD.
The consensus sequence for GRE binding is a palindrome of the 15 base pair (bp)
sequence GGTACAnnnTGTTCT (n can be any nucleotide). The nGRE that leads to
repression of transcription has a more variable sequence (ATYACnnTnTGATCn)
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[Truss and Beato 1993]. The GREs that exhibit the highest affinity for GR are imperfect
palindromes separated by 3 bp, although many regulatory elements only contain one
half of the palindrome. The GR affinity for these half-GREs depends on the
dimerization status as well as on the GR interaction with other sequences. Optimal
binding, however, is seen with homodimers [Truss and Beato 1993]. The number of
GREs as well as their position relative to the transcription start site may be important in
determining the magnitude of the transcriptional response to GCs [Jantzen et al 1987;
Wieland et al 1990]. An increase in the number of GREs and their location relative to
the TATA box appears to increase the GC inducibility of a gene. However, other
transcription factors binding in the vicinity of the GRE may also influence the GC
inducibility.
DNA binding domain structure models of alternatively spliced or mutated GR variants
were constructed by QUANTA-and MODELLER based modelling, using the
crystallographic analysis of the GR DBD as template [Wickert and Selbig 2002].
Receptor function was based on the preservation or destruction of secondary structure.
The results showed that amino acid insertions of one, four or nine residues of existing
receptor splice variants did not have any effect on the secondary structure. In contrast, a
deletion of four amino acids at the splice site junction leads to changes in the secondary
structure of the DNA-recognition helix, which disturbs the receptor-DNA interaction.
Comparison of receptor function based on the molecular models, with experimental
results from in vitro studies, revealed that the two are closely related.
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2.1.2.2.6 Coactivators
The transcriptional activation of nuclear receptors involves the participation of
coactivators and corepressors, which function as amplifiers for receptor-mediated
transcriptional activation and repression, respectively. Coactivators and corepressors
interact with nuclear hormone receptors in a ligand dependent manner. In the hGRa two
domains have been found to be important for optimal transactivation of target genes
[Hollenberg et al 1988; DeRijk et al 2002]. The first one Tl (or AFI domain), is
hormone independent and located in the N-terminal part of the receptor, between amino
acid 77 and 262. The 't2 (or AF2 domain), also has transactivation properties and is
located in the LBD in the C-terminal region of the receptor. Hormone binding is
necessary for the activity of 't2. Binding of hGRa to GREs leads to the initiation of
transcription through a very complex mechanism involving the basic transcription
machinery, consisting of RNA polymerase II and transcription factors such as TBP,
which have to be recruited to the promoter [Beato and Sachez-Pacheco 1996a). The
transcriptional activity of the hGRa is dependent on coactivators that facilitate the
recruitment of the basal transcription machinery or remodel chromatin [Jenkins et al
2001).
Coactivators can be divided into two classes, namely members of the family of
switch/sucrose non-fermentable (SWIISNF) proteins and members of the histone
acetyltransferase (HAT) family (summarised in table 2.2) [reviewed by Collingwood et
al 1999]. Both classes of coactivators are able to modify the chromatin environment,
thus facilitating transcription indirectly by alleviating the repressive effects of histone-
DNA contacts. They can also influence the activity of the basal transcriptional
machinery directly through protein-protein contacts. The SWIISNF proteins were first
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Table 2.2. Nuclear receptor cofactors (taken from Collingwood et aII999).
Protein Nuclear receptor target Function
in vitro
Coactivators
SRC-I, NCoA-I ER, GR, PR, TR, RXR Acetyltransferase
Interacts with CBP
TIF2, GRIPI, NCoA2 ER, AR, GR, PR Interacts with CBP
P/CIP, ACTR, RAC3 ER, PR, TR, RAR Acetyltransferase
AIBI, TRAMI RXR,VDR Interacts with CBP, PCAF
PCAF RAR,RXR Acetyltransferase
Interacts with p300lCBP
p300lCBP ER, TR, RAR, RXR Acetyltransferase
Interacts with SRC-I/PCAF
Corepressors
NCoR,SMRT TR,RAR,RXR Interacts with SIN3 to recruit
ER + hormone antagonist histone deacetylase
PR + hormone antagonist
TIFla, TIFlp RAR Interacts with HP I and
histone deacetylase
characterized in yeast. Ligand-dependent transcriptional activation by the GR in yeast is
facilitated by several SWI gene products which are all part of a large SWIlSNF
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chromatin remodelling complex [Yoshinaga et al 1992]. Histone acetyltransferase
coactivators were identified by their interaction with the LBD of nuclear receptors in the
presence of receptor ligands and their HAT activity [Spencer et al 1997]. One group of
HAT coactivators is the p 160 family of which multiple variants have been isolated.
Their structural features are represented by SRC-l a. Three distinct members of the p 160
family have been isolated which exist as multiple splice variants and include
SRC/NCoA-1, TIF2/GRIPI/NCoA-2 and p/CIP/ACTRlRAC3/AIBl/TRAM-1.
Coactivators formed by CREB-binding protein (CBP) and p300 were shown to interact
directly with r l and indirectly with 't2 of the hGRa [Jenkins et al 2001]. The
coactivators have HAT activity, allowing them to acetylate histones in the promoter,
which enhances transcription. CBP/p300 can be recruited to GR and other nuclear
receptors directly through AF1, or indirectly through coactivators interacting with AF2
(example the p160 coactivator family) [Jenkins et al 2001]. Analysis of coactivators
revealed the presence of multiple highly conserved LXXLL helical motifs [Heery et al
1997]. These motifs are important for mediating the interaction between coactivators
and receptors by associating with critical residues in a coactivator interface region of the
receptor LBD. Mutation of these residues leads to abrogation of coactivator recruitment
and transactivation [Collingwood et aI1997].
Only a few coactivators have been investigated for GR interaction and include the
SWIISNF complex, the p300/CBP-associated factor (P/CAF) complex, CBP/p300, the
p160 coactivators and components of the vitamin D3 receptor-interacting protein
(DRIP) complex [Jenkins et al 2001]. Components of the SWIISNF complex interact
directly with the GR AF-I, and were shown to potentiate GR activity in yeast and
mammalian cells and in vitro. Members of the P/CAF complex were shown to be
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important for GR-dependent transcriptional activation in yeast and mammalian cells.
The SWIISNF complex and the P/CAF complex interact with AFI of the GR. Recently,
the coactivator, SRC-l, was shown to be downregulated by dexamethasone in vivo and
in vitro, indicating that ligand-mediated downregulation of SRC-l plays an important
role in GC action [Kurihara et al 2002]. However, dexamethasone had no effect on the
other coactivactors tested. The AF2 transactivation domain in GR is the only domain
needed for hepatic PEPCK gene expression and mutation of this domain disrupts the
direct interaction of GR with SRC-l [Kucera et al 2002]. TIF2 was shown to interact
directly with the GR in a hormone dependent manner and requires the receptor
interaction domains ofTIF2 [He et aI2002].
2.1.2.2.7 Corepressors
Coactivators facilitate activation of transcription by ligand-bound receptors whereas
corepressors repress transcription depending on the presence of specific receptors in the
absence of ligand (summarised in table 2.2) [reviewed by Collingwood et al 1999].
Many components of chromatin can non-specifically repress transcription but
corepressors are important in targeting the receptor. Two classes of corepressors have
been identified namely NCoR and the silence mediator of retinoic and thyroid receptors
(SMRT) [Chen et al 1995]. Corepressors, like coactivators, appear to exert important
functions through the modification of chromatin. Both classes of corepressors recruit
histone deacetylase to the receptor. The NCoR and SMRT corepressors interact with the
unliganded TR and RAR when associated with the retinoic X receptor (RXR) [Chen et
aI1995]. A region called the CoR box, in the hinge between the receptor DBD and the
LBD, has been identified as important for association with corepressors [Horlein et al
1995]. The TIFla and P family of corerepressors were identified by the ability of
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TIFla to interact with the LBD of the RAR in the presence of hormone [Le Douarin et
al 1996]. The GR antagonist, RU486 promotes interaction between the GR and the
receptor interacting domains of NcoR [Schulz et al 2002]. Ligand independent
interactions between the GR N-terminus and NCoR were identified and dexamethasone
and RU486 were found to recruit NCoR to the GR C terminus. Multiple NCoR motifs
were identified as being capable of interacting with the GR [Schulz et al 2002].
Substitution of Tyr735 in the human GR selectively impairs GC transactivation but not
transrepression, via reducing interaction with SRC-1, both basally and in response to
agonist binding. Recently, one of the three nuclear receptor interacting domains (NCoR-
Nl) of NcoR was found to interact with the GR C terminus in an RU486-specific
manner [Stevens et al 2003]. Substitution of Tyr735phe, Tyr735val and Tyr735ser,
which impairs SRC-1 interaction, enhanced NCoR-Nl recruitment, basally and with
RU486. As SRC-1 and NCoR are predicted to recognize a common hydrophobic cleft in
the GR, it may be that changes favorable to one interaction are not favourable to the
other one, thus identifying a molecular switch [Stevens et a12003].
2.1.2.2.8 Chromatin remodeling
Steroid-induced transcription of eukaryotic genes is tightly controlled and a critical
regulatory mechanism is the organization of the gene into chromatin [reviewed by
Collingwood et al 1999]. In the nucleus, DNA is wrapped around histone proteins,
forming chromatin. Highly compact regions of chromatin are associated with low
transcriptional activity, whereas less compact regions show higher transcriptional
activity [Elgin 1988]. Histone modification and HAT activity might be required to
disrupt chromatin or act subsequently to chromatin disruption [Aranda and Pascual
2001]. HAT activity is discussed in more detail under coactivators. DNA packaged as
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chromatin is resistant to nuclease attack and transcription factors have limited access to
their binding sites [Wolffe and Heyes 1999]. Therefore, the chromatin structure of
promoters is an obstacle to transcription that steroid hormone receptors must overcome.
Cells contain multiple distinct chromatin remodeling complexes, of which each have a
central ATPase subunit. The first complex characterized was the yeast SWIISNF
complex, which contains 11 known subunits [Cairns et al 1994]. In the mammalian
analogue, named SWI2/SNF2, two distinct ATPase subunits have been identified,
termed hBRM and BRG1 [Muchardt and Yaniv 1993]. These chromatin remodeling
complexes have been shown to enhance transcriptional activity by the GR in some
genes [Muchardt and Yaniv 1993].
The GR has been used as a model to study the effect of chromatin on steroid induced
transcription [Wallberg et aI2000]. The MMTV promotor provided general information
on the mechanism of GR-mediated transcription from a chromatin template [Deroo and
Archer 2001b]. In this promoter, chromatin remodeling by the GR is associated with
activation of transcription. When integrated in cellular chromosomes, the MMTV
promoter adopts a specific chromatin organization which consists of six positioned
nucleosome families called nucleosome region A (Nuc-A) to Nuc-F [Fragoso et al
1995]. Activation of the MMTV promoter by the GR is associated with a chromatin
structural transition in Nuc-B of the long terminal repeat. It was later shown that this
transition extends upstream of the B nucleosome, which includes a region larger than a
single nucleosome (LTR). Results also showed that GR-dependent chromatin
remodeling is a multistep process [Fletcher et al 2000]. In the absence of ATP, GR
binds to multiple sites on the chromatin array and prevents restriction enzyme access to
recognition sites. Upon addition of ATP, the GR induces remodeling and an increase in
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access to enzyme sites in the transition region. These results suggest a model in which
the GR binds to chromatin after ligand activation, recruits remodeling activity and is
then lost from the template. This model corresponds to the "hit and run" mechanism for
GR action in living cells which suggests that the receptor undergoes constant and rapid
exchange with HREs in the presence of ligand [McNally et aI2000]. Recently, Fletcher
et al further showed that human SWIISNF was recruited to MMTV chromatin by GR
and that the GR was actively displaced from the chromatin template during the
remodeling process but still participated in binding of the secondary transcription factor,
nuclear factor 1 [Fletcher et al 2002]. These results fit in with the model (hit and run)
where GR first binds to chromatin after ligand activation, recruits a remodeling activity,
facilitates transcription factor binding and is lost from the template.
The SWIISNF complex has been shown to alter nucleosome conformation in an ATP-
dependent way, which leads to increased accessibility of nucleosomal DNA to
transcription factors. In yeast and mammalian cells this complex potentiates the activity
of the GR through the N-terminal transactivation domain, 'ti [Wallberg et a12000]. GR-
r l can directly interact with the SWIISNF complex and r l mutations affect the
transactivation activity in vivo as well as affecting 'ti interaction with SWIISNF. The
SWIISNF can also stimulate r l-driven transcription from chromatin templates in vitro.
These findings suggested that the GR could directly recruit the SWIISNF complex to
target promoters during gene activation by GCs. Using domain mutations of the GR, the
domains required for activation of the MMTV promoter were divided into two
nucleoprotein configurations [Keeton et al 2002]. For activation of a stable template,
both transcriptional domains of the GR (t l and the LBD "t2) are required, but for
activation of the transient template, only the LBD is needed. Two cDNA clones were
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isolated, hOsal and hOsa2, which encode the larger subunits of human SWI/SNF [Inoue
et al 2002]. In mammalian cells, hOsal and hOsa2 stimulate transcription by the GR,
ER and AR, which suggest that they participate in promoting transcriptional activation
by the steroid hormone receptors.
The effect of GCs on the in vivo chromatin structure of the GC-responsive IKBa gene
promoter was also investigated. In the absence of GCs the promoter assembles into
regularly positioned nucleosomes, which does not change in the presence of GCs.
However, GCs may be required for transcription factor binding [Deroo and Archer
2001a]. IKBa is an inhibitor of the transcription factor NF-KB, which regulates many
immune system genes. GCs inhibit NF-KB activity in some tissues by increasing IKBa.
IKBa appears preset for transcription and requires GCs to activate transcription but not
to remodel chromatin. The GR-mediated activation of the IKBa promoter may be a
novel mechanism by which steroid hormone receptors stimulate gene expression from
single copy genes within chromosomes.
2.1.3 Physiological role of GCs
GCs are synthesized in the zonae fasciculata/reticularis of the adrenal cortex. They are
released into the circulation in response to a wide variety of stimuli for example: pain,
starvation, surgery, trauma, stress, extreme heat or cold, inflammation and cellular
damage [McKay and Cidlowski 1999 & Newton 2000]. The release ofGCs is regulated
by the hypothalamic-pituitary-adrenal (HPA) axis. The hypothalamus releases CRH and
arginine vasopressin (AVP), which acts on the anterior pituitary to induce synthesis and
release of adrenocorticotropic hormone (ACTH). ACTH in tum stimulates the adrenal
cortex to release GCs. GCs are transported in plasma bound to CBG with high affinity
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and to albumin with low affinity [Hammond 1990a & Hammond et al 1991]. Once in
the blood, GCs are transported to target organs where they have numerous physiological
effects.
GCs have a wide variety of functions in the body and affect many physiological systems
such as metabolism, immune function, bone density, the cardiovascular system,
behaviour and the HPA axis itself. The metabolic effects of GCs include the increase in
blood glucose levels, stimulation of gluconeogenesis in the liver and the mobilisation of
amino and fatty acids [Rosmond et al 1998] (Fig. 2.5). In addition, GCs have an
important effect on the immune system, as they are potent suppressors of the immune
response and inflammation. They are known to suppress the expression of
pro inflammatory cytokines, which are the key regulators of the immune response [De
Kloet et al 1994]. Synthetic GCs are widely used in the treatment of a broad range of
autoimmune and inflammatory disorders such as rheumatoid arthritis and asthma. They
are also used during organ transplants to suppress the immune system and to prevent
organ rejection [De Kloet et aI1994]. Although GCs are frequently used neonatally for
the prevention of chronic lung disease in premature infants, concern has arisen about the
long-term consequences of these treatments as animal research has shown that neonatal
GC treatment enhances susceptibility to autoimmune diseases in adult life [Bakker et al
2001].
Certain cardiovascular diseases like arteriosclerosis are considered to be the result of a
chronic inflammatory process. Evidence that repeated episodes of acute stress or
chronic physiological stress can induce a chronic inflammatory process have recently
been reviewed [Black and Garbutt 2002]. Stress activates the sympathetic nervous
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system, the HPA axis and the renin-angiotensin system, which causes the release of
various stress hormones like catecholamines, GCs, glucagons, growth hormones, rennin
and high levels of homocysteine. These hormones induce a heightened condition of
cardiovascular activity, injured endothelium and induction of adhesion molecules on
endothelial cells to which inflammatory cells adhere and trans locate to the arterial wall.
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Figure 2.5. Effects of GCs on the HPA axis. This scheme illustrates the sites of
synthesis and action of the main HPA hormones and the targets of GC action. Based on
analysis of dimerization defective mice, most of the effects of GCs are labelled as
dependent on (D) or independent of (I) GR DNA binding. Question marks indicate
those whose mechanism of action is uncertain [taken from Newton 2000].
An acute phase response (APR), characterised by macrophage and mast cell activation
and production of cytokines, other inflammatory mediators, and acute phase proteins
(APPs), is turned on which promotes the inflammatory process. The APR is defined as
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the body's response to any type of tissue damage and infection which causes a series of
physiological reactions to repair the damage, contain the organisms, promote wound
healing or recruit host defence mechanisms. The APPs are induced in the liver and may
be positive (upregulated) or negative (down regulated) in response to injury or infection.
The positive APPs are important during the inflammatory process while the negative
APPs are important carrier proteins like albumin and CBG. Cytokines are the main
inducers of the APR whereas GCs and catecholamines, the major stress mediators, can
enhance the induction to a greater or lesser extent [Baumann and Gauldie 1994]. GCs
can also directly stimulate the expression of most of the APPs.
2.1.4 Dissociative GCs
GCs are widely used for the suppression of inflammation in chronic inflammatory
diseases like asthma, rheumatoid arthritis, inflammatory bowel disease and autoimmune
diseases [Barnes 1998]. All of these inflammatory diseases are associated with an
increase in the expression of inflammatory genes that can effectively be suppressed by
GCs. A large number of side-effects such as diabetes, weight gain, hypertension and
osteoporosis are, however, associated with the long-term use of GCs [reviewed by
Schacke et al 2002a and summarized in table 2.3]. This has led to a search for novel
GCs with improved specificity for anti-inflammatory activity that dissociate between
transrepression and transactivation because many of the side effects of conventional
GCs may be attributed to transactivation [Adcock 2000, Dumont et al 1998, Cato and
Wade 1996].
According to the ability of GCs to induce or inhibit certain functions of the GR they
may be divided into three classes namely agonists and type I and type II antagonists.
Agonists induce AF-2 in the LBD with varying efficiency [Garcia et aI1992].
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Table 2.3. Summary of typical GC side-effects with the affected organs [taken from
Schacke et al 2002a].
Atrophy, stria rubrae distensae
Skin
Delayed wound healing
Steroid acne, perioral dermatitis
Erythema, teleangiectasia, petechia, hypertrichosis
Muscle atrophy/myopathy
Skeleton and muscle Osteoporosis
Bone necrosis
Glaucoma
Eye
Cataract
Disturbances in mood, behavior, memory and
CNS
cognition
"steroid psychosis", steroid dependence
Cerebral atrophy
Cushing's syndrome
Diabetes mellitus
Electrolytes, metabolism, Adrenal atrophy
endocrine system Growth retardation
Hypogonadism, delayed puberty
Increased Na+ retention and K+ excretion
Hypertension
Cardiovasculer system
Dyslipidemia
Thrombosis
Vasculitis
Immune system
Increased risk of infection (e.g. Candida)
Re-activation of latent viruses (e.g. CMV)
Peptic ulcer
Gastrointestinal Gastrointestinal bleeding
Pancreatitis
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In contrast in the presence of a type I antagonist, for example RU486, GR AF-2 will be
inactive. These antagonists, however, do not impair the activity of AF-I located in the
N-terminal region of the GR nor do they affect DNA-binding of the liganded receptor
and therefore may act as cell-specific partial agonists [Garcia et al 1992]. Type II
antagonists, like RU43044, on the other hand are able to impair DNA binding of GR
and do not induce transcriptional activity ofGR target genes [Bocquel et a11993].
A fourth, novel, class of GR ligands have come to the fore lately. These are called
dissociated GCs or selective GR agonists (SEGRAs) [Schacke et al 2002b]. Some
'dissociated GCs' that transrepress but do not trans activate have been described
[Vayssierre et al 1997, Vanden Berghe et al 1999] and it has been suggested that
dissociation may be due to inhibition of GR dimerization [Reichart et al 1998, Heck et
al 1994]. The proposed molecular mechanism of action of dissociative GCs compared
to full agonist is illustrated in Fig. 2.6. The dissociated GCs that have been described
include the synthetic GC, RU24858 (Fig. 2.7), that transrepresses AP-I activity in
HeLA cells but only weakly activates GRE-driven promoters [Vayssierre et aI1997]. In
vivo RU24858 also exhibits anti-inflammatory activity. However transactivation still
occurred with the same potency as for a standard steroid [Belvisi et al 2001]. This
suggests that the in vitro dissociation of transrepression from transactivation activity
does not necessarily mean an increased theurapeutic ratio for GCs in vivo or
alternatively that some of the adverse side effects of GCs may also be due to
transrepression.
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Figure 2.6. The proposed mechanism of action of dissociated GCs compared to full
GR agonists.
Miner et al reported a selective, non-steroidal GR antagonist, AL082D06 (D06), which
binds to the GR but not to the MR, AR, ER and PR [Miner et a12003]. This compound
inhibits GC-mediated transcriptional regulation, partially blocks GR translocation to the
nucleus and completely blocks DNA binding by the receptor. Another non-steroidal GR
ligand, A276575, with high affinity for the GR was described by the same group.
A276575 repressed IL-I induced IL-6 production and antagonised transactivation of a
MMTV GRE reporter construct [Lin et aI2002]. Another non-steroidal GR ligand, AL-
438 (Fig. 2.7), was able to selectively repress and activate genes normally regulated by
GCs [Coghlan et aI2003]. In addition, this compound was also tested in vivo and retains
full anti-inflammatory efficacy and potency compared to steroids, but has less negative
effects on bone metabolism and glucose control. Schacke et al also reported that non-
steroidal ligands that bind to the GR showed a good separation between transactivation
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of a TAT GRE reporter construct and transrepression of IL-8 protein [Schacke et al
2002b].
MPA (Fig. 2.7), an injectable contraceptive with GR agonist activity [Kontula et al
1983], has recently been shown to exert dissociative GC activity in normal human
lymphocytes [Bamberger et al 1999] . MPA treatment caused pronounced
transrepression of IL-2 gene expression whereas MPA-mediated transactivation of a
dexamethasone inducible GRE-dependent promoter was marginal. MPA displayed a
transrepressionltransactivation ratio of 6.6 relative to dexamethasone (ratio of 1)
indicating that it possessed significant dissociated properties [Bamberger and Schulte
2000]. MPA is also used in the treatment of metastatic endometrial, breast and renal
cancer but few studies have looked at the effect of MPA on the immune response. A
reduction in T-cell numbers in female breast cancer patients who received high doses of
MPA treatment was observed [Mallmann et al 1990]. It was also shown that MPA
inhibits lymphocyte proliferation [Kontula et aI1983].
Another compound reported to exert dissociative properties IS a phenyl aziridine
precursor, Compound A (Fig. 2.7) [De Bosseher unpublished results]. Compound A
(CpdA) is a more stable chemical analogue of the active compound in the shrub, Salsola
tuberculatiformis Botsch. The scrub is a a medicinal plant which has traditionally been
used by the Kalahari Bushmen for contraceptive purposes, is contraceptive in rats, and
causes prolonged gestation in sheep [Basson et al 1969]. The active fraction from the
shrub contains a highly labile hydroxyphenyl aziridine or precursor. The stable
analogue, CpdA, also cyclizes to the corresponding aziridine under physiological
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Figure 2.7. Structures of MPA, CpdA, AL-438, D06, dexamethasone and RU24858
[taken from Vayssiere et a11997; Coghlan et al2003 and Miner et aI2003].
conditions. However, in plasma, binding to CBG stabilized the precursor. CpdA and the
active fraction from the shrub, inhibits P450c11, the enzyme responsible for the final
step in the synthesis of corticosterone and cortisol [Louwet al 1997]. In addition, CpdA
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has contraceptive properties in rats by blocking the estrus cycle of these rats, and also
decreases CBG levels and increases free corticosterone levels in rats [Louwand Swart
1999]. CpdA also decreased ACTH and luteinizing hormone (LH) levels in rats. CpdA
repressed androgen-induced activation of both specific and non-specific androgen
response elements but does not compete with androgen for binding to the AR [Tanner et
al 2003]. This compound was shown to exert anti-inflammatory potential by down
modulating TNF-induced IL-6 gene expression, but it did not activate GRE-driven
promoters [De Bosseher unpublished results]. CpdA is therefore a potential non-
steroidal anti-inflammatory agent.
The search for dissociated GCs has up to now focused on the transrepressive effects on
NF-KB and AP-I mediated gene regulation [Dumont et al 1998; Adcock 2000;
Vayssierre et al 1997; Vanden Berghe et al 1999; Bamberger et al 1999]. The
regulation of CBG function, as a key modulator of GC action may, however, also be
important for full evaluation of any such drugs.
2.2 Corticosteroid binding globulin (CBG)
2.2.1 Function of CBG
In plasma GCs are bound to CBG, which when released translocate across the plasma
membrane and exert their effects by binding to a cytoplasmic GR. CBG is a steroid-
binding protein that binds steroid hormones, primarily GCs and progesterone, with high
affinity [Hammond 1990a & Hammond et al 1991]. The steroid-binding protein,
albumin binds these steroid hormones with low affinity but high capacity. Current
theory holds that plasma steroid-binding proteins transport steroid hormones in the
blood and regulate their access to target tissues [Sandberg et al 1966]. Only the
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unbound fraction of steroid hormones can enter target cells. Thus, steroid hormones
exist in two states in plasma, namely free and reversibly bound to proteins. The free,
unbound hormone is the biologically active fraction, which regulates the bio-availability
and metabolic clearance of GCs [Westphal 1986; Mendel 1989]. Binding to CBG has
been shown to affect the metabolic clearance rate of steroid hormones and thereby
protects steroid hormones from rapid metabolism [Siiteri et aI1982].
CBG identified in various cell types (Table 2.4), can arrive at these cells by active
cellular uptake over the cell membrane or by extra-hepatic synthesis. CBG is taken up
by cells, by binding of the CBG-GC complex to a membrane CBG receptor, which
transports the CBG-GC complex over the membrane or it is internalized by endocytosis.
Inside the cell, CBG can be cleaved to release GCs causing an increase in the amount of
free GCs available to activate intracellular receptors. CBG binding sites or likely
receptors have been identified in the human liver, decidual endometrium, placental
syncytiotrophoblast and prostate, rat spleen and liver and rhesus monkey kidney, spleen,
liver and uterus (Table 2.4) [Hryb et al 1986; Singer et al 1988; Strel'chyonok and
Avvakumov 1991; Maitra et al 1993]. Internalization of CBG has been detected in
human breast cancer and rat and human hepatoma cells [Kuhn 1988; Nakhla et a11988;
Khan et al 1984]. It is interesting to note that all reported sites of CBG receptors
correlate with sites where CBG has been reported to occur intracellularly lending
authority to the suggestion that the CBG receptor may be involved in cellular uptake of
CBG (Table 2.4). There is also proof that CBG, bound to its membrane receptor, can
activate intracellular second-messenger systems resulting in increased cAMP within the
cell. These studies were done in a breast cancer cell-line, MCF7, as well as in
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trophoblast cells from human embryos [Nakhla et al 1988; Strel'chyonok and
Avvakumov 1991].
Comparison of the human CBG with other protein sequences revealed that it was
structurally unrelated to any other steroid-binding proteins but shared remarkable
sequence similarity with several members of the serine protease inhibitor (SERPIN)
gene family [Hammond et al 1987]. These proteins may have arisen from a common
ancestral gene by a process of gene duplication [Underhill and Hammond 1989]. al-
proteinase inhibitor (aI-PI), al-antichymotrypsin (aI-ACT) and thyroxin binding
globulin (TBG) are the SERPINs the closest related to CBG. The members of the
SERPIN family contain a functional domain, which interacts with a specific serine
protease. The target enzymes for aI-PI and aI-ACT are elastase and cathepsin G,
respectively, and both are produced by activated neutrophils. Therefore, it was predicted
that CBG might act as a substrate for serine proteases at sites of inflammation.
Neutrophil elastase indeed does cleave the CBG molecule at a position, which is closely
related to the elastase binding site on aI-PI [Pemberton et al 1988]. This results in a
dramatic decrease in CBG steroid binding activity. Elastase cleavage of CBG occurs on
the surface of activated neutrophils from patients with acute inflammatory diseases like
sepsis [Hammond et al 1990b]. This may be an important role for CBG in the delivery
of GCs to the site of inflammation. The formation of free radicals by activated
neutrophils may oxidize an important methionine in the active site of aI-PI, which will
destroy its capability to inhibit neutrophil elastase. The elastases would then attack
CBG, which results in the release of GCs directly to the inflammatory cells. Thus in
addition to its function as transporter of steroid hormones CBG may also play a more
49
Stellenbosch University http://scholar.sun.ac.za
active role in delivering GCs to specific cells via its membrane receptors or at sites of
inflammation via elastase cleavage.
2.2.2 Structural analysis
CBG is a monomeric glycoprotein with a molecular weight of 50-60 kDa
[Strel'chyonok and Avvakumov 1990; Rosner 1991]. The polypeptide consists of 383
amino acids and contains only one steroid-binding site per molecule [Hammond et al
1987]. The amino acid composition of CBG indicates that the molecule is rich in
methionine and contains a few cysteine residues [Westphal 1986]. It also contains an
abundance of negatively charged amino acids that account in part for its acidic
isoelectric point (PI) and may be accentuated by the presence of carbohydrates. A
consensus sequence for N-glycosylation was identified at residue 9 (Asn) in the
sequence of the mature protein. The protein contains six consensus sequences for the
attachment of sugar chains of which five are used for glycosylation [Strel'chyonok and
Avvakumov 1990]. The presence of carbohydrates influences the half-life of plasma
proteins and removal of sialic acid residues by neuramidase clearly increases the
clearance of CBG by the asialo-glycoprotein receptor of the liver. In addition, variations
in carbohydrate composition may modify the interaction between CBG and target cell
membranes, and may thereby influence any biological response [Avvakumov and
Strel' chyonok 1988].
2.2.3 CBG synthesis
The liver is the major organ involved in the synthesis of CBG and more than 90% of
circulating GCs are bound to CBG in humans and rats [Dunn et al 1981]. Although the
liver is the major site of CBG synthesis, other cells have also been reported to
synthesize (extra-hepatic) CBG (Table 2.4). Extra-hepatic synthesis of CBG has been
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Table 2.4. Presence of CBG and CBG receptors in organs, tissue and cell lines.
CBG RECEPTORS
Organs,
Tissue or cell Species References Species References
lines
Brain human Kuhn 1988;
rat Turner 1986
Breast (normal, human Amaral and Werthamer 1976
neoplastic,
MCF7 cells)
Heart rat Turner et al 1986
Kidney human Siiteri et al 1982; Kuhn 1988; rhesus Strel' chyonok
rat Sera1ini 1996; Turner 1986; monkey and Avvakumov
Hammond 1990a; Feldman et al 1991;
1973 Maitra et al1993
Liver human Siiteri et al 1982; Kuhn 1988; human Stre1'chyonok
rat Sera1ini 1996; Turner 1986; rat and Avvakumov
Hammond 1990a; Perrot-Applanat et
rhesus
1991 ;
gumea
al1981 Maitra et al 1993
pIg monkey
Lung human Siiteri et a11982; Kuhn 1988;
rat Sera1ini 1996; Hammond 1990a
Lymphocytes human Kuhn 1988; Werthamer et al1973
Muscle human Siiteri et a11982; Kuhn 1988
Ovary human Seralini 1996; Misao et a11999a;
pIg Misao et al1999b
Pituatary human De Kloet and McEwan 1976; Koch et
rat al 1976; Perrot-App1anat et al 1984;
Kuhn 1988; Siiteri et al 1982;
Seralini 1996; Turner 1986
Placenta human Seralini 1996 human Strel' chyonok
(syncytiotro- and Avvakumov
phoblast
1991
Prostate human Hryb et al1986
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Uterus human Siiteri et al 1982; Kuhn 1988; rhesus Strel' chyonok
(endometrium rat Seralini 1996; Milgrom et al 1970; monkey and Avvakumov
Rosenthal et al 1974; Hammond 1991
& Ishikawa human
1990a; Al-Khouri et al 1980; Misao
cells) et al1994
Spleen Seralini 1996 rat Singer et al1988
rhesus
monkey
Testis human Seralini 1996
monkey
Thyroid rat Kuhn 1988
reported in lung, ovary, endometrium, trophoblast cells, foetal pancreas, neonatal
kidney and foetal pituitary [Hammond et al 1987; Scrocchi et al 1993; Berdusco et al
1995; Misao et a11995; Misao et a11999b; Seralini 1996; Benassayag et a12001]. CBG
mRNA and protein in the mammalian pituitary have been localized to the corticotropes
[Berdusco et al 1995]. The localization of CBG to different tissues may be required to
modulate GC action in these tissues.
2.2.4 eBG gene
2.2.4.1eBG gene organization
The CBG gene is located on chromosome 14q32.l [Seralini 1990]. The human and rat
CBG genes (Cbg) have been cloned [Underhill and Hammond 1989; Underhill and
Hammond 1995]. The human protein was found to be encoded by a single gene
consisting of five exons (exon I-V) distributed over about 19 kb of genomic DNA
[Underhill and Hammond 1988; Underhill and Hammond 1989]. The first exon spans
70 base pairs (bp) while exons II-V, span about 10.5 kb and contain the complete
coding sequence for CBG. Exon II contains a 19 kb untranslated sequence, which is
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followed by a coding region for 205 amino acids that includes the translation initiation
site and signal peptide for the CBG precursor. The translation stop codon is located in
exon Vand the 3' -boundary, which is defined by the polyadenylation site. Sequences
that resemble TATA and CAAT-box motifs were centred 28 bp and 73 bp, respectively,
upstream of the transcription start site.
The nucleotide sequence of the 5'-flanking region of the human CBG gene was
compared with the promoter region of other liver genes (mouse albumin and rat a-
fetoprotein). The results showed a similarity between the promoter regions of CBG and
the human and mouse albumin genes [Lichsteiner et al 1987]. Both contain six (A-F)
highly conserved sequence elements that in the mouse albumin promoter interact with
nuclear proteins for efficient, liver-specific expression. However, these binding sites
occur in a different order in the human CBG promoter and sites C, F and E are repeated.
Thus, the promoter regions of the albumin and CBG genes could have quite different
effects on gene expression.
The CBG gene was also compared to other SERPIN genes and was found to be the
closest related to the human cel-proteinase inhibitor and a1-antichymotrypsin genes.
These proteins may therefore be derived from a common ancestral gene [Underhill and
Hammond 1989]. The human genes encoding o.l-antitrypsin (aI-AT), CBG, aI-ACT,
protein C inhibitor (PCl), kallistatatin (KAL), as well as an antitrypsin related sequence
(ATR) all map to chromosome 14q32.1. An approximately 370-kb cosmid contig,
which includes all six SERPIN genes, has been characterised [Rollini and Fournier
1997]. These SERPIN genes are organised into two discrete subclusters of three genes
each that are separated by more or less 170 kb. The distal subcluster includes KAL, PCl
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and aI-ACT, occupying 63 kb of DNA while the proximal subcluster includes aI-AT,
ATR and CBG, occupying 90 kb of genomic DNA. These genes are all transcribed in a
distal-to-proximal orientation. The organization of the 14q32.1 gene cluster has
implications for the potential regulation of SERPIN gene expression in this region. The
relative proximity of SERPIN genes within each subcluster suggests that they might
share regulatory elements whereas the large distance between the two subclusters may
indicate that they are independently regulated [Rollini and Fournier 1997].
No consensus steroid hormone response elements seem to be present in the rat or human
CBG proximal promoter, although it has been shown that estrogens increase [Westphal
1971; Coolens et al 1987] and GCs repress [Westphal 1971; Smith and Hammond
1992] the CBG gene, suggesting that the steroid receptors may be acting through a
tethering mechanism that may not involve direct binding to the DNA. For example, the
GR may repress transcription via protein-protein interactions with other transcription
factors rather than by direct DNA binding [Boruk et al 1998; Rabek and
Papaconstantinou 1999; Wang et al 1999]. However, transrepression via direct binding
of the GR to DNA, via nGREs, cannot be excluded as nGREs have a very degenerate
sequence [MaIkoski and Dorin 1999; King et al 2002; Tumey and Kovacs 2001;
Subramaniam et al 1998; Zhang et al 1997; Aslam et al 1995]. Steroid hormone
response elements may also be located further upstream or within the introns, which
have not been sequenced.
DNase I footprinting of the rat CBG proximal promoter identified five protein-binding
sites (PI-P5) within 236 bp immediately 5' of the transcription start site in rat liver
nuclear extract [Underhill and Hammond 1995]. These five protein-binding sites are
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highly conserved in the human CBG gene. They resemble recognition sequences for
hepatic nuclear factor-1 (HNF-1), CCAAT-binding protein-2 (CP-2), D-site binding
protein (DBP), HNF-3 and CIEBP or NF1IL6, respectively.
Various luciferase reporter constructs were constructed by Underhill and Hammond to
identify cis-domains that play a role in the regulation of CBG gene expression in
H4IIEC3 rat hepatoma cells [Underhill and Hammond 1995]. The ratCBG295Luc
construct, which contains PI to P5 binding sites, was the most active of the constructs
tested. Deletion of the P3 to P5 sites in the ratCBG 145Luc construct caused a twofold
reduction in promoter activity. Also, removal of all five binding sites in ratCBG52Luc
resulted in a 13-fold loss in luciferase activity, with a further loss of function with the
extending of the promoter region in the ratCBG439Luc construct as well as in the
ratCBG800Luc construct. The repression is partially overcome by addition of sequences
in the ratCBGl200Luc construct. Thus, it was concluded that nt -295 to -52 represent a
positive component of Cbg transcription whereas additional 5' sequences repress
activity.
Electrophoretic mobility shift assays (EMSAs) confirmed that footprint one (P 1) binds
to HNF-1p [Underhill and Hammond 1995] and footprint two (P2) binds to CP2 [Zhao
et a/1997]. Many other genes predominantly expressed in liver, like CBG, also contain
an HNF-1 site in their proximal promoters. This includes several related serine
proteinase inhibitor genes, such as cd-antitrypsin, and thyroxine-binding globulin [De
Simone et a11987; Tani et a11994]. The CBG proximal promoter, containing only PI,
in addition to the TATA and CAAT box sequences, is insufficient to activate
transcription of a luciferase promoter gene. The presence of an additional 5' portion of
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the promoter that includes P2 is needed for transcriptional activity. To determine
whether this is due to synergy between factors binding to PI and P2, or whether P2 is
the main determinant of CBG transcription, PI was mutated, which prevented HNF-l
from binding [Zhao et al 1997]. The disruption of the HNF-l site had no effect on
transcriptional activity of the CBG proximal promoter that only contains PI and P2 but
it may be important for CBG expression in vivo because it is perfectly conserved in the
human and mouse. However, only the involvement of PI in the context of the CBG
proximal promoter was studied. Interactions between HNF-l~ bound to PI and other
upstream factors may affect the overall expression of the rat CBG promoter. The fact
that deletion of P2 from the CBG proximal promoter totally abolishes transcriptional
activity, suggests that P2 and the CCAAT-binding protein that interact with it, may be
important determinants of how under different physiological conditions the CBG gene
is expressed.
2.2.4.2 CBG gene abnormalities
A few rare deficiencies of CBG have been reported in humans. Three separate
mutations in the CBG gene have been described thus far (Fig. 2.8) [Van Baelen et al
1982; Emptoz-Bonneton et al 2000; Torpy et al 2001]. Sequence analysis of the first
mutant, called transcortin-Leuven, showed several mutations within the coding
sequence [Van Baelen et al 1982]. One of the mutations results in an amino acid
substitution and is located within exon 2. It alters the codon (CTC) associated with Leu-
93 in the CBG gene to a codon (CAC) for histidine in the mutant gene. The second
mutation, CBG-Lyon, located in exon 5, alters the codon for residue GAC to AAC,
which results in ASp367substitution for Asn [Emptoz-Bonneton et a12000]. The patient
with this mutation had normal urinary cortisol excretion and normal circadian ACTH
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variations, which indicates that the HPA-axis was unimpaired but low blood pressure
was detected. Both of these mutations lead to reduced cortisol-binding affinity. The
third mutant describes a novel complete loss of function (null) mutation of the CBG
gene [Torpy et al 2001]. This novel exon 2 mutation is a single base substitution
(c.121G to A), which leads to a premature termination codon at residue -12 of the pro-
CBG molecule. This mutation is associated with low blood pressure and fatigue but
ACTH and cortisol levels were normal.
Nul Leuven.... ...
ellen Scale I,____,j
200 bo
Figure 2.8. Schematic diagram of the CBG gene (24-kb region) with the three
mutations described to date in humans. Darker shaded regions of the exons are
untranslated. The mutations include CBG null: c.121G~A; Trp-12x, transcortin
Leuven: c.433T~A; Leu93His, and CBG Lyon: c1254G~A; Asp367Asn [Torpy et al
2001).
2.2.5 Regulation of CBG
CBG protein and RNA are regulated by numerous hormones, conditions and factors
which are summarized in Table 2.5 .
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Table 2.5: Summary of the hormones, conditions and factors known to regulate
CBG protein and mRNA levels.
Effect Hormone, condition Level of Species Site References
or factor effect
Decrease
Cushing's
protein human plasma
Westphal 1971;
syndrome Coolens et al 1987
Westphal 1971; Smith
decrease GCs protein rat; human plasma and Hammond 1992;
Schlechte et al 1987
Westphal 1971;
increase adrenalectomy protein rat plasma Feldman et a11979;
Grasa et al1998
Tinnikov et al 1993;
Tinnikov et a11999;
decrease stress protein rat plasma Fleshner et a11995;
Deak et a11997;
Leonhardt et al 2002
Pugeat et a11989;
decrease septic shock protein human plasma Westphal 1986;
Beishuizen et al2001
decrease burn patients protein human plasma
Garre11996;
Bernier et al1998
coronary artery Roth-Isigkeit et al
bypass patients; 2000;
decrease open hart surgery protein human plasma Tinnikov et al 1993;
major elective Tinnikov et al 1996
surgery Le Roux et al 2003
no effect GCs mRNA; human HepG2 cells Emptoz-Bonneton et alprotein 1997
mRNA; Emptoz-Bonneton et aldecrease IL-6 protein human HepG2 cells 1997; Baratlena et al
1993
decrease IL-6 + GCs mRNA; human HepG2 cells Emptoz-Bonneton et alprotein 1997
protein; foetal Berdusco et a11993;increase GCs plasma & liver Berdusco et a11994;mRNA sheep Jeffray et al1995
protein; Adult Berdusco et al 1993;decrease GCs pregnant plasma & livermRNA
sheep
Berdusco et al 1994
decrease GCs mRNA; baboon plasma & liver Pepe et al1996protein foetus
adult
no effect GCs protein pregnant plasma Pepe et al 1996
baboon
no effect GCs protein human plasma Jeffray et al1999foetus
adult
no effect GCs protein pregnant plasma Jeffray et al1999
human
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human
decrease GCs protein amniotic plasma Jeffray et al1999
fluid
increase progesterone .protein rat plasma Westphal 1971
no effect progesterone Protein; rat plasma & liver Smith and HammondmRNA 1992
increase progesterone mRNA human Luteal cells Misao et al 1999a
decrease progesteroneIMP A mRNA human Ishikawa cells/normal
Misao et a11994;
endometrium Misao et al1998
Westphal 1971;
Westphal 1986;
Abou-Sarnra et a11984;
increase pregnancy protein rat; human plasma Moore et aI1978;
Potter et a11987;
Robinson et a11985;
Hau et al1983
no effect estrogen protein; female rat plasma Westphal 1971;
mRNA Mataradze et al 1992
Westphal 1986;
Hammond 1990a;
increase estrogen protein male rat; plasma Coolens et a11987;human Misao 1999a; Darj et al
1993; Feldman et al
1979
Ishikawa cells; Misao et a11998;increase estrogen mRNA human ovarian corpus Misao et al1999a
luteum
decrease ovariectomy protein female plasma Westphal 1971rats
female
rats; Westphal 1971;
decrease testosterone protein castrated plasma Westphal 1986
rats and Mataradze et al 1992
men
no effect 5a- protein rat plasma Smith and Hammond
dihydrotestosterone 1992
Westphal 1971;
increase castration protein rat plasma Mataradze et a11992;
Nock et al 2000
Smith and Hammond
increase thyroxine mRNA; rat plasma 1992;protein D' Agostino and
Henning 1982
no effect thyroxine protein human HepG2 cells Rosner et al 1984
mcrease hyperthyrodism protein human plasma Westphal 1986;
Rosner 1991
increase triiodothyronine mRNA rat foetus hepatocyte Seralini 1996;Elfahime et al 1994
decrease triiodothyronine mRNA; human HepG2 cells Barlow et al 1994protein
decrease Retinoic acid mRNA rat foetus hepatocytes Seralini 1996;
Elfahime et al 1994
insulin & insulin- mRNA;decrease like growth factor human HepG2 cells Crave et al1995
(IGF-I) protein
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Fernandez-Real et al
decrease obesity protein human plasma
2001;
Fernandez-Real et al
2002
Westphal 1971;
decrease liver disease protein human plasma Westphal 1986;
Rosner 1991
2.2.5.1 GCs and cytokines
GCs, the main steroid transported by CBG, regulate the levels of its own transport
protein in a negative feedback loop. Thus, plasma levels of CBG are suppressed during
prolonged exposure to GCs, whether endogenous as in Cushing's syndrome [Westphal
1971; Coolens et al 1987] or exogenous as during administration of synthetic GCs
[Westphal 1971; Smith and Hammond 1992; Schlecte et al 1987]. In contrast, the
removal of endogenous GCs by adrenalectomy has been shown to increase rat plasma
CBG levels [Westphal 1971; Grasa et al 1998; Feldman et al 1979]. A number of
studies in rats also indicate that physiological and physical stressors down-regulate
CBG production [Tinnikovet al 1993; Tinnikov 1999; Fleshner et a11995; Deak et al
1997; Leonhardt et a12002] while the dramatic fall of human CBG levels during stress,
with concomitant substantial (2 to 20-fold) increases in free GC levels, merits its
classification as a negative acute-phase protein [Pugeat et al 1989; Garrel 1996;
Ingenbleek and Bernstein 1999]. Recent reviews also summarize the important role
played by CBG during the stress reaction [Black and Garbutt 2002; Breuner and
Orchinik 2002]. GCs, released during the stress response, take part in the early stages of
the stress response, including the inflammatory reaction.
A dramatic decrease in serum CBG levels is associated with septic shock in humans.
The decrease in the concentration of CBG during septic shock is associated with a low
binding activity for cortisol in serum [Pugeat et a11989; Beishuizen et aI2001]. Major
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stress, for example in bum patients with elevated serum ll__-6concentration, also results
in an decrease in CBG levels with a concomitant rise in free cortisol [Garrel 1996;
Bernier et al 1998]. In addition, major elective surgery, which is a severe stress that
occurs in a controlled environment, causes a rise in serum total cortisol and a decrease
in serum CBG [Le Roux et a12003]. During coronary artery bypass [Roth-Isigkeit et al
2000] and open-heart surgery [Tinnikovet al 1996] a rise in serum cortisol was also
observed due to a decrease in CBG concentration. Cardiac surgery induces a systemic
inflammatory response, which results in the secretion of mediators of the endocrine and
immunological stress reaction with cortisol playing an important part in the endocrine
stress reaction [Udelsman and Holbrook 1994]. The reason for this stress-induced
decrease in CBG is not fully understood but it has been hypothesized that CBG plays a
role in the delivery of cortisol to the sites of inflammation [Pugeat et al 1989]. This
dramatic decrease in CBG levels has been associated with impaired immune function.
In this regard, pro-inflammatory cytokines alone or in synergy with GCs have also been
shown to decrease CBG protein and hepatic mRNA levels in HepG2 cells, a human
hepatoma cell-line which secretes CBG, while GCs alone appear to have no significant
effect in this cell line [Emptoz-Bonneton et aI1997].
The regulation of CBG by GCs alone varies in mammals. GCs increased CBG protein
and mRNA in fetal sheep, while it decreased CBG protein and mRNA levels in adult
pregnant sheep [Berdusco et al 1993a; Berdusco et al 1994; Jeffray et al 1995]. The
ontogeny of CBG in primates differs from that in the ovine. In baboons, GC treatment
between early and midgestation decreased fetal but not maternal CBG concentrations,
which were unaffected by betamethasone treatment [Pepe et al 1996]. Women with
preterm labour usually receive synthetic GCs, which cross the placenta and promote
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fetal lung maturity. Fetal and maternal human plasma CBG levels were found to be
unaffected by GCs but amniotic fluid CBG concentration decreased significantly
[Jeffray et aI1999].
IL-6, the main mediator of the acute phase response regulates protein gene transcription,
either positively or negatively [Bartalena et al 1992; Morrone et al 1988]. lts action
appears to be mediated by the interaction of one or more transcription factors with IL-6
responsive elements identified in the cis-regulatory region of several acute phase protein
genes. The expression of CBG, TBG, AT and ACT genes is influenced by IL-6 in very
different ways although the genes for these proteins are very closely related in terms of
structural organization and are also derived from a common ancestral gene. IL-6
increases aI-AT and aI-ACT synthesis and decreases T4-binding globulin synthesis in
a human hepatoblastoma-derived cell-line (HepG2), predominantly at a transcriptional
level [Bartalena et a11993]. Hepatic CBG synthesis and CBG mRNA steady state levels
are dose-and time-dependently decreased by IL-6 [Bartalena et al 1993]. No detectable
change in the rate of CBG gene transcription was observed. Thus, IL-6 may affect CBG
synthesis at a posttranscriptional, but pretranslational level. The fact that changes in
CBG mRNA levels preceded by several hours the changes in secreted protein further
supports the pretranslational action of IL-6. In addition, no variations in electrophoretic
mobility of protein occurred in presence of IL-6, and the kinetics of CBG secretion was
unaffected.
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2.2.5.2 Progesterone
Progesterone, like GCs, binds to plasma CBG with high affinity, and changes in CBG
concentration are also thought to modify the bio-availability of this steroid. In addition,
like GCs, progesterone also regulates CBG levels. In rats results are contradictory: one
study reports that rat serum CBG or hepatic CBG mRNA levels were not influenced by
/
progesterone treatment [Smith and Hammond 1992] whereas in another study CBG
protein levels in rat plasma were increased by progesterone [Westphal 1971].
High dose progestin treatment is used in the treatment of advanced or recurrent
endometrial cancers as the cancers are estrogen dependent and regress in response to
progestin therapy. Endometrial adenocarcinomas express a high level of steroid
receptors and CBG [Ehrlich et al 1981; Misao et al 1995]. It was shown that high dose
progesterone or MPA (10-6M) suppresses CBG mRNA expression in a well-
differentiated endometrial cancer cell-line, Ishikawa, and in normal human
endometrium that contains estrogen and progesterone receptors [Misao et al 1994;
Misao et a11998]. Physiological concentrations of progesterone (lO-sM), however, had
no effect on CBG levels. In contrast, human luteal CBG mRNA appears to be
upregulated by progesterone treatment [Misao et al 1999a]. In addition, formation of
colonies of Ishikawa cells treated with a high dose of MPA did not differ from cells
treated with MPA in combination with an antiprogestin (RU486). This indicates that the
anti-tumour effects of high dose progestins may not be brought about via the
progesterone receptor cascade, but rather via cytotoxic effects on the tumour cells.
Thus, the suppression of CBG mRNA expression might be related to the cytotoxic
effects [Misao et al 1999a].
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2.2.5.3 Estrogen and pregnancy
CBG plasma protein levels increase during pregnancy in rats and humans [Westphal
1971; Westphal 1986; Abou-Samra et al 1984; Moore et al 1978; Potter et al 1987;
Robinson et al 1985; Hau et al 1983] or after administration of natural or synthetic
estrogens in humans [Westphal 1971; Westphal 1986; Hammond 1990a; Coolens et al
1987; Misao et al 1999b; Darj et al 1993]. Treatment of rats with natural estrogens
stimulated the rate of CBG production in male rats [Feldman et al 1979] but had no
significant effect on serum CBG or hepatic CBG mRNA levels in female rats despite
the fact that the serum CBG level of mature female rats was more than double that of
male rats [Mataradze et aI1992]. In addition, 17p-estradiol (E2) significantly increased
CBG mRNA expression in a dose- dependant manner, in a well-differentiated
endometrial cancer cell-line, Ishikawa, and was positively correlated with human
ovarian corpus luteum CBG mRNA levels [Misao et a11998; Misao et aI1999a].
2.2.5.4 Androgens
Testosterone decreases CBG protein levels in female or castrated male rats and men
[Mataradze et al 1992; Westphal 1971; Westphal 1986] while castration just before or
after puberty increased CBG concentration in male rats [Nock et al 2000]. The androgen
5a-dihydrotestosterone, however, has no effect on serum CBG nor on hepatic CBG
mRNA levels in rats [Smith and Hammond 1992].
2.2.5.5 Thyroid hormones and retinoic acid
Thyroxine administration to intact rats increases serum CBG as well as hepatic CBG
mRNA levels [Smith and Hammond 1992; D'Agostino and Henning 1982]. It has,
however, been suggested that the increase in CBG mRNA steady state levels may be
due to increased mRNA stability rather than increased transcription [Smith and
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Hammond 1992]. In contrast, in a human hepatoma cell line thyroxine did not affect
CBG levels [Rosner et al 1984] but hyperthyroidism did increase plasma CBG levels
[Rosner 1991; Westphal 1986].
CBG gene expression is regulated in an antagonistic way by triiodothyronine and
retinoic acid in fetal rat hepatocytes [Seralini 1996]. Triiodothyronine activates while
retinoic acid inhibits CBG gene expression [Elfahime et al 1994]. In a human
hepatoblastoma-derived cell line, triiodothyronine attenuates CBG gene expression and
CBG protein levels [Barlow et aI1994].
2.2.5.6 Insulin, insulin-like growth factor (IGF-I), insulin resistance and obesity
Insulin and IGF-1 were shown to dose-dependently inhibit CBG mRNA and protein
levels in HepG2 cells [Crave et al 1995]. In one study, however, no correlation was
found between insulin and CBG levels in the case of insulin variations during diabetes
or obesity [Seralini 1996]. Recently, in other studies, decreased CBG levels were,
however, associated with obesity and indexes of insulin resistance such as body mass
index (BMI), waist to hip ratio (WHR) and fasting insulin resistance index (HOMA) in
both men and women [Fernandez-Real et a12001; Fernandez-Real et a12002].
CBG, a member of the SERPIN family, is a substrate for elastase, which is expressed at
the surface of neutrophils [Rosner et al 1990; Hammond 1990b]. The change in
circulating CBG levels during obesity might be due to the cleavage of CBG by activated
neutrophils [Hammond 1990b] as an increase in peripheral white blood cell count and
neutrophils are found in obesity [Targher et a11996] and insulin resistance [Fernandes-
Real et al 2000]. This might facilitate serine protease availability and CBG cleavage.
This mechanism could contribute to the reduced CBG levels observed during obesity
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and insulin resistance. A 50% decrease in CBG levels was recently found in a woman
with obesity and chronic fatigue, due to a CBG gene mutation [Emptoz-Bonneton et al
2000]. These findings suggest that low CBG levels may not only be a result of obesity
but could contribute to the development of obesity. Thus, low CBG could be a marker
for the development of type 2 diabetes as well as cardiovascular disease.
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CHAPTER3
Corticosteroid binding globulin gene regulation
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3.1 INTRODUCTION
CBG, produced primarily in the liver, transports and modulates the bioavailability of
glucocorticoids and progesterone in plasma [Hammond 1990a; Hammond et al 1991;
Seralini 1996]. According to the free hormone hypothesis only the free fraction of
steroid hormone is biologically active and able to diffuse across the plasma membrane
of target tissues. The ratio between free and bound steroids depends on the number of
binding sites (concentration of plasma CBG) and the affinity (Kd) for the binding sites.
This implies that any changes in the levels of CBG would modify the distribution of
steroids to target tissues [Westphal 1986; Mendel 1989]. Several factors influence CBG
production as discussed briefly below but in more detail under section 2.2.5.
Plasma levels of CBG are suppressed during prolonged exposure to GCs, endogenously
as in Cushing's syndrome [Westphal 1971; Coolens et a11987] as well as exogenously
as during administration of synthetic GCs [Westphal 1971; Smith and Hammond 1992;
Schlecte et al 1987]. In contrast, adrenalectomy has been shown to increase rat plasma
CBG levels [Westphal 1971; Grasa et al 1998; Feldman et al 1979]. In rats
physiological and physical stressors, such as fasting, physical exercise, cold exposure
and water deprivation, down-regulate CBG production [Tinnikovet al 1993; Tinnikov
et al 1999; Fleshner et al 1995; Deak et al 1997; Leonhardt et al 2002]. In humans,
CBG levels are dramatically decreased in septic shock [Pugeat et al 1989; Beishuizen et
a12001; Westphal 1986], severe bum [GarreI1996; Bernier et aI1998], coronary artery
bypass patients [Roth-Isigkeit et al 2000] and open-heart surgery [Tinnikovet a11993;
Tinnikov et al 1996]. Pro-inflammatory cytokines alone, or in synergy with GCs, have
also been shown to decrease CBG protein and mRNA levels in HepG2 cells, a human
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hepatoma cell-line which secretes CBG, while GCs alone appear to have no significant
effect in this cell line [Emptoz- Bonneton et al 1997].
Progesterone or MPA suppresses CBG mRNA expression both in a well-differentiated
human endometrial cancer cell line, Ishikawa, and in normal human endometrium
[Misao et al 1994; Misao et al 1998]. However, in human luteal cells CBG mRNA
appears to be upregulated by progesterone treatment [Misao et al 1999a]. In rats, one
study reports that rat serum CBG or hepatic CBG mRNA levels were not influenced by
progesterone treatment [Smith and Hammond 1992] whereas in another study CBG
protein levels in rat plasma were increased by progesterone [Westphal 1971].
CBG plasma protein levels increase during pregnancy in rats and humans [Westphal
1971; Westphal 1986; Abou-Samra et al 1984; Moore et al 1978; Potter et al 1987;
Robinson et al 1985; Hau et al 1983] or after administration of natural or synthetic
estrogens in humans [Westphal 1971; Westphal 1986; Hammond 1990a; Coolens et al
1987; Misao et al 1999a; Darj et al 1993]. Testosterone on the other hand decreases
CBG protein levels in female or castrated male rats and men [Mataradze et al 1992;
Westphal 1971; Westphal 1986], while castration per se increased CBG concentrations
in male rats [Nock et al 2000]. Insulin and IGF-l were shown to inhibit CBG mRNA
and protein levels in HepG2 cells [Crave et al 1995] and recently, insulin was also
associated with decreased serum CBG levels in humans, as was obesity [Fernandez-
Real et a12001; Fernandez-Real et a12002].
Despite the fact that both the human and rat CBG genes (Cbg) have been cloned, no
regulatory studies to identify possible cis-acting sequence elements involved in their
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regulation by hormones have been done [Underhill and Hammond 1989; Underhill and
Hammond 1995]. DNase I footprinting of the rat CBG proximal promoter, has
identified five protein-binding sites (P1-P5) within 236 bp immediately 5' of the
transcription start site in rat liver nuclear extract [Underhill and Hammond 1995]. These
five protein-binding sites are also highly conserved in the human CBG gene. They
resemble recognition sequences for HNF-1, CP-2, DBP, HNF-3 and C/EBP or NF/IL6,
respectively [Underhill and Hammond 1995]. Organization of the CBG gene is
discussed in more detail under section 2.2.4.1.
Although CBG transcription is modulated by steroid hormones no steroid hormone
response elements seem to be present in the rat or human CBG proximal promoter,
suggesting that the steroid receptors may be acting through a tethering mechanism that
may not involve direct binding to the DNA (see section 2.1.1 for a full discussion of
mechanisms whereby GR regulate gene transcription). For example, the GR may
repress transcription via protein-protein interactions with other transcription factors
rather than by binding to GREs directly. Footprint P3-P5 resemble recognition
sequences for DBP, HNF-3 and C/EBP or NF-IL6 and, although binding of these
transcription factors have not been confirmed, it is interesting to note that HNF-3 and
CIEBP have been reported to form protein-protein interactions with the GR [Boruk et al
1998; Rabek and Papaconstantinou 1999; Wang et a11999; Hoeke et aI1992].
3.2 AIM OF STUDY
In the present study I investigated the effect of various physical stressors on rat liver
CBG mRNA production as well as the effect of several hormones reported to influence
CBG production on CBG mRNA and protein levels in a hepatic cell line. I also
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determined if the mRNA and protein results correlate with the transcriptional regulation
of the rat eBG proximal promoter. Only Ge transrepression was investigated in more
detail. Further experiments were done to delineate the Ge responsiveness on the rat
eBG promoter and to determine if the Ge responsiveness is GR dependent.
3.3 RESULTS
3.3.1 Regulation of eBG mRNA by physical stressors in rats
Physical stressors like exercise have been shown to down-regulate eBG production
with a concomitant increase in free Ge levels. In female rats physical exercise,
influencing metabolic homeostasis, like swimming and fasting were shown to decrease
circulating eBG protein levels [Tinnikov 1999]. They proposed that the need for
substantial mobilization of spare fuel (that takes place during physical exercise or
fasting) is critical in involving eBG in the stress response. Recently, stressful
conditions such as malnutrition and restraint were also shown to decrease eBG protein
levels in rats [Lesage et al 2002]. These data in malnourished rats suggests that an
increase in basal concentration of corticosterone, after reduced eBG levels, will lead to
a larger impact of corticosterone on target cells that mediate the negative-feedback
mechanism on the activity of the HPA axis. In a collaborative study (Physiological
Sciences) we obtained livers from rats that were subjected to exercise stress. This
allowed us the opportunity to investigate the effect of exercise stress on eBG mRNA
levels. In addition we included an extra group of rats to study the effect of Cpd.A on
eBG mRNA levels and to compare the effect of Cpd.A with exercise stress (results in
chapter 4).
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Voluntary exercise causes many positive biological effects whereas endurance training
because of its excessive physical demand can cause injuries, reproductive disturbances,
impaired immunity and chronic stress-like changes in the HPA-axis [Droste et al2003].
In this study we investigated the effect of voluntary running, involuntary swimming and
immobilization compared to the sedentary group, which was used as the control, on rat
mRNA CBG levels (Fig. 3.1).
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Figure 3.1. Regulation of rat CBG mRNA levels by physiological stressors. Adult
male Wistar rats were subjected to voluntary running (Run), involuntary swimming
(Swim) or immobilization (Immob) treatment for ten days (see materials and methods
for details). Rats were decapitated and livers removed for RNA isolation. Statistical
analysis was done to compare values in the presence of test conditions relative to the
corresponding control (sedentary rats) using one-way ANaVA followed by Dunnett's
multiple comparison's posttest (**: P<O.Ol).
The experiment protocol and RNA isolation from rat livers are explained under the
materials and methods section 6.5.2. CBG mRNA levels were determined by Northern
blotting using a rCBG probe and p-actin was used as an internal control (materials and
methods section 6.5.4). Results showed that voluntary running had no significant
(P>O.05) effect on rat CBG mRNA levels but psychological stressors like involuntary
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swimming and immobilization significantly decreased (P<O.Ol) rat CBG mRNA levels
compared to the control and the volutary running group.
3.3.2 Regulation of eBG mRNA and protein levels in hepatic cells
Glucocorticoid levels increase during exercise and are a marker of the physical stress
associated with this activity [Duclos et a12003; Peijie et a12003]. Thus, to follow up on
the rat study and specifically to evaluate the effects of glucocorticoids we investigated
the effect of dexamethasone, a potent synthetic glucocorticoid, on CBG mRNA and
extra-cellular protein levels in HepG2 cells, a hepatic cell line that secretes CBG. CBG
mRNA levels were determined by Northern blotting using a hCBG probe and p-actin
was used as an internal control (materials and methods 6.5.4). Extra-cellular CBG
protein levels were determined by a RIA. E2 was included in the study as a positive
control whereas insulin was included as a negative control, because previous results had
showed that E2 increased [Misao et al 1998] whereas insulin decreased human CBG
mRNA levels [Crave et a11995]. The study was conducted in the presence and absence
of fetal calf serum (FCS) (Fig. 3.2A & B). This was done to study the effect of the
hormones on CBG mRNA and protein levels in the absence (-FCS) as well as in the
presence (+FCS) of exogenous steroids and growth factors [Botti et a11997; Lamb et al
1999].
Dexamethasone and insulin significantly decreased (P<O.Ol) CBG mRNA levels with or
without FCS in HepG2 cells with insulin repression being more pronounced in the
presence of FCS. E2 on the other hand significantly increased (P<O.Ol) only CBG
mRNA levels in the presence of FCS. The fact that FCS enhanced the effect of insulin
and E2 on CBG mRNA levels may be due to the presence of steroids and growth factors
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Figure 3.2. Regulation of CBG (A) mRNA levels and (B) extracellular protein
levels. The effect of dexamethasone (Dex), p-estradiol (E2) and insulin (Ins) on CBG
mRNA and extracellular protein levels was investigated in a human hepatoma cell-line
(HepG2) in the presence or absence of FCS. HepG2 cells were cultured as described in
materials and methods and incubated with test compounds for 72 hrs. The concentration
of all hormones was 1 )lM. Control wells received an equal amount of ethanol.
Statistical analysis was done to compare values in the presence of test compounds
relative to the corresponding control using one-way ANOVA followed by Dunnett's
multiple comparison's posttest (*: P<0.05; **: P<O.OI).
in FCS, which would increase the concentration of insulin and estrogen present [Botti et
al 1997; Lamb et al 1999]. Although controversy exists about whether HepG2 cells
contain endogenous ER, with some authors suggesting that it does [Tam et al 1986]
while others show that only low levels [Marino et al 2001] or no ER [Barkhem et al
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1997] is present, our results seem to indicate that the cells we are using do contain
endogenous ER. However, it has also been shown that HepG2 with low levels of ER
may mediate non-genomic actions of ER and this should not be discounted in our
system [Marino 2001]. To establish whether our HepG2 cell line contains endogenous
ER Western blots and transactivation studies with ERE-containing promoters should be
conducted.
In the absence of FCS, the expression of E2 receptors [Medrano et al 1990] has been
shown to be increased but the presence of FCS down- regulates insulin receptors
[Hwang et al 1985]. Also, when human breast cancer cells are grown without E2
addition, a progressive and transient increase of ER RNA was observed, but when cells
are cultured with E2 the ER RNA increased early and remained higher than in the
absence of E2 [Piva et al 1988]. These results from the literature do not, however,
explain why FCS enhanced the effect of insulin and E2 on CBG mRNA levels. This
study was performed in a human hepatoma cell-line and regulation in this cell-line may
differ. Extracellular CBG protein levels were slightly increased by E2 and decreased by
insulin but only significantly (P<0.05) in the absence of serum. Dexamethasone also
slightly decreased CBG protein levels, both with and without FCS, although not
significantly.
Previous studies done by Crave and Emptoz-Bonneton in HepG2 cells also used 1 I-lM
hormones (E2, insulin and dexamethasone), as we did, but were only done in the
absence ofFCS [Crave et a11995; Emptoz-Bonneton et aI1997]. In the current study 1
I-lMdexamethasone significantly decreased CBG mRNA levels in contrast to the study
by Emtoz-Bonneton et al that showed no effect [Emptoz-Bonneton et a11997]. In their
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study cells were incubated with steroids for 48 hrs whereas in our study the incubation
time was 72 hrs. This may account for the difference in the results. Crave et al also
tested the effect of 1 J.lME2 on CBG mRNA levels in the absence of FCS and like in
this study found no effect on CBG mRNA levels in the absence of FCS [Crave et al
1995]. The decrease in CBG mRNA levels by insulin in their study in the absence of
FCS also corresponds to the decrease in CBG mRNA levels by insulin found in this
study.
3.3.3 Regulation of the rat CBG proximal promoter
To determine if the results of the protein and mRNA determinations correlated with
transcriptional regulation of the rat CBG promoter, mouse hepatoma BWTG3 cells,
were transiently transfected with the full length rat CBG proximal promoter reporter
construct (ratCBGI200Luc) as well as truncated versions thereof (ratCBG295Luc and
ratCBGl45Luc) as described in materials and methods section 6.6.1 (Fig. 3.3A). The
ratCBG295Luc promoter reporter construct contains the five protein-binding sites
identified by DNase I foot printing namely PI-P5 [Underhill and Hammond 1995]. The
transcription factor binding at PI has been identified as HNF-l [Underhill and
Hammond 1995] and at P2 as CCAAT-binding protein-2 (CP-2) [Zhao et al 1997]
while for P3-P5 the putative binding factors are DBP, HNF-3 and C/EBP, respectively.
The ratCBG 145Luc promoter reporter construct contains only the binding sites for
HNF-l and CP-2 [Underhill and Hammond 1995].
An initial experiment was conducted to determine the basal transcriptional activity of
each of the constructs (Fig. 3.3B). Of the three constructs tested the ratCBG145Luc
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Figure 3.3. Rat CBG proximal promoter. (A) A schematic presentation of the full-
length rat CBG proximal promoter reporter construct (ratCBG I200Luc) and truncated
rat CBG promoter reporter constructs (ratCBG295Luc and ratCBGI45Luc) indicating
the position of the five protein-binding sites PI-P5 by showing boxes with the putative
transcription factors binding at these sites. (B) Basal expression levels of the three
constructs represented in (A) were investigated in BWTG3 cells. BWTG3 cells were
cultured as described in materials and methods. The cells were transiently transfected
with the indicated promoter reporter constructs. In addition a p-galactosidase expression
plasmid (pPGKpGopbA) was co-transfected to monitor for transfection efficiency.
Luciferase activity was determined in the cell lysates 24 h after induction and values
were normalized for p-galactosidase. Statistical analysis was done to compare basal
expression levels between constructs using one-way ANOYA followed by Bonferonni's
multiple comparison's posttest comparing all columns (*: P<O.05; ***: P<O.OOI). All
constructs were significantly (P<O.OOI)different from the control.
77
Stellenbosch University http://scholar.sun.ac.za
promoter reporter construct had the highest basal activity followed by the
ratCBG 1200Luc construct, while the ratCBG295Luc promoter reporter construct had
the lowest basal activity (Fig. 3.3B). The ratCBG1200Luc construct differs
significantly from the ratCBG295Luc promoter reporter construct (P<O.05). There is
also a significant difference between the ratCBG295Luc construct and the
ratCBG145Luc promoter reporter construct (P<O.OOl). Reporter studies by Underhill et
ai, using the same constructs showed the opposite, with the ratCBG295Luc promoter
reporter construct having the highest basal activity followed by the ratCBG1200Luc and
then the ratCBG145Luc promoter construct [Underhill and Hammond 1995]. They used
a rat cell-line (H4IIEC3) to transfect these constructs whereas in this study a mouse cell-
line (BWTG3) was used, which may influence the basal expression of these constructs.
We then investigated the effect of vanous test compounds (dexamethasone,
hydrocortisone, progesterone, insulin, IL-6 and E2) on the transcriptional regulation of
each of the CBG reporter promoter constructs transiently transfected into BWTG3 cells,
as well on a stable transfection of the ratCBG295Luc construct in BWTG3 cells (Fig.
3.4). Dexamethasone, as a potent synthetic glucocorticoid, and hydrocortisone, as an
endogenous glucocorticoid, was chosen to further explore the effects of glucocorticoids
on CBG transcription. Insulin and estradiol were chosen because we had also previously
(Fig. 3.2) shown effects on CBG mRNA levels. Finally, IL-6 and progesterone were
included because others had shown that they regulate CBG levels [Emptoz-Bonneton et
a11997; Misao et ai1994; Misao et ai1998].
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Figure 3.4. Hormonal regulation of the rat CBG proximal promoter and deletion
constructs. The effect of the glucocorticoids, dexamethasone (DEX) and
hydrocorticosterone (HC), as well as progesterone (P), insulin (Ins), mouse interleukin-
6 (mIL-6) and 1713-estradiol (E2) on the transiently transfected (A) full length rat CBG
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proximal promoter construct (ratCBGI200Luc) and truncated rat CBG promoter
reporter constructs, (B) ratCBG295Luc and (C) ratCBGl45Luc, was investigated in
BWTG3 cells. BWTG3 cells were cultured as described in material and methods. The
cells were transiently transfected with the indicated promoter reporter constructs.
BWTG3 cells were also (D) stably transfected with the ratCBG295Luc construct. In
addition a ~-galactosidase expression plasmid (pPGK~GopbA) was co-transfected to
monitor for transfection efficiency. Twenty-four hrs after transfection hormones were
added at a concentration of 111M, except in (D) where 10 11ME2 was also used. Control
wells received an equal amount of ethanol. After a further 24 hr incubation cells were
lysed and luciferase activity was determined. Luciferase values were normalized for ~-
galactosidase and values plotted as a percentage of the average control. Statistical
analysis was done to compare values in presence of test compounds relative to the
corresponding control using one-way ANOVA followed by Dunnett's multiple
comparison's posttest (*: P<0.05; **: P<O.OI).
Progesterone (111M) only transrepressed (with 22.4 ± 2.7 % inhibition) the transiently
transfected ratCBG295Luc reporter construct to a significant degree (P<0.05) while in
stable transfections repression was seen but not to a significant degree.
Insulin (111M) also transrepressed all constructs except the ratCBGI45Luc promoter
reporter construct. However, only transrepression (46.5 ± 4.7 % inhibition) of the stably
transfected ratCBG295Luc is significant (P<O.OI) and compares well with the decrease
in CBG mRNA levels (64.6 ± 4.1 % inhibition) by insulin. In transient transfections, the
expression vectors are introduced into cultured cells and expressed transiently, without
replication or integration into the cellular genome [Smith and Hager 1997]. However, in
stable transfections, gene promoters are integrated into mammalian cells and are
subjected to effects from surrounding chromatin. There was no difference in the effect
of insulin between the transiently and stably transfected CBG promoter reporter
constructs, which suggests that insulin regulation of the CBG promoter may not involve
chromatin remodelling.
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Mouse interleukin 6 (mIL-6) at 1 JlM had no significant effect on any of these CBG
promoter reporter constructs whether transiently or stably transfected. However, mIL-6
together with dexamethasone (1 JlM) significantly transrepressed the ratCBG1200Luc
(P<O.Ol) and ratCBG295Luc (P<0.05) promoter reporter constructs transiently
transfected as well as the stably transfected ratCBG295Luc (P<O.Ol). This repression
may only be due to dexamethasone alone as there is no significant (P>0.05) difference
between the repression by dexamethasone only as compared to the repression by
dexamethasone together with mIL-6.
The transiently transfected ratCBG1200Luc reporter construct was unaffected by E2
(1 JlM), whereas the ratCBG295Luc promoter reporter construct was significantly
transactivated (P<O.Ol). The ratCBG145Luc was, however, significantly repressed by
E2 (P<O.Ol). Only at higher concentrations of E2 (lO JlM) was transactivation
significantly increased (P<O.Ol) when the ratCBG295Luc promoter reporter construct
was stably transfected. This indicates that when the ratCBG295Luc was stably
transfected it is less reactive to activation by E2. The differences between transient and
stable transfections could account for the variations in effects observed.
The fact that the transiently or stably transfected ratCBG295Luc construct was
significantly transactivated (P<O.Ol) by E2 (209.5 ± 13.5 % activation of the transiently
(1 JlM E2) transfected ratCBG295Luc and 174.8 ± 5.3 % activation of the stably (10
JlM E2) transfected ratCBG295Luc) while transactivation was abrogated with the
ratCBG 1200Luc reporter construct indicates that transcription factors further
downstream of the ratCBG295Luc may prevent activation by E2. The activation of the
ratCBG295Luc promoter reporter construct (174-209 % activation) by E2 corresponds
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to the increase in CBG mRNA levels (144.5 ± 5.3 % activation) by E2. However, the
comparison between the mRNA effects and the promoter experiments should be treated
with caution as these experiments were done in two different cell lines, one human and
the other mouse.
The GCs, dexamethasone and hydrocortisone, at 1 ~M, significantly transrepressed
(P<O.OI) the transiently transfected ratCBG1200Luc and ratCBG295Luc promoter
reporter constructs as well as the stably transfected ratCBG295Luc construct (Fig. 3.4
A, B and D). However, GCs had no effect on the ratCBG145Luc promoter reporter
construct (Fig. 3.4C). Dexamethasone resulted in a 35.8 ± 7.7 % inhibition (P<O.OI) and
hydrocortisone in a 37.4 ± 4.4 % inhibition (P<O.OI) of the transient ratCBG295Luc
construct. For the ratCBG 1200Luc construct, dexamethasone resulted in a 40.3 ± 4.3 %
inhibition (P<O.OI) and hydrocortisone in a 29.3 ± 2.2 % inhibition (P<O.OI). Also,
dexamethasone resulted in a 41.1 ± 1.1 % inhibition (P<O.OI) and hydrocortisone in a
43.2 ± 2.3 % inhibition (P<O.OI) of the stably transfected ratCBG295Luc construct.
There is no significant difference between the percentage inhibition of the reporter
constructs by dexamethasone and hydrocortisone observed with the ratCBG295Luc
construct and the ratCBG 1200Luc construct nor with the ratCBG295Luc stably
transfected. The fact that results for the transient versus stably transfected
ratCBG295Luc promoter reporter construct, do not differ, indicates that GC regulation
of the CBG promoter does not involve chromatin remodelling. Dexamethasone
repression of the ratCBG295Luc promoter reporter construct correlates with the
decrease in CBG mRNA levels by dexamethasone (Table 3.1).
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Despite the fact that the mRNA experiments were done in a human hepatoma cell line
(HepG2) and the promoter experiments in a mouse hepatoma cell line (BWTG3) we
obtained good correspondence (Table 3.1) between promoter reporter constructs'
responses, especially with the stably transfected ratCBG295Luc construct, and CBG
protein and mRNA levels in the presence of several of the hormones tested (E2, insulin,
and dexamethasone). We, however, chose to focus further investigation on the
transrepression of the rat CBG proximal promoter by GCs. In the case of the GCs
specifically there was also no significant difference between the stably and transiently
transfected ratCBG295Luc construct and thus further studies were performed using
transient transfections.
Table 3.1. Comparison of the percentage expression of CBG mRNA levels vs
ratCBG295Luc promoter activity by 1JlM test compounds. Control levels are
100%; levels> 100% indicate activation while levels < 100% indicate inhibition.
CBG mRNA levels ratCBG295Luc promoter
(Fig.3.2) (Fig.3.4)
209.5 ± 13.5 % (transient)
E2 144.5 ± 5.3 %
174.8 ± 5.3 % (stable at 10JlM)
Insulin 64.6 ± 4.1 % 46.5 ± 4.7 % (stable)
Dexamethasone
35.8 ± 7.7 % (transient)
37.8 ± 3.2 %
41.1 ± 1.1 % (stable)
3.3.4 Delineation of GC responsiveness within the rat CBG proximal promoter
reporter construct
To delineate the region of GC responsiveness on the CBG proximal promoter, BWTG3
cells were transiently transfected with the ratCBGl200Luc, ratCBG295Luc and
ratCBG 145Luc promoter constructs as discussed in materials and methods section 6.6.1
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(Fig. 3.5A). Dexamethasone produced a 53 ± 2.7 % inhibition (P<O.Ol) of the
ratCBG1200Luc and a 32.5 ± l.6 % inhibition (P<O.Ol) of the ratCBG295Luc
construct. Thus dexamethasone (1 j.lM) significantly (P<O.Ol) transrepressed both the
ratCBG1200Luc and ratCBG295Luc promoter reporter constructs whereas the
ratCBG I45Luc construct was unaffected. This indicates that the binding sites for DBP,
HNF3 and C/EBP present in the ratCBG295Luc construct but not in the ratCBG145Luc
construct may be involved in the GC responsiveness of the CBG proximal promoter.
The ratCBG l200Luc construct was transrepressed to a greater extent by dexamethasone
than the ratCBG295Luc construct, which indicates that transcription factors further
upstream of the ratCBG295Luc may also be involved in modulating transrepression by
GCs.
To further characterize the effect of GCs on the CBG proximal promoter, dose response
experiments for transrepression by dexamethasone and hydrocortisone of the
ratCBG l200Luc and ratCBG295Luc promoter reporter constructs transiently
transfected, as well as the ratCBG295Luc stably transfected into BWTG3 cells, were
performed (Fig. 3.5B). EC50 values are defined as the concentration of agonist that
evokes a response half way between the baseline (bottem) and maximal response (top).
The EC50s for dexamethasone and hydrocortisone transrepression were 3.7 nM and 6.9
nM, respectively for the transiently transfected ratCBG295Luc, 2.8 nM and 10.6 nM for
the transiently transfected ratCBG1200Luc and 3.1 nM and 1.2 nM for the stably
transfected ratCBG295Luc (Table 3.2). There was no significant difference (P>0.05) in
the EC50s of dexamethasone for the transiently transfected ratCBG l200Luc and
ratCBG295Luc promoter reporter constructs as well as the stably transfected
ratCBG295Luc construct. There is also no significant difference (P>0.05) in the EC50s
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of hydrocortisone between the transiently transfected ratCBG1200Luc versus the
ratCBG295Luc promoter reporter constructs, but both were significantly different
(P<O.OOl) from the EC50 obtained with the stably transfected ratCBG295Luc construct.
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Figure 3.5. Characterization of the glucocorticoid responsiveness of the rat CBG
promoter reporter construct. (A) Localization of glucocorticoid responsiveness. The
ratCBG1200Luc, ratCBG295Luc and ratCBGl45Luc promoter reporter constructs were
transiently transfected into BWTG3 cells. BWTG3 cells were cultured and transfected
as described in materials and methods. In addition a p-galactosidase expression plasmid
(pPGKpGopbA) was co-transfected to monitor for transfection efficiency. The
concentration of dexamethasone added was 111M. Control wells received an equal
amount of ethanol. Luciferase activity was determined in the cell lysates after 24 h.
Luciferase values were normalized for p-galactosidase and values plotted as a
percentage of the average control. Statistical analysis was done to compare values in
presence of test compounds relative to the corresponding control using one-way
ANOVA followed by Dunnett's multiple comparison's posttest (*: P<O.05; **: P<O.Ol).
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(B) Dose response curves of dexamethasone (DEX) and hydrocorticosterone (HC)
transrepression with transiently transfected ratCBG1200Luc and ratCBG295Luc
promoter reporter constructs as well as stably transfected ratCBG295Luc.
RatCBG1200Luc and ratCBG295Luc promoter reporter constructs were transiently
transfected into BWTG3 cells. A cell line stably transfected with the ratCBG295Luc
promoter reporter construct was also investigated. Cells were treated with increasing
concentrations of hormone as indicated and lysed after 24 hrs. Control wells received an
equal amount of ethanol. Luciferase values were normalized for p-galactosidase and
values plotted as a percentage of the average control. EC50 and maximal repression
values were determined by fitting a dose response curve with one site competition.
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Table 3.2. Summary of ECSOs and maximal repression for dexamethasone and
hydrocortisone of constructs tested. Statistical analysis was done on results obtained
in Fig 5B to compare EC50s and maximal repression between different constructs for
each compound tested using one-way ANOV A followed by Bonferroni multiple
comparison's posttest (a: P<0.05; b: P<O.OI; c P<O.OOI).
ECSO Maximal repression
DEX HC DEX HC
ratCBG 1200Luc 2.8nM 10.6 nM 54.6 ± 2.9% 46.1 ± 2.5%
ratCBG295Luc 3.7nM 6.9nM 34.5 ± 2.7% c 37.2 ± 3.0% c
ratCBG295Luc stables 3.1 nM 1.2 nM C 40.8 ± 1.5% C 38.4 ± 2.0% C
The maximal transrepression by dexamethasone and hydrocortisone was 34.5 ± 2.7%
and 37.2 ± 3.0%, respectively, for the transiently transfected ratCBG295Luc construct,
54.6 ± 2.9% and 46.1 ± 2.5% for the transiently transfected ratCBG1200Luc construct
and 40.8 ± 1.5% and 38.4 ± 2.0% for the stably transfected ratCBG295Luc construct
(Table 3.2). The maximal repression by dexamethasone and hydrocortisone of the
ratCBG295Luc contruct transiently and stably transfected was significantly different
(P<O.OOl) from the maximal transrepression obtained with the ratCBG1200Luc
construct transiently transfected. The fact that the ratCBG 1200Luc construct was
transrepressed to a greater extent than the ratCBG295Luc construct and that the
maximal repression between the two constructs was significantly different, further
indicates that transcription factors further upstream of the ratCBG295Luc construct may
also be involved in transrepression by GCs.
87
Stellenbosch University http://scholar.sun.ac.za
3.3.5 Effect of co-transfected GR and RU486 on glucocorticoid repression of the
ratCBG295Luc promoter reporter construct.
The ligand-activated GR has been shown to repress transcription of various genes,
through protein-protein interactions with other transcription factors. The steroid
induction properties of a transiently transfected gene were found to be sensitive to the
concentration of steroid receptor [Szapary et al 1996]. Therefore whether the
transrepression potential is dependent on the GR expression level, was also investigated.
BWTG3 cells were transiently transfected with the ratCBG295Luc promoter reporter
construct and without and with the rGRa expression vector (Fig. 3.6A). Co-transfection
with rGRa in BWTG3 cells significantly increased the transrepression response of both
dexamethasone [from 35.75 ± 15.4% to 57.4 ± 2.6% (P<0.05)] and hydrocortisone
[from 32.5 ± 7.8% to 49.9 ± 8.4% (P<0.05)], while transrepression by progesterone was
unaffected.
To strengthen the case that the observed dexamethasone repression of the
ratCBG295Luc promoter reporter construct was mediated by the GR the effect of the
GC antagonist, RU486, on transrepression was investigated (Fig. 3.6B). As shown
before dexamethasone (1 ~M) significantly (P<O.Ol) transrepressed the CBG promoter
construct and indeed RU486 (20 ~M)could relieve this repression.
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Figure 3.6. Effect of co-transfected GR and RU486 on glucocorticoid repression of
the ratCBG295Luc promoter reporter construct. (A) Effect of co-transfected GR
expression vector on transrepression by dexamethasone, hydrocortisone and
progesterone. Transrepression of a ratCBG295Luc promoter construct by the
glucocorticoids, hydrocortisone (HC) and dexamethasone (DEX), and progesterone (P)
was investigated in BWTG3 cells, in the absence or presence of co-transfected rGRa.
BWTG3 cells were cultured as described in materials and methods. The cells were
transiently transfected with a ratCBG295Luc, with or without the rat GRa expression
vector, pSVGRl. In addition a p-galactosidase expression plasmid (pPGKpGopbA) was
co-transfected to monitor for transfection efficiency. Twenty-four hrs after transfection
hormones were added at a concentration of 1 IlM. Control wells received an equal
amount of ethanol. After a further 24 hr incubation cells were lysed and luciferase
activity was determined. Luciferase values were normalized for p-galactosidase and
values plotted as a percentage of the average control. Statistical analysis was done to (i)
compare values in presence of test compounds relative to the corresponding control
using one-way ANOVA followed by Dunnett's multiple comparison's posttest (*:
P<O.05; **: P<O.Ol) and to (ii) compare values without GR (-rGRa) to values with co-
transfected GR (+rGRa) for each compound tested using a two-tailed unpaired t-test (a:
P<O.05).
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(BJ Effect of the glucocorticoid antagonist, RU486, on transrepression. A
ratCBG295Luc promoter reporter construct was transiently transfected into mouse
hepatoma cells (BWTG3). BWTG3 cells were cultured as described in materials and
methods. Twenty-four hrs after transfection cells were treated with 1 J.lM
dexamethasone and 20 J.lMRU486 as indicated. Control wells received an equal amount
of ethanol. Luciferase values were normalized for p-galactosidase and values are
plotted as a percentage of the average control. Statistical analysis was done to (i)
compare values in presence of test compounds relative to the corresponding control
using one-way ANOVA followed by Bonferonni's multiple comparison's posttest
comparing all columns (**: P<O.OI; ***: P<O.OOI) and to (ii) compare values of each
compound tested relative to transrepression in the presence of RU486 using one-tailed
unpaired t-test (a: P<0.05; c: P<O.OOI).
3.3.6 Does HNF3a., DBP and CIEBPP influence transactivation by a GRE-
containing promoter reporter construct?
This study has indicated that the transcription factors, CIEBP, HNF3 and DBP may be
involved in the GC responsiveness of the CBG proximal promoter. C/EBP and HNF3
have been shown to form protein-protein interactions with the GR [Rabek and
Papaconstantinou 1999; Wang et al 1999]. In NF-KB mediated transcription that is
transrepressed by GCs, NF-KB has also been shown to physically interact with the GR.
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This interaction results in mutual transcriptional antagonism, which is solely mediated
through the p65 subunit of NF-KB, and co-expression of the p65 subunit dose-
dependently represses GR transactivation [McKay et aI1998].
To test whether transactivation of a GRE-containing promoter by dexamethasone is
influenced by the transcription factors, ClEBP, HNF3 and DBP, the mouse hepatoma
cell-line, BWTG3, was transiently transfected with a (GRE)ztkLuc promoter reporter
construct with or without expression vectors for the transcription factors and treated
with 1 11Mdexamethasone (Fig. 3.7). The results show that dexamethasone significantly
(P<O.01) transacti vated the GRE-dependent promoter reporter construct but that in the
presence of co-transfected HNF3a, DBP and C/EBPP the transactivation was
significantly decreased (P<O.01 for HNF3a and P<O.001 for DBP and C/EBPP). These
results suggest that an increase in the transcription factors HNF3a, DBP and C/EBPP
partially inhibits transactivation of a GRE-containing promoter by dexamethasone. This
indicates that these transcription factors influence GR-mediated transcriptional
regulation most probably by forming protein-protein interactions with the GR. Thus
these transcription factors may potentially be involved in transrepression of the CBG
promoter by GCs although further work is required to elucidate the specific factor
involved and the precise mechanism involved. This experiment can also be repeated on
the CBG constructs and could show whether co-transfection with HNF3a, DBP and
C/EBPP would influence transrepression of the CBG proximal promoter.
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Figure 3.7. Effects of co-transfected CIEBP~, HNF3a. and DBP on dexamethasone
transactivation of a GRE-containing promoter reporter construct. The effect co-
transfection of the transcription factors, C/EBP~, HNF3a. and DBP on transactivation of
a GRE-containing promoter reporter construct by dexamethasone (DEX) was
investigated in BWTG3 cells. BWTG3 cells were cultured as described in materials and
methods. The cells were transiently transfected with (GRE)2tkLuc with or without co-
transfected CAAT/enhancer binding protein (ClEBP or NF/IL6), hepatocyte nuclear
factor-3 (HNF-3) and D-site binding protein (DBP). In addition a ~-galactosidase
expression plasmid (pPGK~GopbA) was co-transfected to monitor for transfection
efficiency. The concentration of dexamethasone added was 1 ~M. Control wells
received an equal amount of ethanol. Luciferase activity was determined in the cell
lysates after 24 hrs. Luciferase values were normalized for ~-galactosidase and values
plotted as a percentage of the average control. Statistical analysis was done to (i)
compare values in presence of test compounds relative to the control using one-way
ANOVA followed by Dunnett's multiple comparison's posttest (*: P<O.05; **: P<O.Ol)
and to (ii) compare values of each construct tested relative to transactivation by
dexamethasone alone using one-tailed unpaired t-test (b: P<O.Ol; c P<O.OOl).
3.4 DISCUSSION
This study investigated the hormonal regulation of CBG by determining effects on
rnRNA levels and on the transcriptional regulation of the CBG proximal promoter. In
addition, transcriptional regulation was compared with effects on mRNA levels to
establish whether a correlation existed.
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Exercise like swimming and stressful conditions such as malnutrition and restraint, were
previously shown to decrease plasma CBG levels in rats resulting in an increase in free
GC levels which are a marker of the physical stress associated with this activity [Duclos
et al 2003; Peijie et al 2003; Tinnikov 1999; Lesage et al 2002]. In the present study,
voluntary running had no effect on rat CBG levels but involuntary swimming and
immobilization decreased rat CBG mRNA levels. The decrease in CBG mRNA levels
with physical stressors like involuntary swimming and immobilization observed in this
study corresponds to the decrease in circulating plasma CBG levels observed during
exercise stress in the literature [Tinnikov 1999].
To evaluate the effects of glucocorticoids we investigated the effect of dexamethasone
as well as various other hormones, known to regulate CBG levels, on CBG mRNA and
protein levels in a human hepatic cell line, HepG2. A previous study had shown that
dexamethasone alone had no effect on CBG mRNA and protein levels in HepG2 cells
[Emptoz-Bonneton et a11997]. However, in the present study dexamethasone decreased
CBG mRNA and protein levels, albeit only significantly in the case of the mRNA. In
both studies the same cells and concentration of steroids were used but the incubation
time differed. In the present study cells were incubated with steroids for 72 hrs whereas
in the study by Emptoz-Bonneton et al cells were incubated for 48 hrs. This might
account for the differences in GC effects observed. The results obtained in this study
could be the result of indirect effects due to the longer incubation time. After 72 hrs
incubation with steroids, other proteins might be upregulated, which could influence
CBG mRNA levels. As expected from the literature E2 increased [Misao et al 1998]
and insulin decreased [Crave et al 1995] CBG mRNA and protein levels in HepG2
cells.
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We also found that dexamethasone and hydrocortisone repressed the full-length,
ratCBG1200Luc promoter reporter construct and the truncated ratCBG295Luc promoter
reporter construct as well as the latter construct stably transfected into BWTG3 cells.
This is in accordance with the decrease in CBG mRNA and protein levels observed in
HepG2. Although caution should be excercised in comparing results from different cell-
lines, especially if they originate form different species as is the case here, the fact that
the mRNA work from both the HepG2 (human liver cell line) and the rat livers correlate
with the promoter work in BWTG3 cells (mouse liver cell line) does lend weight to the
evidence that GCs probably do repress CBG at the transcriptional level. The results
with the promoter reporter constructs can only be compared to mRNA and protein
levels in the literature as no promoter work has been done before. In one study
dexamethasone alone had been shown to have no effect on CBG mRNA and protein
levels in HepG2 cells. However, together with IL-6 dexamethasone synergised in
repressing mRNA and protein, while IL-6 alone also decreased CBG mRNA and
protein levels [Emptoz-Bonneton et a/1997]. IL-6 had no effect on any of the promoter
reporter constructs we tested but IL-6 together with dexamethasone repressed the CBG
promoter reporter constructs. Our work, however, does not suggest a synergy but rather
that there is no significant difference between the effect seen with dexamethasone alone
and dexamethasone together with IL-6.
Progesterone only repressed the ratCBG295Luc promoter reporter construct, which
corresponds to the decrease in CBG mRNA levels by progesterone observed in
Ishikawa cells [Misao et a11994; Misao et a11998] but not with previous work in rats
suggesting that progesterone either has no effect [Smith and Hammond 1992] or
increases plasma CBG levels [Westphal 1971]. Insulin decreased, although not
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significantly, the ratCBG 1200Luc and the ratCBG295Luc promoter reporter constructs.
Significant repression was only seen with the stably transfected ratCBG295Luc
construct and matches the decrease in CBG mRNA and protein levels in HepG2 cells
observed by us and others [Crave et al 1995]. Once again caution is required in
comparing the mRNA work with the promoter work as these were done in different cell
lines. An increase in the expression of the ratCBG295Luc promoter reporter construct,
transiently and stably transfected, by E2 was observed in our study and correlates with
our mRNA results in HepG2 cells (+FCS) and results described in the literature that
show an increase in CBG mRNA levels in Ishikawa cells [Misao et a11998; Misao et
al 1999a] and plasma levels in male rats and humans [Westphal 1986; Hammond
1990a; Coolens et al 1987; Misao 1999a; Darj et a11993; Feldman et a11979] but not
with the results in female rats [Westphal 1971; Mataradze et al 1992] that showed no
effect.
In our study we found a good correlation between the effects of hormones on the
mRNA levels and the expression of the ratCBG295Luc promoter construct (Table 3.1)
despite the fact, as mentioned previously, that the mRNA experiments were done in a
human hepatoma cell line (HepG2) and the promoter experiments in a mouse hepatoma
cell line (BWTG3). For dexamethasone and E2 the correlation was found both with the
transiently and stably transfected systems, while for insulin the effect was only evident
with the stably transfected construct. The study of mammalian genes using transient
transfection assays has helped us understand transcriptional mechanisms. However,
transfected promoter constructs are not always the right stand-in for endogenous genes,
especially in cases where chromatin remodeling must take place [Smith and Hager
1997]. Functional differences between transiently transfected and stably replicating
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templates can thus be used to identify and characterise regulatory mechanisms that
involve chromatin components. Inour study there was no significant difference between
the EC50 and maximal repression values of dexamethasone obtained with the
transiently versus stably transfected ratCBG295Luc promoter reporter constructs (Table
3.2). Although the results with hydrocortisone are not so clear-cut the results with
dexamethasone certainly suggest that GC regulation of the CBG promoter may not
involve chromatin remodelling. A precedent for GC effects that do not require
chromatin remodelling is found in the induction of IKBa by GCs [Deroo and Archer
2001a].
Further investigation of the glucocorticoid responsiveness of the CBG proximal
promoter, showed that dexamethasone transrepressed both the ratCBG 1200Luc and
ratCBG295Luc promoter constructs, whereas the ratCBG 145Luc construct was
unaffected. This indicates that the protein-binding sites for DBP, HNF3 and C/EBP
present in the ratCBG295Luc construct but not in the ratCBG145Luc construct may be
involved in the glucocorticoid responsiveness of the CBG proximal promoter. The
ratCBG 1200Luc construct was transrepressed to a greater extent by dexamethasone than
the ratCBG295Luc construct, which suggests that transcription factors further upstream
of the ratCBG295Luc may also be involved in modulating transrepression by
glucocorticoids. Ar! example of such an effect may be seen in the osteocalcin gene
promoter in which GC suppression of 1.25-dihidroxyvitamin D3-stimulated
transcription occurs independently of distal or proximal GREs [Aslam et al 1995].
Promoter deletion analysis revealed an additional GRE in the distal promoter that
function to suppress osteocalcin transcription.
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Although we clearly demonstrate that CBG transcription is modulated by GCs no
nGREs appear to be present in the rat or human CBG proximal promoter. nGRE's are
present in various genes and the consensus sequence of the nGRE assembled from the
sequences of these genes has been suggested to be very degenerate and may thus not be
easily identified. On the other hand it may suggest that the GR is acting through a
tethering mechanism that does not involve direct binding to the DNA. The GR can
repress transcription via protein-protein interactions with other transcription factors
rather than by binding to a nGRE. GCs have, for example, been shown to repress NF-
KB-mediated activation of proinflammatory genes like IL-8 and ICAMI through
protein-protein interactions between the GR and NF-KB [Nissen et al 2000]. The
collagenase-3 gene repression by GCs is also mediated by the GR forming protein-
protein interactions with AP-I [Rogatsky et al 2001]. Interestingly HNF3 and C/EBP,
present in the ratCBG295Luc construct, have been reported to form protein-protein
interactions with the GR [Boruk et a11998; Rabek and Papaconstantinou 1999; Wang et
al 1999; Hoeke et al 1992]. Although DBP, involved in the circadian rhythm, has not
been shown to form protein-protein interaction with the GR, GCs do induce DBP
expression in liver, kidney and heart [Balsalobre et al 2000]. In this study we showed
that an increase in the levels of the transcription factors HNF3a, DBP and C/EBPP
partially inhibits transactivation of a GRE-containing promoter by dexamethasone,
which indicates that these transcription factors interact with the GR. Thus the converse
may also be valid with the GR negatively modulating the activity of these transcription
factors on the CBG promoter. In this regard the p65 subunit of NF-KB has been shown
to physically interact with the GR, resulting in mutual transcriptional antagonism, which
dose-dependently represses GR transactivation [McKay et al 1998]. Future experiments
should include co-transfection experiments with the three possible factors interacting
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with the GR, namely HNF3a, DBP and CIEBPP, to ascertain if the inhibitory effect of
GR on the CBG promoter can modulated by increasing concentrations of these
interacting factors.
The ClEBP family of transcription factors plays a key role in the development and
maintenance of metabolically important processes [Croniger et al 1998]. Cross-talk
between the C/EBP family members and GR has been documented in various systems
and they have also been shown to bind directly to the LBD of nuclear receptors
including the GR [Boruk et al 1998]. These interactions result in induction or inhibition
of target genes but do not always involve binding of GR to DNA [Boruk et al 1998].
The GC-dependent induction of transcription from the herpes simplex virus thymidine
kinase gene promoter was for example localized to a binding site for C/EBPP and was
independent of GR binding to DNA [Boruk et al 1998]. In addition, the GR, through its
DNA-binding domain, has been shown to suppress the binding of C/EBPP on the
rainbow trout ER promoter by protein-protein interactions and thereby prevents the
enhancer effect of this transcription factor [Lethimonier et al 2002]. Recently, the
PEPCK-C gene was shown to be regulated by GCs and was induced in the liver and
kidney but repressed in white adipose tissue [Olswang et aI2003]. The repression of the
PEPCK-C gene transcription by GR in adipocytes was shown to be via inhibition of
CIEBP-mediated activation and does not require DNA binding of the receptor. Thus, the
GR probably inhibits PEPCK-C gene transcription via protein-protein interactions.
Furthermore, the carbamoylphosphate synthetase gene is expressed in the hepatocytes
of the liver and is controlled by GCs and intracellular cAMP levels [Christoffels et al
2000]. A 102-bp GC response unit, containing binding sites for HNF3, C/EBP and the
GR, was shown to be the main determinant of hepatocyte-specific and hormone-
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controlled activity. Genes coding for the acute-phase proteins are induced by IL-6
through the human transcription factor NF-IL-6 and its rat homologue IL-6-DBPILAP
[Hoeke et al 1992]. It is also synergistically induced by IL-6 plus GCs but the
synergism is blocked by RU486 and was thus dependent on the GR.
Members of the HNF3 family (HNF3a, p and y) play an important role in the regulation
of genes involved in various aspects of cellular metabolism [Zimmermann et al 1997;
O'Brien et a11995; Roux et a11995]. This regulation is accomplished through N-and C-
terminal transactivation domains of which the C-terminal terminal domain is needed for
accessory factor activity in the PEPCK gene GRU [Wang et al 1999]. HNF3 also
functions as an accessory factor in other GRU's for example those located in the
tyrosine aminotransferase, insulin-like growth factor-binding protein-I and 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene promoters [Zimmermann et al
1997; O'Brien et a11995; Roux et a11995]. The adenovirus-mediated expression of an
HNF3p protein with a deleted C-terminal transactivation domain reduces the GC-
induced expression of the PEPCK and glucose-ó-phosphotase genes in H4IIE hepatoma
cells [Wang et aI2000]. Thus the functional interaction between HNF3 and GR appears
to be a common mechanism for GC-regulated gene transcription, especially in the liver.
These findings, together with the results of the present study, suggest that C/EBP and
HNF3 forming protein-protein interactions with the GR, may be involved in GC
repression of the CBG promoter.
This study has for the first time provided information on hormonal regulation of the
CBG proximal promoter as well as correlating transcriptional regulation with mRNA
levels in the case of GCs, insulin and estrogen. This suggests that differences in levels
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of mRNA are due to transcriptional effects and not RNA stability or transport. In
addition, the GC responsiveness of the proximal promoter was delineated to between
-145 and -295bp relative to the transcription start site. This area on the promoter
contains putative binding sites for CIEBP, HNF3 and DBP. These transcription factors
are probably involved in the GR-mediated regulation of the CBG promoter. However,
further work is needed to ascertain which of the three transcription factors identified in
this study are specifically responsible for the GR-mediated regulation of the CBG
proximal promoter and to discover the mechanism of action involved.
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CHAPTER4
Dissociative glucocorticoid activity ofMPA and Compound A, a non-
steroidal plant analogue, in hepatoma cell lines.
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4.1 INTRODUCTION
Endogenous GCs are important in maintaining basal and stress-related homeostasis and
preventing excessive immune responses to antigenic challenges [Chrousos and Gold
1992]. GCs are also the most effective therapy in the long-term treatment of
inflammation and autoimmune diseases [Cato and Wade 1996]. Upon hormone binding
the GR, translocates to the nucleus, where the activated receptor can transactivate or
transrepress specific genes [Beato et a/2000]. GR mediated gene regulation is discussed
in detail in section 2.1. Transactivation is generally mediated by binding of a GR dimer
to GREs in the promoter region of GC responsive genes, followed by recruitment of
coactivators, chromatin remodeling, and increased gene transcription [Adcock 2000].
Transrepression may also be mediated via direct binding to DNA, via nGREs.
Alternatively, transrepression may proceed without direct DNA-binding by the GR but
via protein-protein interactions, that may only require binding of the GR monomer, with
other transcription factors such as NF-KB, AP-I, STAT proteins and C/EBP [McEwan
et a/1997; Webster and Cidlowski 1999].
Most of the anti-inflammatory effects of GCs are mediated through repression of
inflammatory and immune genes that do not contain GREs in their promoters [Cato and
Wade 1996]. The inhibitory effect of GCs are thus mostly due to protein-protein
interactions between activated GR and transcription factors such as AP-I, NF-KB and
ClEBP~, which mediates expression of inflammatory genes [Barnes 1998]. A large
number of side-effects such as diabetes, weight gain, hypertension and osteoporosis are,
however, associated with the long-term use of GCs [Barnes 1998]. This has led to a
search for novel GCs with improved specificity for anti-inflammatory activity that
dissociate between transrepression and transactivation because many of the side effects
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of conventional GCs may be attributed to transactivation (Table 2.3 and Fig. 2.6)
[Adcock 2000; Dumont et al 1998; Cato and Wade 1996]. Some such 'dissociated
glucocorticoids' have been described as dicussed in section 2.1.4 [Vayssierre et a11997;
Vanden Berghe et al 1999] and dissociation may be due to inhibition of GR
dimerization [Reichart et a11998; Heck et a11994]. MPA has recently been shown to
exert dissociative GC activity in normal human lymphocytes [Bamberger et al 1999].
MPA has also been shown to bind to both the GR and PR [Pridjian et a11987; Kontula
et al 1983]. Another compound reported to exert dissociative properties is a phenyl
aziridine precursor, Compound A [De Bosseher unpublished results]. CpdA decreases
CBG levels and increases free corticosterone levels in rats [Louwand Swart 1999]. The
dissociated GC activities ofMPA and CpdA will be further described in this chapter.
The search for dissociated glucocorticoids has focused on the transrepressive effects on
NP-KB and AP-I mediated gene regulation [Dumont et al 1998; Adcock 2000]. We
suggest that regulation of CBG function, as a key modulator of glucocorticoid action, is
imperative for full evaluation of any such drugs. CBG is a central player in
glucocorticoid disposition. In plasma, GCs are bound to CBG that regulates the free
fraction (2- 4%) of glucocorticoids able to diffuse across the plasma membrane of target
tissues and exert biological activity. This implies that any changes in the levels of CBG
would modify the distribution of glucocorticoids to the target tissues [Hammond et al
1990b]. Although the dramatic fall of CBG levels during stress, with concomitant
substantial (2 to 20-fold) increases in free glucocorticoid levels, merits its classification
as a negative acute-phase protein [Black and Garbutt 2002] investigators have up to
now neglected its role in stress and modulation of the acute phase response [Beishuizen
et aI2001]. Recent results, however, indicate that the decrease in CBG during the acute
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phase response releases GCs that actively participate to strengthen all stages of the
stress response and the designation of acute-booster reactants (ABRs) to depict these
modulating properties has been proposed for molecules such as CBG [Ingenbleek and
Bernstein 1999]. In addition, the rapid decline in CBG activity during open-heart
surgery in adults and children suggest a more active role for this acute phase protein in
the stress responses of the body [Tinnikovet al 1996]. Thus, a thorough evaluation of
GC action, including dissociated GC action, is not complete without an investigation of
the effect on CBG. We have shown in chapter 3 that GCs suppress CBG levels by
transrepressing hepatic transcription and that transrepression of the CBG promoter
reporter construct (rat295CBGLuc) is evident in the presence of GCs.
4.2 AlM OF STUDY
In the present study I investigated and compared the dissociative GC activity of MPA
and CpdA relative to conventional GCs by examining transactivation of GRE-
containing reporters and transrepression of CBG gene expression in hepatic cell lines. In
addition, effects on CBG mRNA levels were investigated to establish if these effects
correlate with the CBG promoter reporter results. The effect of these test compounds
were further investigated in the absence and presence of hGR as well as in the presence
ofhGRdim to check for dimerization requirement.
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4.3 RESULTS
4.3.1 MPA, but not CpdA, trans activates GRE-containing promoters in the
presence of co-transfected rGRa
Dissociative glucocorticoid activity requires that a compound can dissociate between
transrepression and transactivation [Adcock 2000]. Thus to compare the dissociative
activity of MPA with that of CpdA, we initially investigated and compared the
transactivation of two GRE-containing promoters. Both of these constructs contain no
other binding sites. The mouse hepatoma cell-line, BWTG3, was transiently transfected
with a (GRE)2tkLuc or a (GRE)z50hIL6PLuc promoter reporter construct as described
in section 6.6.1 (Fig. 4.1A & B, white bars). The result with both constructs show that,
at 1 IlM, dexamethasone and hydrocortisone significantly (P<O.Ol) transactivate the
GRE-dependent promoter constructs while MPA at 1 IlM, progesterone at 1 IlM and
CpdA at 10 IlM have no effect. Dexamethasone results in a 1.6 ± 0.04-fold (P<O.Ol)
induction of the (GRE)2tkLuc and a 9.3 ± 1.2-fold (P<O.Ol) induction of the
(GRE)250hIL6PLuc construct, while hydrocortisone induces a 1.4 ± 0.09-fold (P<O.Ol)
induction of the (GRE)2tkLuc and a 7.4 ± 0.3-fold (P<O.Ol) induction of the
(GRE)250hIL6PLuc construct.
To further investigate transactivation of the GRE-containing promoters, dose response
experiments of transactivation with the (GRE)2tkLuc and (GRE)250hIL6PLuc promoter
reporter constructs by dexamethasone, hydrocortisone, MPA, progesterone and CpdA
(Fig. 4.2A & B) were performed in BWTG3 cells. The EC50s for dexamethasone and
hydrocortisone were 0.1 IlM and 0.6 IlM, respectively, for the (GRE)2tkLuc construct,
and 0.02 IlM and 0.2 IlM, respectively, for the (GRE)250hIL6Pluc construct suggesting
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Figure 4.1. Comparison of the effects of MPA and CpdA, in the absence and
presence of co-transfected GR, on transactivation. Transactivation of a (A)
(GRE)2tkLuc or a (B) (GRE)250hIL6PLuc promoter reporter construct by
medroxyprogesterone acetate (MPA) and Compound A (CpdA) was compared to the
conventional glucocorticoids, hydrocortisone (HC) and dexamethasone (DEX), and to
progesterone (P) in BWTG3 cells, in the absence or presence of co-transfected rGRa.
BWTG3 cells were cultured as described in materials and methods and cells were
transiently transfected with the indicated constructs. In addition a l3-galactosidase
expression plasmid (pPGKI3GopbA) was co-transfected to monitor for transfection
efficiency. Twenty-four hours after transfection hormones were added at a
concentration of 1 JlM for all hormones except for CpdA, which was added at 10 JlM.
Control wells received an equal amount of ethanol. Luciferase values were normalized
for l3-galactosidase and values plotted as a percentage of the average control. Statistical
analysis was done to (i) compare values in the presence of test compounds relative to
the corresponding control using one-way ANaVA followed by Dunnett's multiple
comparison's posttest (*: P<0.05; **: P<O.Ol) and to (ii) compare values without GR (-
rGRu) to values with co-transfected GR (+rGRu) for each compound tested using a
two-tailed unpaired t-test (a: P<0.05; b: P<O.Ol; c P<O.OOl).
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Figure 4.2. Dose response curves of transactivation of GRE-containing promoters
(A: (GRE)ztkLuc or B: (GRE)z50hIL6Pluc) by dexamethasone (DEX),
hydrocorticosterone (HC), medroxyprogesterone acetate (MPA), Progesterone (P),
and Compound A (CpdA). Reporter constructs were transiently transfected into
BWTG3 cells as described in the materials and methods. Cells were treated with
increasing concentrations of hormone as indicated and lysed after 24 hrs. Control wells
received an equal amount of ethanol. Luciferase values were normalized for p-
galactosidase and values plotted as a percentage of the average control. EC50s were
determined by fitting a dose response curve with variable slope.
that dexamethasone is significantly (P<O.OOl) more potent (6 to 10 times) than
hydrocortisone in transactivating via the GRE-containing promoter reporter constructs
used.
To test whether the transactivation potential is dependent on the glucocorticoid receptor
expression level, as has been suggested for MPA, [Bamberger et aI1999], BWTG3 cells
were co-transfected with the rat GR alpha (rGRa) expression vector in the presence of
the GRE-containing promoter reporter constructs (Fig. 4.lA & B, solid bars). Co-
transfection with rGRa almost doubled the transactivation response of both
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dexamethasone (from 1.6 ± 0.04-fold to 2.9 ± 0.3-fold (P<O.Ol) for (GRE)2tkLuc and
from 9.3 ± 1.2-fold to 21.3 ± 2.3-fold (P<O.Ol) for (GRE)z50hIL6Pluc) and
hydrocortisone (from 1.4 ± 0.09-fold to 2.4 ± O.2-fold (P<O.Ol) for (GRE)2tkLuc and
from 7.4 ± 0.3-fold to 17.9 ± 1.5-fold (P<O.OOl) for (GRE)250hIL6Pluc). In addition,
co-transfection with rGRu resulted in significant transactivation by MPA (2.0 ± 0.3-fold
(P<O.Ol) for the (GRE)ztkLuc and 10.8 ± 1.6-fold (P<O.OOl) for the (GRE)250hIL6Pluc)
and progesterone (1.6 ± 0.2-fold (P<0.05) for the (GRE)2tkLuc and 10.2 ± 0.9-fold
(P<O.OOl) for the (GRE)250hIL6Pluc). MPA thus transactivates in the presence of
higher GR levels and in our system results in transactivation levels that are not
significantly (P>0.05) different from that of dexamethasone in the absence of co-
transfected GR. CpdA, however, even at ten times the concentration of the other test
compounds (10 I-lM),did not transactivate even when GR was co-transfected.
4.3.2 CpdA trans represses the rat CBG proximal promoter with a similar potency
(EC50) but with a higher efficacy (maximal repression) than MPA
Next we investigated the second requirement for dissociative glucocorticoids namely
that the compound displays strong transrepression activity. We thus compared the
ability of MPA with that of CpdA in transrepressing the CBG promoter. BWTG3 cells
were transiently transfected with a ratCBG295Luc promoter reporter construct as
discussed in section 6.6.1 (Fig. 4.3, white bars). The results show that, at 1 I-lM, the
glucocorticoids, dexamethasone and hydrocortisone, significantly transrepress (P<O.Ol)
this CBG promoter reporter construct. MPA (1 I-lM),progesterone (1 I-lM)and CpdA (1
I-lM)also transrepress but to a lesser degree than the glucocorticoids.
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Dexamethasone resulted in a 42.7 ± 4.7 % inhibition (P<O.OI) and hydrocortisone in a
37.4 ± 4.4 % inhibition (P<O.OI) of the ratCBG295Luc construct while MPA caused
22.3 ± 1.9 % inhibition (P<O.OI), progesterone a 19.8 ± 2.5 % inhibition (P<O.OI) and
CpdA a 9.8 ± 2.3 % inhibition.
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Figure 4.3. Comparison of the effects of MPA and CpdA, in the absence and
presence of co-transfected GR, on transrepression. Transrepression of a
ratCBG295Luc promoter reporter construct by medroxyprogesterone acetate (MPA)
and Compound A (CpdA) was compared to the conventional glucocorticoids,
hydrocortisone (HC) and dexamethasone (DEX), and to progesterone (P) in BWTG3
cells, in the absence or presence of co-transfected rGRa. BWTG3 cells were cultured as
described in materials and methods and cells were transiently transfected with the
ratCBG295Luc promoter reporter construct. In addition a p-galactosidase expression
plasmid (pPGKpGopbA) was co-transfected to monitor for transfection efficiency.
Twenty-four hours after transfection hormones were added at a concentration of 1 j..tM.
Control wells received an equal amount of ethanol. Luciferase values were normalized
for p-galactosidase and values plotted as a percentage of the average control. Statistical
analysis was done to (i) compare values in the presence of test compounds relative to
the corresponding control using one-way ANOVA followed by Dunnett's multiple
comparison's posttest (*: P<0.05; **: P<O.OI) and to (ii) compare values without GR (-
rGRu) to values with co-transfected GR (+rGRu) for each compound tested using a
two-tailed unpaired t-test (a: P<0.05; b: P<O.OI).
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Dose response curves of transrepresion with the ratCBG295Luc promoter reporter
construct by dexamethasone, hydrocortisone, MPA, and CpdA (Fig. 4.4) were
performed. The EC50s for dexamethasone, hydrocortisone, MPA and CpdA were 3.3
nM, 3.3 nM, 0.11 nM and 0.99 nM, respectively. The maximal repression for
dexamethasone, hydrocortisone, MPA and CpdA were 35.7 ± 3.7%,38.1 ± 4.4%,15.6 ±
2.2% and 23.7 ± 3.6%, respectively. Statistical analysis reveals no significant (P>0.05)
difference between the potency (logEC50) of the compounds tested. However, analysis
of the efficacy (maximal repression) shows that the order of repressive efficacy is
HC=DEX>CpdA>MP A and that CpdA has a significantly (P<0.05) higher efficacy of
repression than MPA.
To test whether the transrepression potential is dependent on the GR expression level,
BWTG3 cells were co-transfected with the rGRu expression vector in the presence of
the ratCBG295Luc reporter construct (Fig. 4.3, solid bars). Co-transfection with rGRu
in BWTG3 cells significantly increased the transrepression response of both
dexamethasone [from 42.7 ± 4.7% to 57.4 ± 1.3% (P<O.OI)] and hydrocortisone [from
37.4 ± 4.4% to 49.9 ± 4.2% (P<0.05)]. Co-transfection with rGRu also significantly
increased the transrepression by MPA [from 22.3 ± 1.9% to 32.3 ± 1% (P<O.OI)] and
CpdA [from 9.8 ± 2.3% to 21.8 ± 2.7% (P<0.05)] while transrepression by progesterone
was unaffected.
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Figure 4.4. Dose response curves of transrepression of the ratCBG295Luc
promoter by dexamethasone (DEX), hydrocorticosterone (HC),
medroxyprogesterone acetate (MPA), progesterone (P), and Compound A (CpdA).
The ratCBG295Luc promoter reporter construct was transiently transfected into
BWTG3 cells as described in the materials and methods. Cells were treated with
increasing concentrations of hormone as indicated and lysed after 24 hrs. Control wells
received an equal amount of ethanol. Luciferase values were normalized for p-
galactosidase and values plotted as a percentage of the average control. EC50s and
maximal repression values were determined by fitting a dose response curve with
variable slope.
4.3.3 Further investigation of the effects of MPA and CpdA on the transactivation
of GRE-containing reporter constructs
Previous results (Fig. 4.1, solid bars) showed that MPA, but not CpdA, could
transactivate via GRE-containing promoters in the presence of co-transfected GR in the
mouse hepatoma cell-line, BWTG3. This effect was investigated further (Fig. 4.5): (a)
by comparing effects in a human cell-line, (b) by investigating the transactivation
responses in the presence of the GR antagonist, RU486, and (c) by investigating the
modulating effects of MPA, progesterone and CpdA on dexamethasone transactivation.
111
Stellenbosch University http://scholar.sun.ac.za
Both cell-lines were transiently transfected with a (GRE)2tkLuc promoter reporter
construct and the appropriate GR expression vector as described in section 6.6.1.
(a) The results comparing transactivation in the mouse vs human (Fig. 4.5A) cell-lines,
showed that dexamethasone significantly (P<O.OI) transactivates the (GRE)2tkLuc
promoter reporter construct in the presence of co-transfected GRu expression vector
in both cell-lines but to different extents (6.9 ± 0.8 fold in BWTG3 cells and 124.4 ±
9.4 fold in HepG2 cells). MPA also significantly (P<O.OI) transactivates the
(GRE)2tkLuc promoter reporter construct in both cell lines and like dexamathasone
to different extents (4.6 ± 0.5 fold in BWTG3 cells and 40.6 ± 2.1 fold in HepG2
cells). However, if MPA transactivation is compared to that of dexamethasone it is
interesting to note that in BWTG3 cells MPA transactivation is 66% of
dexamethasone activation while in HepG2 cells it is only 33%. This is unlikely to be
due to higher levels of GR as dexamethasone activation relative to control is higher
in HepG2 cells (124.4 ± 9.4 fold) than in BWTG3 cells (6.9 ± 0.8 fold).
Progesterone also significantly (P<O.OI) transactivates the (GRE)2tkLuc promoter
reporter construct but only in BWTG3 cells and to a similar extent (4.5 ± 0.6 fold)
as MPA. Interestingly, progesterone does not trans activate the (GRE)2tkLuc
promoter reporter construct in HepG2 cells. The increased transactivation, relative
to dexamethasone, of MPA in BWTG3 cells may thus be due to the presence of the
progesterone receptor for which MPA acts as an agonist [Kontula et al 1983;
Selman et al 1996]. Cpd.A on the other hand, does not activate this (GRE)ztkLuc
promoter reporter construct on its own in either of the cell-lines confirming its
inability to transactivate via the (GRE)2tkLuc promoter reporter construct.
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Figure 4.5. Further investigation of the effects of MPA and CpdA on
trans activation by (a) comparing effects in a human cell-line, (b) investigating the
transactivation responses in the presence of the GR antagonist, RU486, and (c)
investigating the modulating effects of MPA, Pand CpdA on dexamethasone
transactivation. The (GRE)ztkLuc promoter reporter construct together with a rat GRu
(pSVGRl), or a human GRu (pRS-hGRu), expression vector was transiently
transfected into mouse hepatoma cells, BWTG3 (Fig. SA and B), and also into human
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hepatoma cells, HepG2 (Fig. 5A and C) as described in the materials and methods. Cells
were treated with 10 !-lM hormones as indicated. Control wells received an equal
amount of ethanol. For Fig. 5B & Clanes 1-16, compounds were added to the cells at
the same time. To investigate the effects of the order of addition of CpdA we first added
CpdA (Fig. 5A & B, lanes 15' & 16') to the cells and after 10 minutes added
dexamethasone (lane 15') or dexamethasone and RU486 (lanes 16'). Luciferase values
were normalized for B-galactosidase and (A) values plotted directly or (B and C)
plotted as a percentage of the average transactivation by dexamethasone alone.
Statistical analysis was done to (i) compare values in presence of test compounds
relative to the corresponding controls (control for A, and lane 1 or 2 for B and C) using
one-way ANOYA followed by Dunnett's multiple comparison's posttest (*: P<0.05;
**: P<O.OI) and to (ii) compare values of each compound tested relative to
transactivation by dexamethasone alone (lane 3 for B and C) using a one-tailed unpaired
t-test (a: P<0.05; b: P<O.OI; c: P<O.OOI).
(b) The glucocorticoid antagonist, RU486, abolishes the dexamethasone (Fig. 4.5B and
C compare lanes 3 and 4), MPA (Fig. 4.5B and C compare lanes 5 and 6), and
progesterone (Fig. 4.5B compare lanes 9 and 10) transactivation of the (GRE)2tkLuc
promoter reporter construct. RU486 is also a PR antagonist and thus will also
abolish the effects of progesterone via the PR [Crains et aI1993].
(c) Finally, we examined the ability of the test compounds to modulate dexamethasone
transactivation of the (GRE)ztkLuc promoter reporter construct. MPA significantly
decreased dexamethasone transactivation of the (GRE)2tkLuc promoter reporter
construct in both cell-lines: in BWTG3 cells (Fig. 4.5B compare lane 3 with 7) to
74.7 ± 3.2% of dexamethasone activation (P<0.05) and in HepG2 cells (Fig. 4.5C
compare lane 3 with 7) to 42.8 ± 1.6 % (P<O.OOI). Progesterone also decreased
dexamethasone transactivation in both cell lines: in BWTG3 cells (Fig. 4.5B
compare lane 3 with 11) to 73.8 ± 2.5 % of dexamethasone activation (P<0.05) and
in HepG2 cells (Fig. 4.5C compare lane 3 with 11) to 58.8 ± 3.5 % (P<O.OI).
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The modulatory effect of CpdA on dexamethasone transactivation of the
(GRE)2tkLuc promoter construct is more complex in that it depends on the order of
addition of CpdA. If dexamethasone was added together with CpdA (as in other
lanes), CpdA has no effect on dexamethasone transactivation (Fig. 4.5B and C
compare lanes 3 and 15). On the other hand, if CpdA was added before
dexamethasone, CpdA significantly (P<0.05) decreased dexamethasone
transactivation: in BWTG3 cells (Fig. 4.5B compare lanes 3 and 15') to 64.8 ± 2.3
% of dexamethasone activation and in HepG2 cells (Fig. 4.5C compare lanes 3 and
15') to 79.9 ± 4.2 %. In all cases RU486 could abolish the transactivation of test
compounds in the presence of dexamethasone (Fig. 4.5B and Clanes 8, 12, 16 and
16').
4.3.4 RU486 relieved transrepression by dexamethasone and CpdA
To strengthen the case that the observed repression of the ratCBG295Luc promoter
reporter construct by CpdA was mediated by the GR the effect of the glucocorticoid
antagonist, RU486, on transrepression in BWTG3 cells was also investigated (Fig. 4.6).
The ratCBG295Luc promoter reporter construct is slightly increased by RU486. RU486
has been shown to exhibit partial agonist activities in a cell-type-dependent manner [Liu
et al 2002]. The effect on transcription correlated with different ratios of endogenous
coactivators and corepressors in cells [Schulz et al 2002]. As shown before
dexamethasone (1 J.lM) significantly (P<O.Ol) transrepressed the CBG promoter
construct and indeed RU486 (20 J.lM) could relieve this repression (Fig. 4.6 compare
lanes 3 and 4). The significant (P<0.05) transrepression by CpdA (10 J.lM)could also be
relieved by RU486 (Fig. 4.6 compare lanes 5 and 6). In addition, CpdA (10 J.lM)added
together with dexamethasone (1 J.lM) slightly increases, although not significantly
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(P>O.05), the transrepression seen by dexamethasone alone (Fig. 4.6 compare lanes 3
and 7). Once again, RU486 could relieve the combined repression of CpdA and
dexamethasone. These results therefore strongly suggest that repression of the
ratCBG295Luc promoter reporter construct by dexamethasone as well as CpdA is
mediated by the GR.
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Figure 4.6. Effect of the glucocorticoid antagonist, RU486, on transrepression. A
ratCBG295Luc promoter reporter construct was transiently transfected into mouse
hepatoma cells (BWTG3). BWTG3 cells were cultured as described in materials and
methods. Cells were transfected as described in the materials and methods and treated
with the compounds as indicated. Control wells received an equal amount of ethanol.
Luciferase values were normalized for ~-galactosidase and values are plotted as a
percentage of the average control. Statistical analysis was done to (i) compare values in
presence of test compounds relative to the corresponding control (lanes 1 or 2) using
one-way ANOVA followed by Dunnett's multiple comparison's posttest (*: P<O.05;
**: P<O.Ol) and to (ii) compare values of each compound tested relative to
transrepression in the presence of RU486 using a one-tailed unpaired t-test (b: P<O.O1;
c: P<O.OOl).
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4.3.5 Regulation of CBG mRNA levels in hepatic cells.
To determine if the transcriptional regulation of the rat CBG promoter correlates with
the regulation on mRNA level, the effect of dexamethasone, progesterone, MPA and
CpdA was investigated on CBG mRNA levels in a human hepatoma cell-line (HepG2)
in the absence (-hGR) and presence of transfected hGR (+GR) or hGRdim (+hGRdim)
(Fig. 4.7) (Materials and methods section 6.6.1). The hGR dim receptor was constructed
by inserting the point mutation A458T into the GR dimerization domain (D-loop); this
prevents dimerization and activation of GRE promoters [Reichardt et al 2001]. The
effect of the test compounds was thus tested in the presence of hGRdim to check for a
dimerization requirement in transrepression of CBG mRNA [Reichardt et al 2001].
Transrepression may be mediated through direct binding of the GR to nGREs or via a
tethering mechanism that does not require DNA binding by the GR. The first
mechanism is reported to require dimerization of the GR while the latter mechanism
may be mediated by monomeric GR [Schacke et al 2002a].
Dexamethasone resulted in a 23.1 ± 8.8 % inhibition of CBG mRNA levels in the
absence oftransfected hGR (endogenous) and a 19.5 ± 2.7 % inhibition in the presence
of co-transfected hGR. The presence of transfected hGR therefore did not significantly
(P>0.05) increase the percentage inhibition of CBG mRNA levels. Co-transfected
hGRdim, however, practically abolished dexamethasone repression and only resulted in a
1.3 ± 7.9 % inhibition of CBG mRNA levels. In spite of this, statistical analysis reveals
that not only are none of the mRNA values significantly (P>0.05) repressed relative to
the control values but that there is no significant (P>0.05) difference between the
different GR conditions (Table 4.1) tested for dexamethasone.
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Figure 4.7. Regulation of CBG mRNA levels in HepG2 cells. The effect of
dexamethasone (Dex), progesterone (P), medroxy-progesterone acetate (MPA) and
Compound A (CpdA) on CBG mRNA levels was investigated in the absence (-hGR),
and presence of transfected hGR (+GR) or hGRdim (+hGRdim) in a human hepatoma
cell-line (HepG2). HepG2 cells were cultured as described in materials and methods.
The concentration of dexamethasone added was 1 JlM and of that of MPA, P and CpdA
10 JlM. Statistical analysis was done to compare values in the presence of test
compounds relative to the corresponding control using one-way ANOVA followed by
Dunnett's multiple comparison's posttest (*: P<O.05; **: P<O.Ol).
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Progesterone resulted in 8.5 ± 5.0 % inhibition in the absence oftransfected hGR, a 14.4
± 0.7 % inhibition in the presence oftransfected hGR and 29.2 ± 3.2 % inhibition in the
presence of transfected hGRdim. Inhibition by progesterone was only significantly
(P<0.05) different in the presence oftransfected hGRdim.
MPA, on the other hand, significantly (P<O.OI) inhibited CBG mRNA levels in the
absence of transfected hGR (34.7 ± 3.8 % inhibition) as well as in the presence of
transfected hGRdim (48.7 ± 1.7 % inhibition). Statistical analysis, however, indicate that
although MPA in the presence of transfected hGR resulted in 26.5 ± 2.5 % inhibition
this is not significantly (P>0.05) different from the control. Comparison and statistical
analysis of the effect of the different GR constructs on repression by MPA (Table 4.1)
shows that only hGRdim differs significantly (P<0.05) from repression with endogenous
hGR.
Table 4.1: Summary of percentage inhibition of CBG mRNA levels. Statistical
analysis was done on results obtained in Fig. 4.7 to (i) compare values in the presence of
test compounds relative to the corresponding control using one-way ANOV A followed
by Dunnett's multiple comparison's posttest (*: P<0.05; **: P<O.OI) and to (ii) compare
values without transfected GR (-rGRa) to values with transfected GR (+rGRa and
hGRdim) for each compound tested using a two-tailed unpaired t-test (a: P<0.05; b:
P<O.OI; c P<O.OOI).
-hGR +hGR +GRdim
Control 0±5.4 o ± 12.3 o ± 11.8
DEX 23.1 ± 8.8 19.5 ± 2.7 1.3 ± 7.9
P 8.5 ± 5.0 14.4 ± 0.7 29.2 ± 3.2*
MPA 34.7 ± 3.8** 26.5 ± 2.5 48.7 ± 1.7**' a
CpdA 11.6±3.1 48.5 ± 4.8**,a 25.7 ± 0.4
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Cpd A caused a small and insignificant (11.6 ± 3.1 %) inhibition of CBG mRNA levels
in the presence of endogenous hGR while CpdA in the presence of transfected hGR
resulted in a significant (P<O.Ol) inhibition (48.5 ± 4.8 % inhibition) of CBG mRNA
levels. The presence of transfected hGRdim resulted in a 25.7 ± 0.35 % inhibition of
CBG mRNA levels, which is not significantly different from the control. Comparison
and statistical analysis of the effect of the different GR constructs on repression by
CpdA (Table 4.1) shows that only co-transfection with wild type hGR and not hGRdim
differs significantly (P<0.05) from repression with endogenous hGR.
Previous results from the literature has shown that GCs had no effect on CBG mRNA
levels in human liver cells (HepG2) [Emptoz-Bonneton et al 1997] although they
decreased plasma levels in both rats and humans [Westphal 1971; Smith and Hammond
1992; Schlechte et al 1987] whereas progesterone and MPA decreased CBG mRNA
levels in a human endometrial cancer cell-line (Ishikawa cells) [Misao et a11994; Misao
et a11998] but had no effect on rat plasma CBG levels [Smith and Hammond 1992] or
increased rat plasma levels [Westphal 1971]. We showed that co-transfection with rGR
in BWTG3 cells increased repression of the CBG promoter (Fig. 4.3, solid bars) by all
the test compounds, except progesterone, but transfection with hGR in HepG2 cells only
increased repression of CBG mRNA levels by CpdA. Despite the fact that no significant
repression was shown with CpdA in HepG2 cells (in the presence of endogenous GR)
we found significant repression (P<O.Ol) of CBG mRNA levels in rat livers by CpdA
(Fig. 4.8). This could support the idea that CBG mRNA levels may be differently
regulated in different species but caution must be exercised in interpreting these results
as we did not measure effects on CBG mRNA in BWTG3 cells nor did we examine
promoter-reporter studies in HepG2 cells.
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Although the effect of transfected GRdim was investigated to ascertain a requirement or
not for GR dimerization, the results are inconclusive. Despite the fact that
dexamethasone and CpdA decreased CBG mRNA more in the presence of hGR than in
the presence of GRdim (P<0.05), this occurred within the background of endogenous
GR. It has to be acknowledged that this experiment has certain limitations since the
amount of endogenous GR present as well as the proportion of cells transfected with the
above mentioned constructs is unknown. Thus the dexamethasone results of endogenous
versus GRdim, where transrepression is abrogated do not correspond to those with CpdA
where transrepression is increased and interpretation is difficult. A possible hypothesis
for these results are that dexamethasone may be acting via a dimer and CpdA acts via a
monomer but this is a highly unlikely hypothesis. Dimerization requirements for
transrepression of the CBG gene could be more convincingly tested by using the GRdim
mice constructed by Reichardt et al [Reichardt et al 2001]. In these mice, no wild-type
GR would be present that could influence the results, like in the cument sytem.
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Figure 4.8. Regulation of rat CBG mRNA levels by CpdA. Adult male Wistar rats
were injected with CpdA (see materials and methods for details). Rats were decapitated
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and livers removed for RNA isolation. Statistical analysis was done to compare values
in the presence ofCpdA relative to the corresponding control (sedentary rats) using one-
way ANOVA followed by Dunnett's multiple comparison's posttest (*: P<0.05; **:
P<O.OI).
4.4 DISCUSSION
High doses of synthetic GCs remain the most effective treatment of inflammatory or
autoimmune diseases [Barnes 1998; Schacke et al 2002a]. GC therapy is used for
reduction of inflammation and immune activation in asthma and allotransplantation as
well as in allergic, collagen, rheumatoid, vascular, dermatological, inflammatory bowel
and other systemic diseases [Schacke et al 2002a]. The use of GCs has increased
dramatically over the years and in the United States alone about IOmillion new
prescriptions for oral corticosteroids are written each year.
The effects of GCs are mediated by the GR via activation and repression of gene
expression. The desired anti-inflammatory effects of GCs are mainly mediated via
transrepression of gene transcription. Some genes coding for anti-inflammatory proteins
are induced by the GR via GR-DNA interactions [Schacke et a12002a]. However, most
pro-inflammatory genes like cytokines, chemokines and adhesion molecules are
regulated by the transcription factors NF-KB and AP-I and GR causes repression of the
expression of these pro-inflammatory proteins by interacting, probably as a monomer
[Heck et aI1994], with the transcription factors NF-KB and AP-I, thus inhibiting their
activity [Barnes 2001]. It has been hypothesized that the above transrepression
mechanism mediated by the GR monomer via GR-protein interactions is sufficient to
achieve most anti-inflammatory effects [Schacke et al 2002a]. A large number of side-
effects are, however, associated with the long-term use of GCs [Schacke et al 2002a].
Though most side effects are mediated via GR transactivation and DNA-binding of GR
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dimers (diabetes mellitus, glaucoma) recent results suggest that some side-effects are
mediated via transrepression (skin atrophy, suppression of HPA axis). In addition, the
precise molecular action of some side effects is not known or may be due to both
transactivation and transrepression (osteoporosis). Despite the above caveats it is still
proposed that novel GCs that can dissociate between transrepression and transactivation
may produce drugs with an improved therapeutic profile [Adcock 2000].
In the present study the dissociative GC activity of MPA and CpdA was investigated
and compared to GCs in hepatoma cell-lines. Compared to GCs which strongly
transactivate the GRE-dependent promoters, MPA and Compound A had no effect in
the presence of endogenous GR. Co-transfection with GR, however, increased
transactivation by MPA while CpdA did not trans activate the GRE-containing
promoters even at 10 !-lMand in the presence of co-transfected GR. The second aspect
of dissociative GC activity, which is transrepression, was investigated by studying the
effect of these compounds on the CBG proximal promoter as well as on CBG mRNA
levels. The rationale for this was that CBG plays an integral role in the disposition of
both endogenous and administered glucocorticoids and thus any investigation of
potential dissociated drugs should address effects on CBG. In addition, De Bosseher has
dealt with the obvious investigation of effects on inflammatory genes. She found that
CpdA exerts anti-inflammatory potential by down-modulating TNF-induced 1L-6 gene
expression as well as other NF-KB and AP-I regulated genes, but that, as we found, did
not activate GRE-driven promoters [De Bosseher 2003 unpublished results]. In the
present study we found that, like dexamethasone and hydrocortisone, both CpdA and
MPA transrepress the rat CBG proximal promoter. CpdA represses with a similar
potency but with a higher efficacy than MPA. Dexamethasone, progesterone, MPA and
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CpdA slightly decreased CBG mRNA levels in HepG2 cells in the presence of
endogenous GR, which does not correspond well with the significant repression of the
CBG promoter by these compounds. Co-transfection with GR in BWTG3 cells
increased repression of the CBG promoter by these compounds but only increased
repression of CBG mRNA levels by CpdA in HepG2 cells. Although the discrepancy
between promotor and mRNA results may only be a matter of statistics, which may be
corrected if more experiments are done, another possibility exists. The promoter
experiments were performed in a mouse hepatoma cell-line (BWTG3) whereas the
mRNA experiments were done in a human hepatoma cell-line (HepG2) and thus GC
regulation may differ due to species differences. The amount of receptors, co-activators
and co-repressors may also differ between these two cell-lines, which might be a reason
for the different effects observed. However, we did in Chapter 3 show significant
repression of CBG mRNA levels by dexamethasone in HepG2 cells and thus would
need to expand the current study to definitively answer the question of whether
dexamethasone significantly represses CBG mRNA levels in HepG2 cells.
Bamberger et al showed that MPA marginally transactivates III the presence of
endogenous GR and, like us, found that co-transfection with GR significantly increased
transactivation [Bamberger et al 1999]. In their study MPA displays a
transrepressionltransactivation ratio of 6.6 relative to dexamethasone (ratio of 1), which
indicates significant dissociated properties [Bamberger and Schulte 2000]. MPA
displays a transrepressionltransactivation ratio of 0.8 for the (GRE)2tkLuc and 1.1 for
the (GRE)z50hIL6Pluc reporter constructs in the presence of co-transfected GR relative
to dexamethasone (ratio of 1) in this study, which suggests that it is significantly less
dissociated in our system than in the one Bamberger describes. In another study MPA
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repressed IL-6 and IL-8 promoter reporter constructs, as well as a GRE-containing
promoter construct in L929sA cells and thereby exhibiting no dissociative GC
properties [Koubovec et al unpublished results]. While both MPA and CpdA
transrepress the CBG proximal promoter, CpdA, does not activate GRE-containing
promoters on its own in either of the cell-lines tested, which makes it a better
dissociative GC than MPA although it does preclude the calculation of a dissociation
ratio. This compound is therefore a potential non-steroidal anti-inflammatory agent.
Although it is clear that CpdA cannot transactivate in either cell line investigated it is
interesting to note that it can modulate dexamethasone transactivation of the GRE-
containing promoters (Fig. 4.5). This effect, however, depends on the order of addition
of CpdA. If dexamethasone was added together with CpdA, CpdA has no effect on
dexamethasone transactivation but if CpdA was added before dexamethasone, CpdA
decreased dexamethasone transactivation in both cell-lines. Binding of CpdA to the GR
has been shown to be reversible, and therefore it can be concluded that CpdA does not
covalently modify the receptors and thus prevent binding of other compounds to the GR
[unpublished results]. A possible, albeit revolutionary, hypothesis to explain this effect
is that CpdA may be accommodated in the ligand-binding pocket together with
dexamethasone, only when CpdA is added before dexamethasone, but not when they are
added together. This may then result in a liganded-GR that is unable to transactivate.
GR antagonists such as RU486 and ZK 98,299 have a bulky side chain at position
Cllbeta [Modarress et a11997] that is similar in size to CpdA and thus it is conceivable
that both compounds could be accommodated in the ligand-binding pocket. The
structures of dexamethasone, ZK 98.299 and RU486 are shown in Fig. 4.9. This
hypothesis presumes that dexamethasone has a higher affinity for the GR than CpdA
125
Stellenbosch University http://scholar.sun.ac.za
and that once bound to the GR cannot accommodate CpdA binding. Thus when CpdA
and dexamethasone are added together, CpdA does not significantly compete with
dexamethasone for binding to the receptor and does not reduce dexamethasone
transactivation as does MPA and progesterone. In addition, the hypothesis presumes
that CpdA bound GR can accommodate dexamethasone binding without displacement
of already bound CpdA. Thus, if CpdA is added first, dexamethasone is not present to
compete for binding and a greater proportion of the receptors would be occupied by
CpdA. The CpdA-bound GR could then subsequantly bind to dexamethasone. Itmay be
that there would be a requirement for the CpdA-occupied receptor to have a greater
affinity for dexamethasone that the unoccupied recptor. To sum up the hypothesis
assumes that when CpdA and dexamethasone are added together a much smaller
percentage of the liganded receptors accommodate both ligands together than when
CpdA is added before dexamthsone.
Another possible hypothesis may be that CpdA is binding to a second binding site on
the GR. Compounds like ketoconazole, cortivazol, ursodeoxycholic acid, p-Lapachone,
carbenoxolone and free fatty acids have been proposed to bind to a second binding site
on the GR [Suthers et a11976; Yeakly et a11980; Schmidt et a11984; Svec 1988; Svec
et al 1989; Srivastava and Thompson 1990; Valette et al 1991; Tanaka and Makino
1992; Soro et al 1997; Miura et al 2001; Yoshikawa et al 2002]. Once again some
presumptions have to be made to accommodate the hypothesis: firstly that once
dexamethsone is bound CpdA cannot bind to the second binding site and secondly that
once CpdA has bound dexamethasone can still bind to the GR LBD. Interestingly,
ketoconazole has been shown to inhibit P450c20 [Santen et al 1983], whereas CpdA
inhibits P450c11 [Louwet al 1997]. Both hypotheses suggested are controversial and
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we have little evidence at present to support them so they should be treated with caution
until additional evidence is provided.
Dexamethasone CH~H
IOu}
111111111
o
ZK 98,299
o
Rli 38,4l!6 (RU 486)
o
Fig. 4.9. Structures of dexamethasone, ZK 98.299 and RU486.
Progesterone significantly transactivated in BWTG3 cells but not in HepG2 cells
whereas MPA transactivation relative to dexamethasone in BWTG3 cells was higher
than in HepG2 cells. This is unlikely to be due to higher levels of GR in BWTG3 cells
as dexamethasone activation relative to control was higher in HepG2 cells. MPA has
been shown to bind to both the GR and PR [Pridjian et al 1987; Kontula et al 1983].
127
Stellenbosch University http://scholar.sun.ac.za
Thus the higher transactivation by MPA in BWTG3 cells may be due to the presence of
PR in this cell-line trans activating via the GRE [Song et al 2001]. MPA also altered
dexamethasone transactivation of the GRE-containing promoter by decreasing
dexamethasone transactivation in both cell-lines. These two ligands, dexamethasone and
MPA, can compete for binding to the GR and thereby explain the decrease III
dexamethasone transactivation of the GRE-containing promoter in the presence of
MPA. Not only is the affinity of MPA for the human [Kontula et al 1983] and rat
[Pridjian et al 1987] GR receptors between 2-10 times less than for dexamethasone but
MPA has also been shown to be much less potent than dexamethasone in activating
HRE-tk-Iuciferase activity through the GR [Zhang et aI2000]. As already suggested the
difference in the progesterone results between BWTG3 cells and HepG2 cells may be
due to the presence of more PR in BWTG3 cells as both the PR and GR can bind and
activate transcription from the same HRE [Song et al 2001]. Less obvious to explain is
that progesterone like MPA decreased dexamethasone transactivation of the GRE-
containing promoter in both cell-lines.
Two possible explanations are put forward. Firstly, in BWTG3 cells, where PR is
proposed to be present, a possible explanation could be that it has been shown that
steroid receptors can compete for coactivators and are differentially affected by
corepressors. Progestin antagonism of GR-mediated transcription from the MMTV-
promoter has for example been shown to be due to competition for the BRG-l
chromatin remodeling complex [Deroo and Archer 2002]. Thus, the competition
between the PR and GR for binding coactivators in cells that express both of these
receptors can decrease dexamethasone transactivation. It has also been shown that
changes in the concentration of the corepressors NcoR and SMRT can modify the
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transcriptional properties of the GR differently from the PR [Song et al 2001].
Secondly, in an attempt to explain the decrease of dexamethasone repression by
progesterone in the HepG2 cells that we have argued does not contain PR we have to
resort to a more controversial proposal: that progesterone modulated GR activity via a
second binding site on the GR. Progesterone has been shown to increase the dissociation
rate of dexamethasone-receptor complexes in liver and kidney cytosol [Suthers et al
1976; Svec et al 1989]. It was postulated that GC receptors have two classes of binding
sites and that occupation of the second binding site increased the dissociation rate of
agonist from GR. Alternatively progesterone may be activating directly via the GR as it
was recently shown that progesterone and cortisol antagonism of the prostaglandin
dehydrogenase gene may not require PR but that progesterone could act via the GR
[Patel et a12003].
Based on the molecular mechanisms of GC-mediated action, it has been hypothesized
that activation of the GR with compounds that induce a predominant induction of
transrepression over transactivation, should lead to the majority of the anti-
inflammatory effects of GCs with less side effects. A novel class of synthetic GCs has
been reported to differentiate between transactivation and AP-10r NF-KB
transrepression [Vayssiere et al 1997; Vanden Berghe et al 1999]. Belvisi et al
investigated these compounds, specifically RU24858, in vivo. RU24858 was shown to
be dissociative in vitro in human HeLA cells and rat hepatoma cells but did not show a
separation between anti-inflammatory and side-effects in vivo in rats [Belvisi et al
2001]. Specifically, this compound exhibited comparable anti-inflammatory properties
to standard steroids in the sephadex model of lung edema but decreased osteocalcin
levels, indicating inhibition of bone turnover in rats [Belvisi et al 2001]. This suggests
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that it is crucial to confirm any in vitro data of dissociative compounds with in vivo
testing as in vitro separation of transrepression from transactivation does not necessarily
translate to an increased therapeutic ratio for GCs. Alternatively it may suggest that
more of the side-effects than thought are a result of transrepression rather than
transactivation.
Non-steroidal ligands for GR have previously been reported. Miner et aI, for example,
reported that a selective, non-steroidal GR antagonist, AL082D06 (D06), inhibits GC-
mediated transcriptional regulation, partially blocks GR translocation to the nucleus and
completely blocks DNA binding by the receptor [Miner et a12003]. This compound has
a high affinity for the GR, binds competitively with other known GR ligands and may
occupy the same hydrophobic pocket in the LBD as steroids. The receptor is in an
antagonist conformation when bound to D06 and this conformation is different from
that elicited by both the partial antagonist (RU486) and the full agonist (dexamethasone)
[Miner et al 2003]. Another non-steroidal ligand, with high affinity for the GR,
A276575 repressed IL-l induced IL-6 production and antagonised transactivation of a
MMTV GRE reporter construct [Lin et al 2002]. Schacke et al also reported that non-
steroidal ligands that bind to the GR showed a good separation between transactivation
of a TAT GRE reporter construct and transrepression of IL-8 protein [Schacke et al
2002b]. Recently a non-steroidal GR ligand that does not dissociate but rather
selectively activates or represses GR-regulated genes was described [Coghlan et al
2003]. To distinguish these compounds from steroidal dissociated GCs the term
selective GR agonists (SEGRAs) was introduced and refers to compounds that are non-
steroidal, partially displays the molecular effects of GCs and are dissociated in their
clinical profile [Schacke et al 2002b]. Coghlan et al show that AL-438, a non-steroidal
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GR ligand, is able to selectively repress and activate genes normally regulated by GCs
[Coghlan et al 2003]. This compound was also tested in vivo and retains full anti-
inflammatory efficacy and potency compared to steroids but has less negative effects on
bone metabolism and glucose control. This is thus not a classical dissociated compound
in dissociating transactivation from transrepression but rather a selective GR modulator
that both transactivates and transrepresses GR-regulated genes but in a tissue-specific
manner. Coghlan proposes that the selectivity of the ligand action is based on the
structural changes in the receptor that influences co-activator interactions and that for
AL-438 this reduces the ability of the GR to bind to the co-factor peroxisomal
proliferator-activated receptor y coactivator-1 (PGL-1), a co-factor critical for steroid-
mediated glucose up-regulation in the liver, while maintaining normal interaction with
GRIP-1 [Coghlan et aI2003]. The rate-limiting enzyme in the gluconeogenic pathway,
phosphoenolpyruvate carboxy kinase, requires the action of PGC-1 to effectively
respond to GCs.
The search for new dissociated glucocorticoids has up to now focused on the
transrepressive effects on NF-KB and AP-I mediated gene regulation [Dumont et al
1998; Adcock 2000; Vayssierre et a11997; Vanden Berghe et a11999; Bamberger et al
1999; Miner et al 2003; Coghlan et al 2003]. The results of this study showed that GCs
regulate the CBG promoter and thus it may be important to consider the effect of these
dissociative GCs on CBG function for full evaluation of these drugs. The primary role
of CBG is to regulate the bioavailability and metabolic clearance of GCs [Westphal
1983] and synthesis of CBG, a negative acute phase protein, is down-regulated in
response to injury or infection [Beishuizen et a/2001]. In addition, there is also growing
support for CBG playing a more active role in mediating physiological responses
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[Breuner and Orchinik 2002]. Thus it may be important to consider the effect of these
dissociative GCs on CBG function for complete assessment of these drugs.
Presently, drug finding programs are developing dissociative GCs based on the
differential molecular regulation of the major anti-inflammatory actions of GCs and
their side-effects. Schacke et al reviewed the mechanisms involved in the side-effects of
GCs, which are complex and not completely understood [Schacke et al 2002a]. This
study has shown that in vitro CpdA can completely dissociate between transactivation
and transrepression, which makes it an even better dissociative GC than MPA.
According to Schacke's criteria CpdA could thus be classified as a SERGA but in vivo
data is needed to confirm this. Up to now steroidal and non-steroidal ligands have been
described that seems to dissociate between activation and repression in vitro [Vayssiere
et al 1997; Belvisi et al 2001; Bamberger et a11999]. In vivo tests showed that although
they are effective anti-inflammatory agents, they do not always have a useful side-effect
profile. At this stage it is unclear if simple dissociation of activation from repression in a
ligand will result in a beneficial therapeutic profile as evidenced by the results of
Coghlan and co-workers with AL-438 [Coghlan et al 2003]. Thus in addition to in vivo
function more information is also needed on the mechanism of action of CpdA. A
priority is to establish if indeed CpdA acts via the GR. The fact that RU486 reverses
transrepression and co-transfection of GR enhances transrepression of the CBG
promoter by CpdA is preliminary proof that CpdA is working through the GR. This can
be investigated further by testing if CpdA binds to the GR, if CpdA bound to receptor
can translocate to the nucleus or whether transrepression of the CBG promoter by CpdA
is mediated by the GR forming protein-protein interactions with other transcription
factors and thus acts via a GR monomer. In addition, to further elucidate the mechanism
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of action of CpdA, the importance of the functional domains of the GR in mediating
repression by CpdA can also be investigated (discussed in the introduction chapter
section 2.1.2.1.3), as could the effects of CpdA on the kinetics of nuclear translocation
(discussed in the introduction chapter section 2.1.2.2.4). If indeed CpdA is found to be
completely dissociated, not only in vitro but also in vivo, it could be used as a drug or
lead compound with less side-effects for the treatment of inflammatory and autoimmune
diseases. In addition, an understanding of the means whereby CpdA elicits its effects
through GR should expand our knowledge of the molecular mechanisms involved in
GR-mediated gene regulation.
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Since 1948, it has been known that hydrocortisone (cortisol), the primary GC produced
by the adrenal cortex, when administrated pharmacologically, has potent anti-
inflammatory and immunosuppressive effects [Asadullah et a12002]. Major progress in
discovering the underlying molecular mechanisms of this effect has only been made in
the last 10-15 years. Currently GCs are standard therapy for disorders like rheumatoid
arthritis, allergic reactants, asthma, connective tissue diseases, psoriasis, vasculitis,
inflammatory bowel disease and eczema [Schacke et al 2002a]. However, during
prolonged treatment with GCs, their beneficial effects are overshadowed by side-effects
like osteoporosis, skin atrophy and diabetes [Schacke et al 2002a]. Despite these
complications, prednisone and dexamethasone are routinely used for a wide range of
inflammatory conditions [Miner et al 2002]. Therefore, scientists are searching for
drugs that separate the beneficial effects of GCs from their undesired effects.
Elucidation of the molecular mechanisms of GC-mediated action led to a hypothesis
that activation of the GR with compounds that produce a predominant induction of
transrepression over transactivation, should lead to the majority of the anti-
inflammatory effects of GCs with less side effects, as the major side-effects are
mediated via transactivation. Genes coding for anti-inflammatory proteins are induced
by the GR via a GR-DNA interaction whereas the major pro-inflammatory genes coding
for cytokines, chemokines and adhesion molecules are regulated by the transcription
factors AP-lor NP-KB [Barnes 2001]. In this case the GR interacts as a monomer with
these transcription factors, inhibiting their activity and thereby repressing expression of
pro-inflammatory proteins. Synthetic GCs that differentiate between transactivation and
AP-lor NF-KB transrepression in vitro, but not in vivo, have been reported [Vayssiere
et al 1997; Vanden Berghe et al 1999; Belvisi et al 2001]. Currently, drug screening
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programs are developing dissociative GCs based on the differential molecular regulation
of the major anti-inflammatory actions of GCs and their side-effects [Schacke et al
2002a]. The term selective GR agonists (SEGRAs ) distinguishes steroidal dissociated
GCs from compounds that are non-steroidal, partially display the molecular effects of
GCs and are dissociated in their clinical profile [Schacke et al 2002b]. Different groups
have recently identified several promising SEGRAs. Schacke et al analysed compounds
with an in vitro dissociation between transactivation and transrepression in rodents
[Schacke et al 2002b]. As a parameter for anti-inflammatory activity they measured the
inhibition of ear edema and both classical GCs and dissociative GCs was very effective.
They reached a similar efficacy compared to GCs after treatment of mice and slight
differences in potency were observed. These dissociated GCs showed a good separation
between inhibition of edema and TAT induction in contrast to classical GCs. Belvisi et
al focussed on a lung edema model in rats to demonstrate anti-inflammatory activity
and their compound showed a potency better than GCs in vivo but was as effective as
GCs in induction of side-effects [Belvisi et al 2001]. Coghlan et al described what
appears to be a true SEGRA. They showed that AL-438, a non-steroidal GR ligand,
selectively represses and activates genes normally regulated by GCs [Coghlan et al
2003]. Anti-inflammatory activity was measured in rats using the carrageeman-induced
paw edeema assay, which is a model of acute inflammation, as well as a more chronic
model of inflammation, the adjuvant-induced arthritis [Coghlan et al 2003]. AL-438
retains full anti-inflammatory efficacy and potency compared to steroids but has less
negative effects on bone metabolism and glucose control. Although these results are
very encouraging to definitively state that a compound could dissociate between
transactivation and transrepression, micro-array or proteomic screens involving GC
responsive genes should be done [Komamura et aI2003].
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In the present study we investigated and compared the dissociative GC activity of the
steroidal compound, MPA, and the non-steroidal compound, CpdA, relative to GCs by
examining transactivation of GRE-containing reporter constructs and transrepression of
CBG gene expression in hepatic cell lines. Results showed that MPA, but not CpdA,
only transactivates GRE-containing promoters in the presence, but not in the absence, of
co-transfected GR. As CBG transports and modulates the bioavailability of
glucocorticoids and progesterone in plasma, we studied the second aspect of
dissociative GCs, namely transrepression, by examining effects on the CBG promoter
[Hammond et a11990b; Hammond et a11991; Seralini 1996]. Only the free fraction of
steroid hormones is biologically active and able to diffuse across the plasma membrane
of target tissues. This implies that any changes in the levels of CBG would modify the
distribution of steroids to target tissues [Westphal 1986; Mendel 1989]. Several factors
have been shown to influence CBG production. Exercise and stressful conditions such
as malnutrition and restraint decrease CBG levels in rats resulting in an increase in free
GC levels [Duclos et al 2003; Peijie et al 2003; Tinnikov 1999; Lesage et aI2002]. In
this study we also investigated the effect of various physical stressors on rat liver CBG
mRNA levels as well as the effect of several hormones known to influence CBG
production on CBG mRNA and protein levels in a human hepatic cell line. Voluntary
running had no effect on rat CBG levels but involuntary swimming and immobilization
decreased rat CBG mRNA levels, which corresponds to the observed decrease in
circulating plasma CBG levels during exercise stress reported in the literature [Tinnikov
1999; Lesage et a12002]. To support these findings we also showed that GCs decreased
CBG mRNA and protein levels in a human hepatoma cell-line.
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Although both the human and rat CBG genes (Cbg) have been cloned no work has been
done to identify possible cis-acting sequence elements involved in their regulation by
hormones [Underhill and Hammond 1989; Underhill and Hammond 1995]. DNase I
footprinting of the rat CBG proximal promoter identified five protein-binding sites (PI-
PS) within 236 bp immediately 5' of the transcription start site with rat liver nuclear
extract which resemble recognition sequences for HNF-l, CP-2, DBP, HNF-3 and
ClEBP or NF/IL6, respectively [Underhill and Hammond 1995]. EMSAs confirmed that
footprint one (P 1) binds to HNF -1P and footprint two (P2) binds to CP2 [Underhill and
Hammond 1995; Zhao et a11997]. Even though CBG transcription has been shown to
be regulated by steroid hormones [Westphal 1972; Smith and Hammond 1992; Misao et
al 1998; Coolens et al 1987] no hormone response elements seem to be present in the
rat or human CBG proximal promoter. This suggests that the steroid receptors might be
acting through a tethering mechanism without direct DNA binding. The GR may thus
repress transcription via protein-protein interactions with other transcription factors
rather than by directly binding to nGREs. The present study is the first that investigated
the effect of GCs on the CBG proximal promoter. Results showed that hydrocortisone
and the synthetic GC, dexamethasone, repressed the full-length, ratCBG 1200Luc,
proximal promoter reporter construct and the truncated ratCBG295Luc promoter
reporter construct as well as the second construct stably transfected into BWTG3 cells.
MPA and CpdA, like GCs, repress both the ratCBG 1200Luc promoter reporter
construct and the truncated ratCBG295Luc promoter reporter construct. Although MPA
and CpdA both repress the CBG promoter, CpdA transrepressed the CBG proximal
promoter with a similar potency but with a higher efficacy than MPA.
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Further examination of glucocorticoid responsiveness on the CBG proximal promoter,
showed that dexamethasone transrepressed both the ratCBG 1200Luc and
ratCBG295Luc promoter constructs whereas the ratCBG 145Luc construct was
unaffected. This indicates that the protein-binding sites for DBP, HNF3 and C/EBP
present in the ratCBG295Luc construct but not in the ratCBG145Luc construct may be
involved in the glucocorticoid responsiveness of the CBG proximal promoter. The
transcription factors HNF-3 and C/EBP or NF-IL6 have been reported to form protein-
protein interactions with the GR [Boruk et al 1998; Rabek and Papaconstantinou 1999;
Wang et a11999; Hoeke et a11992] and we have showed that DBP, HNF3 en C/EBP all
partially inhibit transactivation of a GRE-containing promoter by dexamethasone. Thus
DBP, HNF-3 and C/EBP or NF-IL6 appears to be likely candidates for mediating the
repressive effect of GR on the CBG promoter. Additional work is, however, needed to
determine the precise mechanism of action involved as well as which of the three
transcription factors identified in this study are specifically responsible for the GR-
mediated regulation of the CBG proximal promoter. Future experiments could include
site-directed mutagenesis to mutate the DBP, HNF3 and C/EBP binding sites, which
may identify, which one of these transcription factors is involved in GC repression of
the CBG promoter. By using EMSAS it can also be confirmed if the transcription factor
involved in repression of the CBG promoter forms protein-protein interaction with the
GR. For example, using EMSAS, the GR has been shown to suppress the binding of
C/EBPP on the rainbow trout ER promoter by protein-protein interactions [Lethimonier
et al 2002]. In addition, further study of upstream modulators is warranted as we found
that the ratCBG 1200Luc construct was transrepressed to a greater extent by
dexamethasone than the ratCBG295Luc construct, which suggests that transcription
factors further upstream of the ratCBG295Luc may also be involved in modulating
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transrepression by glucocorticoids. The full-length CBG proximal promoter also needs
to be sequenced to identify the binding sites upstream of the ratCBG295Luc construct
that contributes to repression of the CBG promoter. The present study has, however, for
the first time provided information on hormonal regulation of the CBG proximal
promoter.
Other hormones known to regulate CBG mRNA levels include progesterone, E2, and
insulin. CBG mRNA levels were shown to be suppressed by progesterone but
stimulated by E2 in a human endometrial cancer cell-line, Ishikawa, whereas insulin
was shown to decrease CBG mRNA levels in a human hepatoma cell-line, HepG2
[Misao et al 1998; Crave et al 1995]. The present study has shown that this regulation
occurs at the level of the CBG promoter, as progesterone and insulin decreased, while
E2 increased transcription from the ratCBG295Luc promoter reporter construct.
Despite the fact that our mRNA experiments were done in a human hepatoma cell line
(HepG2) and the promoter experiments in a mouse hepatoma cell line (BWTG3) and
that results from the literature are also from different cell lines and species our promoter
studies correlate nicely with the regulation of CBG mRNA levels by these hormones
reported in the literature as well as with our own mRNA results.
It is important to test the effect of dissociative GCs compared to standard GCs on CBG
expression as standard GCs decrease CBG expression resulting in an increase in the
amount of active, free GCs available to target tissues. Repression of CBG levels may
thus act to amplify the effects of administered GCs. In addition, CBG has recently been
proposed to play a more active role in the stress response that goes beyond its function
of regulating the free GC concentration by acting as a GC reservoir [Breuner and
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Orchinik 2002]. In this regard it has been suggested that CBG may be involved in the
targeted release of GCs to specific inflammation sites [Hammond et al 1990b], that
extra-hepatic CBG may act to modulate GC action locally [Berdusco et al 1995], and
that CBG may have intrinsic biological activity through eliciting an intracellular
response via its membrane receptor [Nakhla et a11988; Strel'chyonok and Avvakumov
1991]. We submit therefore, that to evaluate the full physiological effect of dissociative
GCs it may be essential to investigate their effect on CBG expression.
To conclude, the results of this study showed that MPA displays partial dissociation
between transactivation and transrepression whereas the non-steroidal CpdA, in vitro,
can completely dissociate between transactivation and transrepression. According to the
criteria for SEGRA's, CpdA could thus be classified as such but in vivo data is needed
to confirm this. If CpdA is found to be completely dissociative in vitro and in vivo with
less side effects than conventional GCs, it could possibly be developed as a drug for the
treatment of anti-inflammatory and auto-immune diseases.
Further investigation into the mechanisms of GC-mediated effects, especially their side-
effects is needed. Analyzing the side-effects of standard GCs compared to SEGRAs in
GRdimldimmice will help in understanding the molecular mechanisms of side-effect
induction [Schake et al 2002a]. Most importantly, in vivo investigations and first
clinical trials will demonstrate the safety and efficacy profile of SEGRAs and will also
contribute to a better understanding of the molecular basis of GC-mediated effects.
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CHAPTER6
Materials and Methods
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6.1 Materials
Dexamethasone, hydrocorticosterone, MPA, progesterone, E2, insulin, and mifepristone
(Ru486) were obtained from Sigma chemical Co (South Africa). The aziridine precursor
Compound A, was synthesised as described previously [Louwet al 1997] and the
structure and purity was verified by NMR and electro spray-mass spectrometry (ESMS).
The recombinant mIL-6 was provided by G. Haegeman (Department of Molecular
Biology, University of Gent-VIB).
6.2 Plasmids
(GRE)250hIL6PLuc was constructed by inserting a glucocorticoid-responsive element
with protruding BglII-PstI ends, into the multieloning site of p50hIL6Pluc [De
Bosseher et al 2000]. The (GRE)2tkLuc construct and the rat GRu (pSVGR1)
expression vector was kindly provided by S. Okret (Department of Medical Nutrition,
Karolinska Institute, Sweden). The rat GRu (pSVGR1) expression vector was
constructed by Miesfeld et al (UCSF) and contains the SV40 enhancer/early promoter
region, the coding region of the rat GRu cDNA and the SV40 polyA region [Miesfeld
1986]. The human GR (pRS-hGRu) was a kind gift from R.M. Evans (Howard Hughes
Medical Institute) and the GRdim construct from G. Haegeman (Department of
Molecular Biology, University of Gent-VIB, Belgium). Various rat CBG-luciferase
reporter plasmids as well as hCBG and rCBG cDNA were kindly provided by G.L.
Hammond (London regional Cancer Centre, London) of which the rat CBG-295Luc
construct contains the five protein-binding sites identified by DNase I footprinting
[Underhill and Hammond 1995]. The ~-galactosidase reporter plasmid (pPGK~GopbA)
constitutively expressing a neomycin-resitant/B-galactosidase fusion protein under the
143
Stellenbosch University http://scholar.sun.ac.za
control of the pPGK promoter from the mouse houskeeping enzyme, 3-
phosphoglycerate kinase was a gift from P. Soriano (Fred Hutchinson Cancer Research
Centre, Seatle, WA). The hepatocyte nuclear factor-3 (HNF-3a) construct was provided
by Eseng Lai (Memorial Sloan-Kettering Cancer Center, New York), the D-site binding
protein construct (pBS-DBP) by Pascal Gos (Department of Molecular Biology,
University of Geneve, Switzerland) and the CAAT/enhancer binding protein construct
(C/EBPP) by Weihua Xiao (NCl-Frederick Cancer Research and Development center,
Frederick, USA). PGL2 basic vector was a kind gift from D. Hamish (Womens's Health
Research Institute, Wyethayerst labs, Pensylvania). p-actin cDNA was provided by H.
Okayama.
6.3 Preparation of test substances
Steroids were dissolved and diluted in ethanol and added to cells with medium. Only
ethanol was added to control groups. Compound A (CpdA), prepared just before
addition, was dissolved and diluted in ethanol, sonicated until fully dissolved and kept
on ice before adding to cells. The final concentration of ethanol added to cells was
0.001%. Insulin and IL-6 were directly diluted in serum-free medium.
6.4 Tissue culture
Dulbecco's modified eagle medium (DMEM) and penicillin-streptomycin (PIS) solution
were purchased from GIBCO, L-glutamine from Sigma and fetal calf serum (FCS) from
Sterilab. The mouse hepatoma (BWTG3), obtained from G. Haegeman (Department of
Molecular Biology, University of Gent-VIB), and the human hepatoma (HepG2),
obtained from the Medical research council (MRC, Tygerberg, South Africa), cell-lines
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were grown in Falcon T150 and T75 flasks at 37°C in a 5% CO2 atmosphere in DMEM
supplemented with 10% fetal calf serum (FCS), penicillin-streptomycin (40 000 UIL)
and L-glutamine (30 giL).
6.5 Protein and mRNA studies:
6.5.1 Hormone inductions, protein and RNA isolations from HepG2 cells
For the induction experiment in chapter 2, 5x 105 HepG2 cells were plated in 5 ml
DMEM supplemented with 10% fetal calf serum (FCS), penicillin- streptomycin (40
U/ml) and L-glutamine (30 gIL) in T25 flasks. The next day medium was replaced with
or without 10% FCS. In chapter 3, 2.5x105 HepG2 cells were plated in 3 ml DMEM
supplemented with 10% fetal calf serum (FCS), penicillin- streptomycin (40 U/ml) and
L-glutamine (30 giL) in 6 well plates. The next day cells were either transfected using
Fugene™6 (Roche Molecular Biochemicals) transfection reagent (10 Ill/well) with 2 ug
rat GRu construct (+GR) or a rat GRdim construct (+GRdim) or not transfected (-GR).
After 24 h, cells were induced in DMEM with or without test compounds. For each
concentration of each test compound, three culture flasks or wells were prepared. After
72 h of incubation, the medium from each flask was removed and saved for protein
analysis. Total ribonucleic acid (RNA) was extracted according to the trizol method as
described by the manufacturer (Sigma). After extraction, the final RNA pellet was
dissolved in 50 III formazol (Molecular research center, Inc) and kept at -70°C until
used. The RNA concentration was determined by reading the absorbance at 260 nm.
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6.5.2 Inductions and RNA isolations from rat livers
Carine Smith from the department of Human Physiology, University of Stellenbosch
performed the rat experiment. In this study 40 adult male Wistar rats (350 g) were used.
These rats were divided into four groups of ten rats each of which Group 1 (SED) acted
as the control sedentary group and underwent no intervention treatment. Group 2 (RUN)
was housed in rat wheels designed for this purpose and allowed to run at will and
subjected to voluntary exercise stress only. Group 3 (SWIM) was subjected to
involuntary swimming exercise of one hour per day for the duration of the experiment
(10 days). Group 4 (IMOB) was subjected to immobilization for one hour per day in
small perspex cages (8x 11x 17 cm) for the 10 days of the experiment. Rats were fed rat
chow and water ad libitum, and were housed in groups of three or four in standard rat
cages, except for the RUN group, which was housed individually in specially designed
rat wheels. The rats were subjected to a 12-hour light-dark cycle and weighed daily.
Since rats are nocturnal animals, all interventions were carried out in the late afternoon.
All rats were sacrificed by decapitation on day 11 of the protocol at noon, to counter
diurnal changes in endocrine measures. The livers were removed and total ribonucleic
acid (RNA) was immediately extracted according to the trizol method as described by
the manufacturer (Sigma). After extraction, the final RNA pellet was dissolved in 50 !-lI
formazol (Molecular research center, Inc) and kept at -70°C until used. The RNA
concentration was determined by reading the absorbance at 260 nm.
6.5.3 CBG protein levels
Extracellular CBG protein levels (from medium) were determined by using a RIA and
was done by A. Emptoz-Bonneton at the Hospital De l' Antiquaille, Laboratoire de la
Clinique Endocrinologique, Lyon, France [Emptoz-Bonneton 1997].
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6.5.4 Northern blotting
Twenty micrograms of total RNA were loaded and run on a 1% formaldehyde-agarose
gel and transferred to a nylon membrane (Hybond-W, Amersham). To check RNA
preparation integrity, ethidium bromide staining was used to demonstrate the presence
of intact 18S and 28S ribosomal bands. RNA was fixed on the membrane by using UV
cross linking for 12 s. The membrane was prehybridized in a hybridisation oven at 50°C
for l h with prewarmed Dig easy Hyb solution (Roche). Plasmids carrying hCBG or
rCBG, complementary DNAs were amplified in a DH5a. competent Escherichia coli
strain and digested to cut out the insert. Inserts were isolated by agarose gel
electrophoresis. Hybridization was performed overnight at 50°C with 25 ng cDNA
probes labelled with [a._32p] dCTP (50 !lCi) using the random priming technique
(Amersham megaprime labelling kit). Membranes were washed twice for 5 min in
2xSSC, 0.1 % SDS at room temperature, followed by two washings for 15 min in
O.lxSSC, 0.1% SDS at 50°C. Membranes were wrapped in cling wrap and underwent
autoradiography for between 24 and 48 h at -70°C. Autoradiograms were scanned
using the densitometry program UN-SCAN-IT. Membranes were stripped using a hot
0.5% SDS solution and reprobed with human e2P]~-actin.
6.6 Promoter reporter construct studies:
6.6.1 Transient transfeetions
For transient transfections 5x 104 cells (BWTG3 or HepG2) were plated in DMEM
supplemented with 10% fetal calf serum (FCS), penicillin-streptomycin (40 U/ml) and
L-glutamine (30 gIL) in 24-well tissue culture plates. Cells were transfected 24h later
using Fugene™6 transfection reagent (3 ul/well) as described by the manufacturer
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(Roche Molecular Biochemicals). All reporter constructs ((GRE)250hIL6PLuc,
(GRE)2tkLuc, rCBG295Luc, rCBG145Luc and rCBG1200Luc) were transfected using
360 ng of Luc reporter plasmid with or without 200 ng of rat (pSVGR1) or human
(pRS-hGRa) GRa expression vectors. In addition, 40 ng of the ~-galactosidase reporter
plasmid (pPGK~GopbA) was included in all samples as internal standard for
transfection efficiency.
6.6.2 Transient transfeetions with HNF3a, CIEBP~ and DBP
For transient transfections 5xl04 cells BWTG3 cells were plated in DMEM
supplemented with 10% fetal calf serum (FCS), penicillin- streptomycin (40 U/ml) and
L-glutamine (30 g/L) in 24-well tissue culture plates. Cells were transfected 24h later
using Fugene™6 transfection reagent (3 ul/well) as described by the manufacturer
(Roche Molecular Biochemicals). The (GRE)2tkLuc reporter construct was transfected
using 640 ng of Luc reporter plasmid, 400 ng of rat (pSVGR1) GRa expression vector
and 600 ng pGL basic vector. In addition, 640 ng (GRE)2tkLuc reporter constructs, 400
ng of rat (pSVGR1) GRa expression vector, 200 ng pGL basic vector with 400 ng
HNF3a, C/EBP~ or DBP was transfected. In all samples 60 ng of ~-galactosidase
reporter plasmid (pPGK~GopbA) was included as internal standard for transfection
efficiency.
6.6.3 Stable transfeetions
For stable transfections 7.5x106 cells were plated in DMEM supplemented with 10%
fetal calf serum (FCS), penicillin- streptomycin (40 Ulml) and L-glutamine (30 gIL) in
T75 flasks. The next day, medium was removed and replaced with 10 ml MEM-HEPES
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without FCS. Next transfection solutions were prepared: Al contains 120 III CaCh,480
III TE buffer and 34.5 ug total DNA (consists of 15 ug rat CBG295Luc construct, 1.5
ug p-galactosidase reporter plasmid and 18 ug carrier DNA (genomic DNA from
HeLA cells)) and Bl contains 600 III BS-HEPES buffer. The DNA mix, AI, was then
slowly dripped into Bl and incubated for 10 minutes in a waterbath at 37°C for the
precipitate to form. The solution was then vortexed for 30 seconds before adding 1 ml
per flask. Thereafter 100 III cloroquine was added to each flask and incubated for 4 h at
37°C. After 4 h, DMEM containing 10% FCS was added. Cells were incubated for 48 h
to grow and then plated at 2x106 cells in a T150 flask in DMEM containing 10 % FCS
and 1000 mM G418 antibiotic. Cells were grown for one week. After one week medium
was replaced with fresh medium containing 10% FCS and 750 mM G418. Cells, which
did not contain the p-galactosidase reporter plasmid died as the expression plasmid
contained a resistance gene to G418. Colonies of cells were pooled and kept growing in
DMEM supplemented with 10% fetal calf serum (FBS), penicillin-streptomycin (40
U/ml) and L-glutamine (30 giL) in T75 flasks.
6.6.4 Hormone inductions, and Luciferase and p-galactosidase assays
Hormones were added to cells 24 h after transfection. After 24 h, cells were washed
with phosphate buffered saline (PBS), lysed with 100 III lysis buffer (PE Biosystems)
and frozen at -20°C overnight. Luciferase and p-galactosidase activities were
determined using the luciferase assay kit (Promega) and the Galacto-star assay kit (PE
Biosystems) according to the instructions of the manufacturers. Light emission was
measured in a luminoskan plate reader (Labsystems).
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6.7 Data and statistical analysis
Data are expressed as the mean ± SEM for triplicate values of each experiment and
analysed by ANaVA followed by the Dunnett's or Bonferroni's multiple comparison's
posttest (P<O.Ol**; P<0.05*; P>0.5 not significant) or when comparing two groups only
a one-tailed unpaired t-test was used. Each experiment was repeated at least twice, in
triplicate each time. GraphPad Prism® version 3.0 for Windows, GraphPad Software,
San Diego California USA, www.graphpad.com was used for graphical representation
and statistical analysis. The EC50s were determined using non-linear regression (curve
fit) and dose response curves with variable slope in chapter 3 whereas in chapter 2 the
EC50 and maximal repression was determined by fitting a dose response curve with one
site competion.
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